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Ab  Antibody. 
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CMI  Cell Mediated Immunity. 
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i.p  Intraperitoneal. 
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rRNA  Ribosomal RNA. 
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STAT-1 Signal Transducer and Activator of Transcription 1. 
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ABSTRACT 
 
 
Development of subunit vaccines for malaria that elicit a strong, long-term memory response is 
an intensive area of research, with the focus on improving the immunogenicity of a 
circumsporozoite (CS) protein-based vaccine. In this study, we found that a chimeric protein, 
formed by fusing vaccinia virus protein 14K (A27) to the CS of Plasmodium yoelii, induces 
strong effector memory CD8+ T cell responses in addition to high-affinity Abs when used as a 
priming agent in the absence of any adjuvant, followed by an attenuated vaccinia virus boost 
expressing CS in murine models. Moreover, priming with the chimeric protein improved the 
magnitude and polyfunctionality of cytokine-secreting CD8
+
 T cells. This fusion protein formed 
oligomers/aggregates that led to activation of STAT-1 and IFN regulatory factor-3 in human 
macrophages, indicating a type I IFN response, resulting in NO, IL-12, and IL-6 induction. 
Furthermore, this vaccination regimen inhibited the liver stage development of the parasite, 
resulting in sterile protection. In summary, we propose a novel approach in designing CS based 
pre-erythrocytic vaccines against Plasmodium using the adjuvant-like effect of the immunogenic 
vaccinia virus protein 14K. 
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Malaria, meaning ‘bad air’ in Italian due to its prevalence in marshy areas, continues to present a 
major public health challenge and burden on economic development in many countries. 
Plasmodium falciparum, the main causative agent of malaria in humans, is known to cause 
approximately 225 million cases and about 781,000 deaths annually. Malaria continues to be a 
key factor involved in the mortality and morbidity among young children and mothers in African 
and Sub-Saharan areas (World Malaria Report, 2010). Areas which were previously declared 
malaria free are also under constant threat of resurgence due to changes in global weather and 
globalization. The situation has further worsened due to emergence of drug resistance parasites 
and ineffective vaccines. With several drugs in pipeline an effective vaccine is need of the hour 
in the fight against malaria. 
To date vaccines have played an important role in the elimination of many diseases. However 
development of a malaria vaccine is curtailed by the ability of the parasite to deceive the immune 
system. Natural immunity to malaria is observed in endemic areas which also requires repeated 
exposure and takes considerable time to develop. However this kind of immunity ranges from 
partial to complete protection and is usually observed in older population. Therefore the 
development of an effective malaria vaccine is essential. Even though a large repertoire of 
antigens from various stages of malaria is available selecting a successful candidate is still an 
ongoing task. A successful vaccine should overcome several constraints such as it should provide 
long lasting protection irrespective of genetic variations that exists between human as well as 
parasite populations. Additionally it should be easy to produce and transport with minimal costs. 
In addition the vaccine may incorporate antigens from different developmental stages of the 
parasite. With the advent of new technologies in vaccine development an effective malaria 
vaccine might not be a distant dream now. 
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1.1 PLASMODIUM. 
Plasmodium, the causative agent of malaria, belongs to the order coccidia a member of the 
Protista animal kingdom and Apicomplexa phylum . The family of Plasmodium is large with 172 
different members infecting various eukaryotic species ranging from mammals, birds and 
reptiles. Only four members are known to infect humans viz; P.falciparum, P.vivax, P.malariae 
and P.ovale. Of these P.falciparum is the most prevalent with high mortality rates. Studies 
involving mouse malaria models, caused by P.yoelii and P.bergeii, helped us to understand 
malaria biology and are essential in development of various vaccines.  
1.2 LIFE CYCLE OF MALARIA. 
The vicious cycle of malaria requires two different species, one involving the host and other a 
vector. 
1.2.1 DEVELOPMENT INSIDE HOST. 
The host cycle is initiated with the blood meal by the infectious female Anopheles mosquito. 
During the meal the mosquito injects the sporozoites, contained in its salivary gland, into the 
subcutaneous tissue of the host. Recent studies has shown that not all sporozoites inoculated 
enters the bloodstream, some of them migrate into the draining lymph nodes (Chakravarty et al., 
2007). The sporozoites are then transiently circulated in the blood before it home to the liver. 
The parasites pass through a number of hepatocytes before it establishes an infection, aided by 
CD81 marker on hepatocytes, and then replicates (Silvie et al., 2003). The whole process takes 
approximately 30 minutes and is known as the pre-erythrocytic stage. Inside hepatocytes the 
parasite undergoes several cycles of asexual replication to produce exoerythrocytic schizonts, 
each of which contains several thousands of merozoites; this typically takes about 2 to 15 days. 
These exoerythrocytic schizonts ruptures releasing the infectious merozoites which then infects 
the circulating RBC’s initiating the erythrocytic stage. During this stage the ring shaped parasite 
develops in a parasitophorus vacuole into trophozoites. This stage lasts for 48 to 72 hours during 
which the infected RBC’s harboring the merozoites ruptures releasing them which then infect 
more RBC’s. This stage is responsible for the clinical manifestation of the disease. Some 
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merozoites escape and undergo sexual replication forming the male and female gametes. Several 
factors are known to promote gametogenesis. These gametes are taken up by the mosquito 
during the blood meal. 
1.2.2 DEVELOPMENT INSIDE VECTOR. 
Among the different species of mosquitoes only the female sex of the Anopheles genus transmits 
malaria in humans. The vector is not just a repertoire for harboring the male and female gametes 
taken up from the host but its biological variations effects the development and transmission of 
the parasites (Beier, 1998; Chugh et al., 2011). During a blood meal the female mosquito ingests 
the sexual stage of the parasites which then undergoes fertilization to produce a zygote which 
differentiates into motile ookinete. Fertilization occurs in the midgut of the mosquito following 
which the ookinete penetrates through the epithelial cell wall of the midgut to form oocyst. The 
oocyst undergoes meiosis to produce sporozoites which then migrates into the salivary gland. 
These sporozoites are then inoculated into the host during the blood meal. 
1.3 PATHOLOGY AND CLINICAL MANIFESTATION OF MALARIA. 
Pathological symptoms of malaria are associated with the asexual replication of the parasite 
during the erythrocytic stages. The clinical manifestation of the disease is linked to the frequent 
bouts of fever linked to the rupture of erythrocytes and the subsequent release of merozoites. 
Other symptoms includes myalgia, nausea etc and in severe cases leads to seizures, coma, renal 
failure, jaundice etc.  Studies have elucidated the role of toxins and other factors that when 
released during the rupture of erythrocytes results in the activation of pro-inflammatory 
cytokines such as IL-12, IL-1, TNF-α etc. The main culprit is GPI (Glycosyl Phosphatidyl 
Inositol), a glycolipid (Arrighi and Faye, 2010). Evidences suggest that purified GPI from 
parasite is able to stimulate a pro-inflammatory response (Kamena et al., 2008).  
In patients with severe malaria comparatively high levels of parasitemia has been reported 
(Anstey and Price, 2007). This usually leads to an increase in the expression of adhesion 
molecules such as CD36, ICAM-1 etc by vascular endothelial cells which aids the sequestration 
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of infected RBC’s into post capillary venules effecting the oxygen supply (Cserti-Gazdewich et 
al., 2012; Serghides et al., 2003). This leads to organ failure and when the organ involved is the 
brain (cerebral malaria) it leads to coma and eventually death. The main parasitic protein 
involved in this process is called PfEMP-1 (P.falciparum Erythrocyte Membrane protein) (Miller 
et al., 2002). Another complication associated with high parasitemia is the binding of sequestered 
iRBC’s with iRBC’s or uninfected ones to, this is known as rosetting, which often hampers the 
development of immunity against malaria (Vigan-Womas et al., 2008).  
1.4  MALARIA IMMUNOLOGY. 
Immunity to malaria is a slow process and is influenced by factors such as age, area of 
transmission and the frequency of exposure to the parasite. So naturally acquired immunity 
against malaria occurs in only malaria endemic areas and in older generation through continuous 
exposure. However such immunity is known to wane faster and in most cases is unable to 
prevent disease severity (Doolan et al., 2009; Greenwood, 1999). There is a fine line between 
immunity and immunopathology in malaria. The presentation of large repertoire of antigens 
further confuses the immune system in mounting an appropriate response (Fig 1). An important 
question which continues to baffle malaria immunologists is the requirement of a chronic 
infection in order to maintain natural immunity. Even though studies have shown the importance 
of both innate and adaptive responses, we are yet to define the correlates of protection in 
controlling malaria.  
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Figure 1: Immunology of malaria. A schematic representation of immune responses directed 
during various stages of parasite invasion (Riley and Stewart, 2013). 
1.4.1 INNATE RESPONSES IN MALARIA. 
Innate immune responses are carried out by a variety of cells including macrophages, monocytes, 
NK cells, granulocytes etc and generally acts as the first line of defense. They are also essential 
in shaping up the adaptive response via presentation of antigens and production of cytokines. An 
early innate response involving type I IFN response is essential in nipping the infection at the 
pre-erythrocytic stage (Arnold et al., 2010; Nussler et al., 1991; Shio et al., 2010). Like many 
parasitic diseases, TLR´s play a significant role in driving the immune response during malaria. 
Role of TLR´s are controversial due to its pros and cons during the infection (Coban et al., 2007; 
Franklin et al., 2011). 
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Macrophages, the sentinels of the innate immune response, have tremendous parasiticidal 
activity which involves direct and indirect actions. Several studies has emphasized the direct role 
of macrophages by phagocytosing iRBC´s which reduces the initial parasitemia by complement 
system (Silver et al., 2010) or ADCI (Langhorne et al., 2008). Additionally, recent studies have 
also shown macrophage dependent secretion of cytokines and reactive oxygen species aids not 
only in controlling the initial parasitemia but also helps to shape long term memory immune 
response. However recent studies have shown that like in Leishmaniasis, the sporozoite has also 
evolved mechanisms to impair the functions of macrophages. Excessive activation of 
macrophages results cytokine storm which does more harm than protection (Perkins et al., 2011). 
The abnormalities in iRBC´s results in rapid phagocytosis by the macrophages of both iRBC´s 
and the uninfected ones leading to severe anemia (SMA) (Kai and Roberts, 2008).  
Thus the role played by macrophages in malaria is indispensable and a fine line exists between 
its role in protection or pathology. 
1.4.2 ADAPTIVE RESPONSE IN MALARIA. 
Development of adaptive response against malaria via natural infection is a slow process and the 
major mediators involved are the antibodies and members of cell mediated immune system.   
1.4.2.1  Humoral responses. 
The role antibodies play in malaria is quite indispensable considering the fact that they are one of 
the early mediators of protection in malaria. Seminal studies based on transfer of purified 
antibodies from immune donors to naïve individuals have shown the role played by antibodies in 
building malaria immunity (Ak et al., 1993; Cohen et al., 1961). The humoral response to 
different antigens during each stage of parasite development whether within host or vector is 
known to provide protection. During the pre-erythrocytic stages antibody developed against 
circumsporozoite protein (CSP) (Tapchaisri et al., 1985) and sporozoite surface protein (SSP-2) 
(Rogers et al., 1992) prevents infection. In the next stage i.e. erythrocytic level, the iRBC´s 
express on its surface variety of highly polymorphic parasitic protein known as VSA (Variant 
Surface Antigens). Antibodies against VSA´s are known to protect individuals from severe 
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malaria (Chan et al., 2012). Additionally, antibodies against Pfemp-1 protein of malaria are also 
known to reduce the incidence of the disease especially in people residing in malaria endemic 
areas. Vaccines based on MSP-1 (Merozoite Surface Protein) capable of inducing antibodies are 
also gaining importance due to its effectiveness in reducing parasitemia. Another class of 
antibodies targeting the sexual stages of parasite, acting as a transmission blocking agents, are 
also of critical importance (Carter and Mendis, 1991). However not in all cases seropositivity 
against malaria antigens results in lifelong antibody titers. This could be explained by the 
defective development of B-cells (Dorfman et al., 2005). 
Quality of the antibodies influences the outcome of the disease. Enhanced levels of cytophilic 
antibodies such as IgG1 and IgG3 have been reported in providing protection against malaria 
(Duah et al., 2010; Elliott et al., 2005). Antibodies produced against various surface antigens of 
merozoites were able to activate monocytes via FcRγII to release TNF and other mediators 
eliminating the infected erythrocytes in process known as antibody dependent cell mediated 
inhibition (ADCI) (Jafarshad et al., 2007). Antibodies are also known to neutralize the infection 
of RBC´s by merozoites (Williams et al., 2012). The role played by IgE antibodies in malaria is 
confounding due to reports which suggest its role in protection (Bereczky et al., 2004) as well as 
pathology (Perlmann et al., 1997).  
An insight into the development of humoral response in malaria and the potential antigens could 
open up whole new aspects in our understanding of malaria and develop effective vaccines. 
1.4.2.2  Cell mediated immune response. 
In a seminal study the importance of cell mediated response in controlling malaria was first 
proven in animals that were thymectomized, making them more susceptible to infection (Brown 
et al., 1968). Protection in T-cells depleted animals by adoptive transfer of different antigen 
specific CD4
+
 and CD8
+
 T-cells further bolstered the importance of CMI in controlling malaria 
(Chakravarty et al., 2008; Stephens et al., 2005; Stephens and Langhorne, 2010). 
 
INTRODUCTION  
 
10  
 
CD8
+
 T-cells:  
Studies from animals vaccinated with multiple doses of γ-irradiated sporozoites, the only vaccine 
which induced sterile protection in animals, is mainly mediated by IFN-γ secreting CD8+ T-cells 
(Malik et al., 1991). Evidence for the role of HLA Class I mediated CD8
+
 protection against 
severe malaria was shown in children carrying the HLA-B53 MHC I allele in Gambia (Hill et al., 
1992). Though most of our understanding about the role of CD8
+
 cells in malaria was restricted 
to the pre-erythrocytic stage, recent advances have made it possible to evaluate the responses in 
the liver stage as well. Studies have illustrated that an effective CD8
+
 response is influenced by 
IL-12 dependent production of IFN-γ, TNF-α and NO (Stevenson et al., 1995). CD8+ responses 
known to provide protection during the pre-erythrocytic and liver stages, cannot mediate 
protection during the blood stages. Studies based on CD8 transfer and in ß2 microglobulin 
deficient mice demonstrated that CD8 T-cells are not effective against the blood stages (van der 
Heyde et al., 1993). Initial studies considered liver to be the homing organ for anti-malaria CD8
+ 
T-cells, however in a pioneering work carried out by Zavala and colleagues showed that in fact 
the skin draining lymph nodes are the primary sites for the induction of CD8
+
 T-cells against the 
liver stages (Chakravarty et al., 2007). Therefore in order to design effective CD8 T-cell based 
vaccine against malaria an important point to be considered is the skin immunity.  
CD4
+
 T-cells: 
Accumulating evidence supports the role of CD4
+
 T-cell response in regulating parasitemia or 
elimination of parasites (Meding and Langhorne, 1991; Shibui et al., 2009). Other than the direct 
effector function these cells are also important in the maintenance and survival of malaria 
specific CD8
+ 
T-cells (Overstreet et al., 2011). Even the most advanced malaria vaccine, 
RTS,S/AS01E a protein in adjuvant vaccine, mediates protection via memory CD4
+
 T-cells 
secreting IFN-γ and TNF-α (Lumsden et al., 2011). In addition, effector CD4+ T-cells producing 
IL-10 via IL-27 dependent path is known to protect from the severe immunopathology associated 
with malaria (Freitas do Rosario et al., 2012). Furthermore in malaria endemic areas FOXP3
-
CD45RO
+
CD4
+
 T-cells were linked to reduced pathological condition seen in severe malaria 
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(Walther et al., 2009). These cells were in fact independent of TCR stimulation but rather 
dependent on cytokines such as IL-10, TGF-ß and IL-2 (Scholzen et al., 2009).  
Thus a strong balanced CMI response along with a quality humoral response is required to 
mount an effective strike against parasite. Therefore this concept should always pave the way 
while developing effective vaccines.    
1.5 MALARIA VACCINES. 
Vaccines are an essential tool in the armory for a fight against malaria. Considering the evolution 
of insecticide and drug resistance parasites, development of an effective vaccine is imperative. 
Development of a cost-effective vaccine is obscured because of the confounding ability of the 
parasite to manipulate the host immune system. In spite of the wide array of the antigens 
available, which are expressed by the parasite at various stages in its life cycle, pointing down a 
specific antigen has been quite intricate. Depending on the life cycle of the parasite, vaccines 
developed can be classified under three classes (Fig 2); viz (1). Pre-erythrocytic Vaccines (2). 
Erythrocytic Vaccines and (3). Transmission Blocking Vaccines. Since the most ideal vaccine 
should be the one that prevents the onset of clinical symptoms, we will be discussing more about 
the pre-erythrocytic vaccines. 
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Figure 2: Types of malaria vaccines. Classification of malaria vaccines based on its action at 
different stages (Adapted from Malaria Path Initiative website). 
1.5.1 PRE-ERYTHROCYTIC VACCINE. 
Pre-erythrocytic vaccines involve antigens expressed right from sporozoite inoculation till the 
liver stage development. Therefore these vaccines prevent the occurrence of the disease. 
However an important drawback with this vaccine is that the window to mount an attack against 
the sporozoite is very short before it homes to the liver. In addition it has to overcome the 
problems associated with the polymorphic nature of T-cell epitopes. Even though the main 
protagonists during this stage are the antibodies, CD8
+
 T-cells are also known to play a 
significant role during the liver stage. Liver being an immuno-tolerant organ, generating 
appropriate responses is a big hurdle. However there are overwhelmingly adequate data which 
supports the development of IFN-γ and TNF-α secreting CD8+ T-cell in liver, especially in the γ-
irradiated sporozoite vaccine model (Epstein et al., 2011). Activation of macrophages, by the 
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IFN-γ secreted by CD8+ T-cell, helps in phagocytosis and also increases NO within hepatocytes 
(Seguin et al., 1994).  
RTS,S vaccine, the current advanced vaccine against malaria, is a pre-erythrocytic vaccine. This 
vaccine comprises the CS protein fused with HbSAg in excess of HbSAg to form VLP´s (Stoute 
et al., 1997). Main mediators of protection in this model are CD4
+
 T-cells in addition to 
antibodies (Lumsden et al., 2011). Even the golden model for malaria vaccines, γ-irradiated 
sporozoites, also promotes the development of intra-hepatic CD8
+
 T-cells. The latest data from 
RTS,S phase III clinical trials shows an overall efficacy of 16.8% in children after 4 years (Olotu 
et al., 2013). The dismal performance of the vaccine can be attributed to the waning immunity 
especially the antibody titers of CS with time. Therefore better pre-erythrocytic vaccines could 
prove beneficial in controlling malaria.  
1.5.1.1  Circumsporozoite protein: - A potent pre-erythrocytic antigen. 
Most of the pre-erythrocytic stage vaccines target the proteins that are expressed on the surface 
of the sporozoite. The most valued antigens that are targeted during this stage are the CS protein 
and TRAP protein. However a vaccine based on CS protein was found to be more promising and 
has successfully entered the phase III clinical trials in the form of RTS,S.   
CS protein is a major monomeric protein found on the surface of the sporozoites. The importance 
of CS protein as a major vaccine candidate was first reported by Nussenzweig and colleagues 
(Nussenzweig and Nussenzweig, 1985). Most of the protection in γ-irradiated and genetically 
attenuated sporozoite vaccine model was mediated by CS specific humoral and CMI responses 
(Kumar et al., 2009). The protein maintains similar structural, biochemical and immunological 
properties across different species of Plasmodium. The central domain of all Plasmodium species 
contains a repeat region which contains immunodominant repeat regions of B and T-cell epitopes 
(Lal et al., 1987). This region is usually flanked by conserved region I at the N-end and region III 
and region II+ at the C-end. Binding of sporozoites to the GAG chains of HSPG of hepatocytes 
is mediated by the region II of CS protein (Pinzon-Ortiz et al., 2001). Native CS has rod like 
structure which in anchored to the surface of the sporozoites by a GPI motif found at the C 
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terminal region (Plassmeyer et al., 2009). In a seminal study it was shown that CS binds to the 
ribosomes disrupting protein synthesis in infected hepatocytes (Frevert et al., 1998). CS protein 
also aids in the survival of sporozoites in hepatocytes by blocking the translocation of p65 into 
the nucleus thereby blocking the NFkB pathway. In addition it also promotes the expression of 
various genes vital in the metabolic process to allow the parasite to thrive inside the infected 
cells (Singh et al., 2007). Inspite of certain disadvantages vaccines based on CS protein are 
continuingly making progress.   
1.5.2 ERYTHROCYTIC VACCINE. 
Vaccines designed against this stage targets the blood stage antigens. Immune response 
generated at his stage can only reduce the intensity of the disease by reducing the parasitemia. 
Antigens expressed at this stage undergo rapid mutations and are highly polymorphic to 
overcome the pressure from the immune responses. Due to the lack of MHC I molecules on 
RBC´s an ideal erythrocytic vaccine candidate must induce high titer, high avidity antibodies. 
These antibodies, mainly directed against merozoites, prevent merozoites from infecting new 
RBC. However reports of malaria specific T-cell responses during this stage are also reported. 
This is mainly due the cross presentation of the antigens by professional APC (Miyakoda et al., 
2008). In fact IFN-γ secreting CD8+ T-cells against blood stage antigens were reported in 
patients in malaria endemic areas (Sinigaglia et al., 1985). 
MSP is the most widely studied blood stage protein. Abundance of this immunogenic protein on 
the surface of the merozoites makes it an ideal candidate for vaccine development. Clinical trials 
based on this antigen have progressed to phase II (Schwartz et al., 2012). MSP19, a cleavage 
product of proteolysis, is highly conserved and is the main vaccine candidate. Rapid sero-
conversion associated with this vaccine results in high titer antibodies capable of neutralizing 
merozoites (Hirunpetcharat et al., 1997). Sera transfer from vaccinated mice to 
immunocompromised mice did not result in protection even though a delay in parasitemia was 
observed suggesting that other factors also play an important role in this vaccine model. Some of 
the other blood stage vaccine candidates include AMA-1, PfEMP-1, RESA etc.  
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Thus a blood stage vaccine can ameliorate the symptoms associated with malaria the individual 
still remains susceptible to infection. Therefore sterile protection with these vaccines is not 
possible which is reflected by reduced number of candidates entering clinical trials. 
1.5.3 TRANSMISSION BLOCKING VACCINES. 
Vaccines belonging to this category mainly target the sexual stage antigens of the parasite. The 
main goal with this vaccine is to reduce the disease morbidity in an area by preventing the 
development of the parasite in the vector thereby preventing new infections. Mostly antibody 
mediates this kind of protection wherein during a blood meal the antibodies taken up by the 
vector hampers with the proper development of the gametocytes in the vector (Carter, 2001). 
Although various vaccine candidates have been tested such as PfS25, PfS28, PfS230 etc, only 
PfS25 has gone to clinical trials (Wu et al., 2008).  
1.6 VACCINE DESIGN STRATEGIES. 
Traditional vaccines were mostly live or attenuated organism which provided long term sterile 
immunity and therefore was effective in eliminating many diseases. However dependence of 
traditional means of preparing vaccines especially one involving live/attenuated organisms is not 
much popular today because of the ability of the pathogen to revert back to its virulent state. 
With mankind facing life threatening diseases, development of improved vaccines with minimal 
side effects has become a necessity.  
1.6.1 DNA VACCINE. 
A DNA vaccine is one of the new generation vaccines wherein a plasmid of bacterial DNA 
encoding the desired antigen under a strong mammalian promoter is inoculated into the 
individual. The presence of bacterial backbone containing appropriate selection gene makes it 
easy for the large scale production. The strong CMI response associated with DNA vaccines 
makes it a very viable technology for producing effective vaccines (Davis et al., 1995). The 
discovery of DNA vaccines was quite a surprise for the scientific community considering that for 
direct transfection of cells would be impossible. However studies show that the naked DNA is 
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rapidly taken up by the muscle tissues which is then expressed and presented in context of MHC 
I (Ulmer et al., 1993). Endogenously synthesized proteins can be then cross-presented by 
professional antigen presenting cells. This could explain why DNA based vaccines induce strong 
CTL responses. Overwhelmingly abundant data signifying the viability of DNA based approach 
in designing vaccines for influenza (Kim and Jacob, 2009), tuberculosis (Hanif et al., 2010), 
leishmaniasis (Masih et al., 2011), malaria (Hoffman et al., 1997b) etc has been reported.  
Inspite of being a good vector for expression of foreign gene, there are potential risks and 
disadvantages associated with DNA vaccines. They have recently come under renewed scrutiny 
for a number safety factors such as integration of the DNA into host gene (Wang et al., 2004) 
and also by their induction of tolerance against the antigen (Mor et al., 1996). When compared 
with conventional vaccines, DNA vaccines are poor inducers of antibodies (Gramzinski et al., 
1998; Polack et al., 2013). A potential risk that could be linked with DNA vaccines are the 
induction of inflammatory cytokines due to the bacterial DNA backbone of the plasmid 
construct. Even though such an induction of cytokines can have an adjuvant like effect, too much 
production can lead to chronic inflammation. 
1.6.2 SUBUNIT VACCINE. 
Family of these vaccines is not limited to the native recombinant proteins but also incorporates 
short peptides. Modern technology has facilitated the production of recombinant proteins from 
various expression systems which closely resemble the native proteins (Hansson et al., 2000). 
These vaccines mostly drive the humoral immune responses against the antigen. However the 
inclusion of adjuvants aids in skew the Th2 response towards a Th1 response. An advantage with 
these vaccines is the maintenance of conformational stability of the immunodominant epitopes.  
Subunit vaccines based on peptides are currently being evaluated for their efficacy against 
malaria (Mahajan et al., 2010), cancer (Naz and Dabir, 2007) and other diseases. Synthesis of 
peptides also rules out the potential contamination associated with purification from heterologus 
systems. Since the peptide vaccine basically involves inoculation with immunodominant B-cell 
and T-cell, it prevents unnecessary responses directed against other non-protective epitopes 
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(Crowe et al., 2006). For the peptides it becomes essential to couple them with a carrier protein. 
One such malaria vaccine was based on the coupling of the central repeat domain of 
P.falciparum CS protein to the tetanus toxoid (Herrington et al., 1987). However to overcome 
the dependence on tetanus toxoid Tam and colleagues designed a multiple antigen peptide, in 
which different branches of the repeat region were synthesized on a polylysine core to form a 
macromolecular structure (Nardin et al., 1995). In another study a MAP was synthesized by 
incorporating antigens from different stages of the parasite cycle which generated responses 
directed against different stages of parasite development (Mahajan et al., 2010).    
So despite the ease with which subunit vaccines can be produced most of them require an 
adjuvant to obtain a strong response.      
1.6.2.1 Adjuvants. 
Subunit vaccines are poorly immunogenic and therefore require additional components to 
improve its immunogenicity. These components, known as adjuvants, help to create a favorable 
niche for the antigen processing and presentation. This can be by enhancing the innate responses 
which in turn primes an effective adaptive response (McKee et al., 2007; Yuki and Kiyono, 
2003). Majority of the adjuvants target the pattern recognition receptors (PRR) for instigating an 
effective response. One of the earliest adjuvant developed was the Freunds adjuvant, which 
contained heat killed mycobacteria, signaling via NLR, inflammasome and TLR´s (Freund and 
Bonanto, 1946). Depending on the adjuvants used, it is possible to skew the response from Th2 
to Th1 or the induction of CD8
+
 T-cells instead of CD4
+
 T-cells and vice-versa (Carson and Raz, 
1997; Cribbs et al., 2003; Morrow et al., 2010). They can also influence humoral responses by 
effecting the isotype (Gomez et al., 1998), quantity (Gavin et al., 2006) and avidity (Khurana et 
al., 2010) of the antibodies produced against the antigen. 
Though the number of adjuvants being developed has increased considerably over the last 
decade, the number of licensed ones for human uses is very limited. In fact the only licensed 
adjuvant for human purpose is Alum. Despite considerable advances made in immunology 
development of an effective adjuvant with minimal side effects is still an area of active research. 
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One of the main reasons for the slow incorporation of new adjuvants with licensed vaccines is 
the fear of aggravating the inflammatory responses leading to auto immune disorders (Zandman-
Goddard and Shoenfeld, 2005). A recent study about ASO3, a proprietary adjuvant from Glaxo, 
was reported to increase the incidence of childhood narcolepsy (Nohynek et al., 2012). A variant 
of this adjuvant, ASO1, is currently used for the RTS,S malaria vaccine.     
1.6.3 POXVIRAL VECTORS. 
Since the elimination of smallpox by vaccinia virus, use of poxvirus as effective delivery vehicle 
for heterologus antigens has gained increased popularity. Ability of vector to accommodate large 
foreign gene combined with the low cost and ease of production makes it an ideal vaccine vector 
candidate (Pastoret and Vanderplasschen, 2003). Furthermore an effective long lasting humoral 
and CMI against the heterologus antigen could be developed with these vectors (Smith et al., 
1983). Attempts to further enhance the immunogenicity of these vectors gave rise to highly 
attenuated strains of vaccinia such as Modified Virus Ankara (MVA) and NYVAC. Moreover 
deletion of immunomodulatory genes from these attenuated strains, such as C6L (Garcia-Arriaza 
et al., 2011), F1L (Perdiguero et al., 2012) resulted in the production of better vaccine 
candidates. Earlier studies from our lab also show the importance of the vectors to stimulate 
mucosal immune cells making them an ideal tool in the fight against diseases which infects via 
mucosal routes (Gherardi and Esteban, 2005; Gherardi et al., 2003).     
An alternative approach to further enhance the immune responses is the prime-boost strategy 
(Dunachie and Hill, 2003; Ramshaw and Ramsay, 2000). Priming agents such as recombinant 
DNA, protein, VLP´s, adenoviruses etc when combined with poxvirus are known to induce long 
lasting immune response (Gomez et al., 2012; Rodriguez et al., 2012; Sanchez-Sampedro et al., 
2012). The antigen specific memory CD8
+
 T-cells induced by this approach exhibits an effector 
phenotype and are highly polyfunctional for IFN-γ, TNF-α and IL-2 (Sanchez-Sampedro et al., 
2012). Since an effective malaria vaccine should produce high levels of CD8
+
 T-cells, prime-
boost approach is an effective measure for fighting malaria (Li et al., 1993; Schmidt et al., 2010). 
In fact many clinical trials based on poxvirus prime-boost in combination with different agents 
are reported (Table 1).  
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A27 (14K) Vaccinia Protein:  
Poxviruses are known to contain many genes that encode for immunogenic proteins such as 
A27L, A4L, A33, H3L, B5, L1 and many more (Davies et al., 2005; Xiao et al., 2007). Poxvirus 
antigens have also being used as a strategy to enhance the immunogenic characteristics of other 
antigens when expressed from viral vectors (Rodriguez et al., 1991). In fact our laboratory has 
shown that HIV envelope protein fused at the C-terminus with 14K (A27L) or 39K (A4L) 
protein of vaccinia virus enhanced the immunogenicity of Env, when expressed from the virus 
vector and inoculated in mice by homologous prime/boost approach, as indicated by an increase 
in broadly reactive antibodies and CD8
+
 T-cell responses to Env (Collado et al., 2000).  
Previous study from our lab has shown the structural organization 14K protein (Vazquez et al., 
1998). 14K protein comprises of a structure less region from amino acids 1 to 28 responsible for 
producing neutralizing antibodies, a helical region from residues 29 to 37, a triple coiled-coil 
helical region from residues 44 to 72, and a Leu zipper motif at the C terminus. Recently it was 
reported that amino acid region between 21-32 is responsible for the binding of 14K protein to 
the heparin sulfates on the cell surfaces, which in turn is aided by the coiled-coil region (Ho et 
al., 2005).    
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Table 1: Prime-boost regimen for malaria vaccine in clinical trials. 
 
Priming Agent 
 
Boosting Agent 
Immune responses 
CD4
+ 
CD8
+ 
IgG 
 
AdCh63_ME-TRAP 
 
MVA_ME-TRAP
(Reyes-Sandoval 
et al., 2010) 
 
- 
 
+++ 
 
- 
 
FP9-CS 
 
MVA-CS
(Imoukhuede et al., 2006) 
 
+++ 
 
++ 
 
- 
 
DNA-CS 
 
MVA-CS
(Schneider et al., 1998) 
 
- 
 
++ 
 
- 
 
RTS,S/ASO2 
 
MVA-CS
(Dunachie et al., 2006) 
 
- 
 
+ 
 
+ 
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Development of an efficient vaccine against malaria is a long sought goal of vaccinologist. 
Decades of research has finally yielded a vaccine, RTS,S in combination with a powerful 
adjuvant ASO1E. However, with 50% protection and that too limited for 6 months in children, 
and with 16.8% after 4 years, this vaccine is far away from being a successful one. With reports 
suggesting the side effects of adjuvant, the negative factors outweigh its benefits.  
The molecular complexity of an antigen is known to influence its immunogenicity. Large 
oligomeric antigens are more efficient in mounting an effective immune response compared to 
its monomeric counter parts (Kovacs et al., 2012; Qian et al., 2012). Hence, based on this 
principle the main objective of this work was to improve the immunogenicity of CS protein 
based on this principle. 
AIMS OF CURRENT STUDY. 
 Develop a novel way to enhance the immunogenicity of CS protein of Plasmodium by 
fusing it with the oligomeric A27 (14KDa) vaccinia virus protein (referred to as CS-
14K). 
 Expression and purification of the fusion protein CS-14K from E.coli. 
 Physical and biochemical properties of CS-14K. 
 Characterization of innate properties of CS-14K protein in cell-cultures. 
 Evaluate the immunological properties (adaptive and memory responses) of CS-14K in 
mice based on a prime-boost strategy with poxvirus vector MVA expressing CS. 
 Analyze the efficacy of CS-14K in protecting mice from malaria. 
 Define immune correlates of protection. 
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3.1 CELL LINES. 
 In this study the following cell lines were utilized: 
DF-1 (ATCC: CRL-12203) 
 DF-1 is an immortalized chicken embryo fibroblast cell line. This adherent cell line is 
mainly used in the propagation of virus. They are grown in Dulbecco´s Modified Eagle Medium 
supplemented with 2mM of L-Glutamine, 100 μg/ml of streptomycin, 100 IU/ml of penicillin 
and 10% of heat inactivated fetal calf serum. The cells are maintained at 39ºC with 5% CO2 and 
95% humidity. The medium is changed two times a week and are passaged with trypsin EDTA 
following which they are subcultivated at 1:5 ratio.  
J774 (ATCC: TIB 67) 
 Mouse macrophage cell line (Balb/C). These adherent cell line exhibit antibody 
dependent phagocytosis and synthesize large amounts of lysozyme. The cells were maintained in 
RPMI1640 medium contained L-Glutamine supplemented with 100 μg/ml of streptomycin, 100 
IU/ml of penicillin, 50μM β-mercaptoethanol and 10% of heat inactivated fetal calf serum. The 
cells are maintained at 37ºC with 5% CO2 and 95% humidity. The cells are dislodged using cell 
scrapper during passages and are subcultivated at a ratio of 1:6. 
THP-1 (ATCC: TIB 202) 
 It is a human monocyte cell line isolated from the peripheral blood from a patient 
suffering from acute monocytic leukemia. They are grown in suspension and maintained in 
RPMI 1640 medium containing L-Glutamine supplemented with 100 μg/ml of streptomycin, 100 
IU/ml of penicillin, 50μM β-mercaptoethanol and 10% of heat inactivated fetal calf serum. To 
differentiate into macrophages, cells were treated with 0.5mM PMA (Sigma Aldrich, Spain) 
overnight.  
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3.2 GENERATION OF RECOMBINANT VIRUS. 
3.2.1 CONSTRUCTION OF VIRUS. 
Construction of recombinant MVA virus expressing circumsporozoite protein of P.yoelii 17XNL 
strain (MVA-CS) has been describe previously (Gonzalez-Aseguinolaza et al., 2003). Briefly the 
gene encoding the entire CS protein of P.yoelii was isolated from the plasmid, pBS-PY1993, and 
cloned into the vaccinia insertion vector pJR101, which contains the p7.5 promoter for CS 
expression and the flanking regions for the HA locus of MVA. The recombinant virus was 
generated by homologous recombination in DF-1 cells. After several rounds selection based on 
the expression of B-galactosidase expression the stable recombinant virus was selected.  
3.2.2 PURIFICATION OF VIRUS. 
Twenty confluent P150 plates of chicken embryo fibroblast, from 11 day old embryonated SPF 
eggs (Intervet, Spain), was infected with 0.01 PFU/cell of recombinant virus in 5ml of serum free 
DMEM medium. Following incubation for 1 hour at 37ºC with 5% CO2 the inoculum was 
removed by aspiration and fresh DMEM medium with 2% FCS was added for 72 hours. After 
incubation the cells were centrifuged down and washed once with PBS and resuspended in 20 ml 
of 10 mM Tris-HCl pH9.0. Cells were lysed using sonication (Misonix Sonicator 3000). The 
sonicated lysate was layered onto 45% sucrose solution and centrifuged in a Beckman SW-28 
rotor. The viral pellet was resuspended in 10 mM Tris-HCl pH 9.0 in desired volume. 
3.3 GENERATION OF RECOMBINANT PLASMIDS. 
pCI-Neo-CS. The PyCSP gene was amplified MVA-CS using the primers CS-XhoI-F (5´-
ACTTACTCGAGATGTGTTACAATGAAGAAAATG-3´) and CS-NotI-R (5´-
ATTGCGGCCGCTTTAAAATATACTTGAAC-3´) to yield a 972 bp fragment lacking the N-
terminal signal sequence and C-terminal GPI sequence. The gene was inserted into a mammalian 
expression vector, pCI-Neo, that had been previously digested with XhoI and NotI followed by 
SAP treatment (Shrimp Alkaline Phosphatase). The CS gene in both the virus and plasmid were 
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sequenced (Secugen; Spain). The plasmid was purified using Qiagen Mega Prep Kit according to 
manufacturer’s protocol. Expression of CS from pCI-Neo-CS was confirmed by transfecting DF-
1 cells followed by western blot analysis with CS specific antibodies. 
pGEX-CS / pGEX-CS-14K. The CS gene from pCI-Neo-CS plasmid was amplified using the 
primers CS-EcorI-F (5´-ACTTAGAATTCATGTGTTACAATGAAGAAAATG-3´), CS-NotI-R 
(5´-ATTGCGGCCGCTTTAAAATATACTTGAAC-3´) for pGEX-CS and with primers CS-
EcorI-F and CS-14K-NotI-R (5´-ATTGCGGCCGCTATTAAATATACTTGAAC-3´) for pGEX-
CS-14K. The A27L ORF from Vaccinia strain WR (Accession number- YP_233032, 
www.ncbi.nlm.nih.gov/genbank/) was amplified with the primers A27L-NotI-F (5´-
GCTGCTAGCGGCCGCGAGGCTAAACGCGAAG-3´) and A27L-XhoI-R (5´-
CCCTCGAGTGGGTTACTCATATGGACG-3´) to generate a 276 bp fragment which lacks the 
first 28 amino acids from the original sequence. The chimeric gene fragment was generated by 
digesting with Not I followed by ligation. The fusion gene fragment was then inserted into 
pGEX-6p-1 plasmid to produce pGEX-CS-14K plasmid.  
The recombinant plasmid was transformed into DH5α E.coli. The positive clone was selected 
and purified using Megaprep Kit (Qiagen). 
3.4 RECOMBINANT PROTEIN PURIFICATION. 
The recombinant proteins were purified from E.coli strain DH5-α. The starter culture was diluted 
1:100 in fresh LB media and allowed to grow at 37ºC till the OD600 reached 0.7, following which 
IPTG was added to a final concentration of 1 mM. The culture was then incubated in an orbital 
shaker at 18ºC and 200 rpm for 24 h. After the incubation the cells were harvested and the pellet 
was suspended in extraction buffer (50 mM Tris-HCl pH 7.5, 250 mM NaCl, 1 mM EDTA and 
protease inhibitor tablets ROCHE). The cells were then lysed with lysozyme, added to a final 
concentration of 1mg/ml and incubated on ice for 20 min. Following lysozyme treatment 1% 
sarkosyl detergent and 1% triton X-100 was added and incubated at 37ºC for 10 min. Clarified 
supernatant from the lysis was incubated with Glutathione Sepharose 4B beads at 4ºC overnight. 
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The beads were then washed using three washes with wash buffer I (Extraction buffer with 0.5% 
Triton X-114) and three with wash buffer II (Extraction buffer with 0.1% Triton X-114) 
followed by two washes with extraction buffer. The purified protein was then eluted with 20mM 
reduced glutathione. The protein was desalted using Amicon centrifugal concentrator and the 
protein concentration was determined using Bradford reagent. The GST tag from the protein was 
cleaved using preScission protease according to manufacturer’s protocol (GE Healthcare). The 
proteins were tested for LPS contamination using chromogenic Limulus Amebocyte Lysate kit 
(QCL-1000, Lonza) which was maintained below 2 EU per microgram of protein. 
3.5 NEUTRALIZATION ASSAY. 
Sera from immunized rabbit were inactivated at 56ºC for 30 min, following which two fold serial 
dilutions of the serum were made and incubated with 200 PFU of MVA at 37ºC for 1 h. 
Afterwards, confluent DF-1 cells were infected in triplicate and were visualized by 
immunostaining with anti-WR serum after 48 h. As a control, non-immune serum from non 
immunized animal was used. The number of plaques obtained from each serum dilution was 
normalized to this control value.  
3.6 NITRITE MEASUREMENT. 
NO synthesis was measured by estimating the levels of nitrite present in the supernatant. Briefly, 
J774 cells were stimulated with proteins. For in vivo nitrite analysis, 10
6
 splenocytes from 
vaccinated animals, sacrificed after 53 days post boost was treated with 5 µg/ml of CS protein. 
Nitrite accumulation was measured by treating 50 μl of supernatant with 50 μl of Griess reagent I 
(1% sulfanilamide solution in 2.4 N HCl) for 10 min in dark followed by the addition of 50 μl of 
Griess reagent II (0.1% naphthylethlyenediamine in 2.4 N HCl) for 10 min. The assay was read 
by a spectrophotometer at 540 nm. 
          MATERIALS & METHODS 
 
 31 
 
3.7 RNA EXTRACTION AND RT-PCR. 
Total RNA was extracted from cells treated with respective proteins for 24 h, using RNeasy mini 
Kit according to manufacturer´s instructions. Analysis of RNA was carried out using RT-PCR as 
described in the kit for reverse transcriptase (Invitrogen). Briefly, 1 μg of RNA was reverse 
transcribed into cDNA using oligo dT primers (Invitrogen). For relative quantitative PCR, 2 μl of 
cDNA was used as a template with primers specific for iNOS, IL-12p40 and GAPDH (Maffei et 
al., 2004). All the experiments were done in triplicates and the bands from gel electrophoresis 
were quantified using Adobe Photoshop CS4. 
3.8 CONFOCAL MICROSCOPY. 
Immunostaining was carried out as described previously (Guerra et al., 2003). Briefly, after 
fixation (30 min; 4% formaldehyde in PBS; 37ºC), permeabilisation in 0.1% Triton X-100 
(Sigma) and blocking with 10% FCS in PBS, cells were incubated with primary antibody (anti 
CS antibody 1:500; C3-anti14K 1:400; NF-κBp65 1:500) along with DNA staining dye, DAPI 
(1:200) for 1hour at room temperature. Following extensive washing with PBS secondary 
antibodies (Alexa 546 goat antimouse and Alexa 488 goat antirabbit; 1:500) were applied for 1 
hour at room temperature. The slides were washed three times with PBS and mounted in Prolong 
Antifade medium and analyzed with Bio-Rad Radiance 2100 confocal laser microscope. 
3.9 ANIMALS AND IMMUNIZATION. 
All animal procedures were approved by the Ethical Committee of Animal Experimentation 
(CEEA-CNB) of Centro Nacional de Biotecnologia (CNB-CSIC). Female Balb/C mice (H-2
d
), 
6-8 weeks old, were obtained from Harlan U.K. A standard immunization protocol based on a 
heterologus prime-boost approach designed in the laboratory was followed (Garcia-Arriaza et al., 
2010). In short, animals were primed with DNA (100 µg; DNA-CS or DNA- ) or protein (20 µg; 
CS or CS-14K) via intradermal (i.d) route and were boosted after two weeks with 2 x 10
7
 PFU of 
the respective sucrose-purified viruses (MVA or MVA-CS) through intraperitoneal (i.p) 
injection. All the preparations were made in endotoxin free PBS.  
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3.10 P.YOELII SPOROZOITE CHALLENGE. 
Challenge experiments were performed as previously described (Bruna-Romero et al., 2001). 
Briefly, sporozoites were obtained from the salivary glands of Anopheles stephensi mosquitoes. 
Two weeks post-boost, mice were challenged with 2×10
4 
sporozoites via intravenous route 
through tail vein. After 42 hours, animals were sacrificed and levels of P.yoelii 18s rRNA levels 
were assessed by qRT-PCR. To determine sterile protection two weeks post immunization, mice 
were challenged intravenously with 300 P. yoelii sporozoites. Parasitemia was monitored by 
performing daily blood smears from days 3 to 21. 
3.11 ELISA AND ANTIBODY AVIDITY MEASUREMENT. 
Antibodies present in the serum of immunized animal were determined using ELISA as 
previously described (Garcia-Arriaza et al., 2010). Purified CS protein was coated to the 96 well 
Nunc Maxisorp plates at concentration of 2 μg/ml in coating buffer (NaHCO3 Na2CO3)  at 4ºC 
overnight. Bound antibodies were detected using 1:2000 dilution of alkaline phosphate 
conjugated goat anti mouse antibody total IgG or IgG1 or IgG2a (Southern Biotechnology 
Associated, Birmingham). Plates were developed by adding TMB substrate (3,3’,5,5’ 
Tetramethylbenzidine; Sigma) and stopping the reaction with 1M H2SO4. OD was read at 450 
nm. Endpoint titer values were determined as the last positive dilution of serum giving an 
absorbance value three times higher than naïve serum. For analyzing the avidity of antibodies, an 
initial serum dilution which gave an absorbance of 2.7 ELISA units was selected. Following 
incubation, with serum, the antigen-antibody interaction was disrupted using a range of dilutions 
from 0 to 5 M Urea (Invitrogen) in Tris-HCl pH 8.0 for 15 min before the addition of secondary 
antibody. Effective concentration of urea which reduced the initial value of absorbance by 50% 
(EC50) was then calculated by linear regression (R
2
=0.99) between 1-5 M Urea concentration 
(Log of 50% reduction = 1.699). 
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3.12 IFN-γ ELISPOT ASSAY. 
The vaccine- specific cellular immune response in mice was determined using ELISPOT assay 
measuring the secretion of IFN-γ by splenocytes after stimulation with different peptides pools. 
Briefly, 10
6
 splenocytes were plated in triplicate in 96-well nitrocellulose-bottomed plates 
previously coated with 6 µg/ml of anti-mouse IFN-γ mAb R4-6A2 (Pharmingen, San Diego, 
CA). CS peptide was resuspended in RPMI 1640 supplemented with 10% FCS and added to the 
cells at a final concentration of 1 µg/ml. Plates were incubated at 37°C, 5% CO2 for 48 h, washed 
extensively with PBS containing 0.05% of Tween20 (PBS-T) and incubated 2 h at room 
temperature (RT) with a solution of 2 µg/ml of biotinylated anti-mouse IFN-γ mAb XMG1.2 
(Pharmingen, San Diego, CA) in PBS-T. Afterwards, plates were washed with PBS-T and 100 µl 
of peroxidase-labeled avidin (Sigma, St Louis, Mo) at 1:800 dilution in PBS-T was added to 
each well. After 1 h of incubation at RT, wells were washed with PBS-T and PBS. The spots 
were developed by adding 1 µg/ml of the substrate 3,3′-diaminobenzidine tetrahydrochloride 
(Sigma, St Louis, Mo) in 50 mM Tris-HCl, pH 7.5 containing 0.015% hydrogen peroxide. The 
spots were counted with the aid of a stereomicroscope. The responses were given as the number 
of spot-forming cells per million of splenocytes. In all the cases the background levels were 
subtracted to each specific peptide pool. 
3.13 MULTIPARAMETER FLOW CYTOMETRY. 
Flow cytometry and intra cellular cytokine staining (ICS) analysis were performed to detect the 
different phenotype of lymphocytes secreting cytokines, as reported previously (Garcia-Arriaza 
et al., 2010). Briefly, 4×10
6
 splenocytes were stimulated with 1μg/ml of CD8+ peptide, PyCS280-
288 (SYVPSAEQI), with Golgi Plug (BD Bioscience) for 6 h in a 96 well plate. The cell were 
then washed and Fc receptors were blocked using anti CD-16/CD-32 following which the cells 
were stained with surface specific mouse antibodies namely, CD4 Alexa700, CD3 FITC, CD8 
Percp; for adaptive response studies or CD8 FITC, CD44 PeCy5 and CD62L PE for memory 
studies. Cells were permeabilized using the BD Cytofix/Cytoperm™ Kit (Becton Dickinson) and 
were stained for intracellular cytokines, IFN-γ APC, IL2 PE and TNF-  PeCy7 for adaptive or 
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with IFN-γ PeCy7, IL2 APC and TNF-α Pe for memory. A million cells were then passed 
through a LSRII flow cytometer (Becton Dickinson) and the data was analyzed with FlowJo 
(Tree Star. Inc) and Spice (ver 5.0). Appropriate controls were used and the values from 
unstimulated samples were subtracted. 
3.14 STATISTICAL ANALYSIS. 
Statistical analysis was performed using Minitab for Windows. For ELISA in order to determine 
the differences between groups we performed a linear regression of the logarithmic absorbance 
versus the logarithmic dilution, removing those samples clearly not following a linear trend (R
2
 > 
0.98). Then we computed the logarithmic dilution at which this regression line was crossing the 
threshold given by twice the absorbance of the control values for that mouse. Doing this for the 4 
mice we have 4 estimates of the logarithmic dilution beyond which the absorbance is smaller 
than twice the absorbance given by the control. We will refer to this value as the critical 
logarithmic dilution. Finally, we compared with a Student- T Test the hypothesis that the critical 
logarithmic dilution between the groups. For ICS and ELISPOT, statistical analysis was done 
based on previously described method (Garcia-Arriaza et al., 2010). Briefly, Given the total 
number of cells, , and the number of cells responding to a given antigen, , an estimate of 
the proportion of cells responding to this antigen is given by . The Bayesian a 
posteriori distribution of without any a priori assumption (i.e., assuming that the true 
proportion is uniformly distributed between 0 and 1) is the Beta distribution with parameters 
. Let us call the corresponding probability density function a 
posteriori. Analogously, we can derive the distribution of the proportion of cells responding to 
RPMI, obtaining the distribution . To test whether the antigen response is significantly 
larger than the RPMI response, we computed the probability density function of the variable 
as . The cumulative 
density function of this variable is defined in the usual way . 
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The  percentile of this variable is defined as such that . We computed the 
symmetric 95% confidence interval for the RPMI corrected proportion as . Finally, 
we consider to be significantly larger than if . In such a case, 
gives the 95% symmetric confidence interval for . The average is 
computed as the expected value of (note that this expected value needs not be in the 
middle of the confidence interval, ).Whenever two corrected proportions need to be 
summed, , we convolved their probability density 
functions to obtain the probability density function of the summed proportion, 
, in this way confidence intervals for any 
sum of corrected proportions can be obtained. Antigen responses were not added unless each 
component was significantly larger than the corresponding RPMI. 
In the ELISPOT experiment, three replicates were obtained for each kind of antigen. The average 
response to that antigen was computed using only the corrected proportions significantly larger 
than the corresponding RPMI.
  
RESULTS 
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4.1 CHARACTERIZATION OF RECOMBINANT PROTEINS. 
 
 
 
 
 
 
 
 
4.1.1 EXPRESSION AND PURIFICATION OF RECOMBINANT PROTEINS. 
The CS of plasmodium is a GPI anchored protein thereby making its purification difficult. 
Elimination of GPI motif is beneficial, with some studies supporting its role in improving the 
immunogenicity (Bruna-Romero et al., 2004). Therefore in this study we removed the signal 
peptide and GPI motif of CS in both DNA and protein vaccines with the exception of MVA 
vector which expresses the full length CS protein. 
A schematic representation depicting the construction of various plasmids used for the 
production of recombinant protein is shown in Figure 3. Both CS and CS-14K gene was then 
inserted into pGEX-6P-1 vector for expressing the proteins in E.coli. The proteins were then 
purified according the protocol as mentioned in Materials and Methods. 
Circumsporozoite (CS) is a monomeric surface protein of Plasmodium sporozoite, the 
causative agent of malaria (Nussenzweig and Nussenzweig, 1985). However, the native CS 
from sporozoites is also known to form some aggregates/oligomers which may facilitate the 
binding of CS to hepatocytes (Pinzon-Ortiz et al., 2001). Considering that CS is largely a 
monomer, we hypothesized that higher levels of CS aggregates/oligomers would be required 
to attain improved immunogenicity and protection.   
Based on this hypothesis we decided to fuse CS with an immunogenic protein of vaccinia 
virus, A27 (14K), which facilitates the formation of higher oligomers via its coiled-coil 
domain.  
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Figure 3: Design and construction of plasmid encoding CS-14K. A schematic representation 
of gene encoding the CS protein of P.yoelii and that of 14K of vaccinia virus is shown. For 
generating the CS fragment of chimeric protein, the signal sequence represented by 37 amino 
acids of amino terminal and GPI motif involving the 19 amino acids at the carboxy terminal of 
CS gene was removed by PCR amplification. The C terminal of amplified CS fragment was then 
fused in frame to the N terminal of gene, A27L of vaccinia, lacking the first 28 amino acids. All 
PCR amplifications were carried out using appropriate primers carrying restriction enzyme sites. 
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This fusion construct was then fused in frame with the GST tag present within the pGEX-6P-1 
vector. 
Briefly, DH5-α E.coli strain expressing the recombinant protein was grown at 18ºC for 24 hours 
induced with 1mM IPTG. The cells harvested were then suspended in extraction buffer (50mM 
Tris-HCl; pH 7.5, 250mM NaCl, 1mM EDTA and protease inhibitor cocktail tablets). Lysis was 
carried out with lysozyme (1mg/ml) followed by treatment with 1% Sarkosyl and 1% Triton X-
100. Clarified supernatants were allowed to bind to Glutathione Sepharose 4B beads at 4ºC 
overnight. The beads were then washed and proteins were eluted with 20mM reduced 
Glutathione. Proteins were desalted and concentrated using Amicon centrifugal concentrators. 
GST tag from the proteins were cleaved using PreScission protease. Purified proteins dialyzed 
against PBS were then irradiated and aliquots of 1mg/ml were made and frozen at -20ºC.  
The proteins were analyzed on SDS-PAGE under both reducing and non reducing conditions to 
study the extent of oligomerization. Also the reactivity of the proteins against NYS1, a well 
defined antibody against P.yoelii CS protein was also done. Under reducing conditions CS-14K 
has a molecular mass of ~60 kDa, compared with ~50 kDa for CS, whereas under non-reducing 
conditions CS-14K has a size apparently >250 kDa, in contrast to 50 kDa for CS (Figure 4). 
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Figure 4: Biophysical and biochemical properties of recombinant proteins: Coomassie-Blue 
stained SDS page and immunoblot with monoclonal antibody against CS (NYS1; 1:1000 
dilution) of 1 µg of recombinant (A) CS protein or (B) CS-14K protein, under reduced (R) and 
non reduced (NR) conditions. 
Formation of oligomers/aggregates is not antigen dependent since the fusion of 14K to 
P.falciparum CS protein as well as GP120 of HIV-1 also formed oligomers/aggregates (Figure 5 
A & B). Even the formation of the oligomers is not dependent on the system used for producing 
the chimeric protein. The GP120 fused to the 14K protein was produced in mammalian cells, 
CHO-K1 (Figure 5 B). 
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Additional experiments by analytical ultracentrifugation revealed that CS-14K protein has a 
main sedimenting species with a standard s-value of 4.3 S ± 0.1S. The CS-14K has high 
tendency to form oligomers/aggregates which is also evident when the protein were run on 5-
40% sucrose gradient. The presence of higher oligomers was detected even in the last fraction 
(40%). However majority of the protein was found between 3
rd
 and 7
th
 fractions (Figure 6).  
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Figure 5: 14K fusion protein forms oligomers/aggregates irrespective of antigen used. (A). 14K 
fused with CS protein of P.falciparum. Protein is recognized by a monoclonal antibody against CS 
(B). 14K fused with GP120 protein of HIV-1, clade IIIB, purified from mammalian cells. 
Immunoblot analysis carried out with GP120 antibody. NR and R indicates under non-reducing and 
reducing conditions.       
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Figure 6: Sucrose gradient analysis of CS-14K protein: Ultracentrifugation of 100µl of CS-
14K protein was carried out on 5-50% w/v sucrose gradient at 50,000 rpm for 4 hrs. Fractions of 
300 µl were collected from top to bottom of the tube. Proteins in each fraction were then 
precipitated using TCA/Acetone mixture. Protein was then run in a 7% SDS-PAGE gel under 
non reducing condition. The protein was transferred into a nitro-cellulose membrane and probed 
with NYS1 antibody. 
4.1.2 CHARACTERIZATION OF CS PROTEIN EXPRESSED BY MVA. 
Attenuated poxvirus provides a good platform for developing effective vaccines because of its 
ability to accommodate and express large proteins in addition to their enhanced immunogenic 
nature. MVA expressing full length CS protein of P.yoelii was previously generated in our lab.  
New plaques of the recombinant virus were picked and grown in DF-1 cells to prepare new 
stocks for animal studies. A single plaque was selected for the analysis. Insertion of CS gene 
does not cause any change in the viral replication as seen from the viral growth curve. The stocks 
were routinely checked to ensure it is free of mycoplasma and bacteria. To determine the kinetics 
of CS expression by the vector MVA-CS, we performed time-course analysis of cells infected 
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with the MVA recombinant expressing CS (Figure 7 A). We observed that after infection with 
MVA-CS, CS was detectable 2 h p.i., and these expression levels remained elevated up to 6 h p.i. 
Next, to study if CS expressed by MVA undergoes post translational modifications, we 
incubated infected cells in the presence of tunicamycin, an inhibitor of glycosylation, and 
observed that most of the CS expressed in the virus infected cells was glycosylated, as indicated 
by the reduced intensity and size reduction of the protein bands (Figure 7 B).  
 
Figure 7: Kinetics of CS expression by MVA-CS: Western blots of DF-1 cells infected with 
MVA-CS virus at 1 MOI for (A). 2, 6 and 8 hours or for (B). 16 hours in the presence and 
absence of 10 µg/ml of tunicamycin, and probed with NYS1 antibody. 
We also investigated if there was any difference in the localization of proteins in macrophages 
expressed by virus or upon transient transfection. To study the subcellular localization of full 
length CS during infection with MVA-CS, J774 cells were infected at an MOI of 5 PFU/cell for 
18 hours. We observed MVA-CS expresses CS as punctuated spots with complete cytoplasmic 
spread (Figure 8). In contrast, when macrophages were transfected with DNA encoding CS and 
CS-14K, we observed that CS and CS-14K were strongly localized around the nuclear membrane 
of the cell.  
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Figure 8: Localization of proteins in macrophages. Confocal microscopy analysis of CS and 
CS-14K localization in macrophages using NYS1 antibody at a dilution of 1:500. (A). Pattern of 
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CS expression by MVA-CS. Confluent J774 cells were infected with MVA-CS at an MOI of 5 
PFU/cell for 18 hours. (B). Protein localization in transfected macrophages. CS and CS-14K 
encoding plasmids, pCINeo-CS (10 µg) and pCDNA-CS-14K (10 µg), both lacking the signal 
and GPI motifs were transfected into confluent monolayers of J774 cells for 24 hours. 
4.1.3 ANTIBODIES AGAINST CS-14K DO NOT NEUTRALIZE VACCINIA VIRUS. 
Since the fusion protein containing 14K protein is used in prime-boost strategy with MVA, can 
vaccination with this protein induce antibodies against MVA? In order to answer this question 
we produced antibodies against CS-14K protein in rabbit. The sera were heat inactivated and 
different serum dilutions were incubated with a known titer of MVA virus. We observed that 
even low serum dilution could not inhibit the infection of MVA virus (Figure 9). 
 
 
 
             1/8                                     1/16                                        1/32 
             1/64                                     1/128                                 Mock 
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Figure 9: CS-14K fusion protein does not induce neutralizing antibodies against MVA. 
Serum from rabbits injected with CS-14K protein was not able to neutralize the infectivity of 
MVA virus in-vitro. 200 PFU of MVA virus were incubated with two fold dilutions of serum 
from rabbit injected with CS-14K protein. Following infection of DF-1 cells with the serum 
treated virus, immunostaining was carried out using anti-vaccinia antibody used at a dilution of 
1:1000. Virus incubated with rabbit serum was used as mock control. The numbers of plaques 
formed by the viruses were counted to determine the extent of infection. 
4.2 CS-14K PROTEIN PRIMING CONFERS STERILE PROTECTION AGAINST MURINE 
MALARIA. 
 
 
 
 
 
 
 
4.2.1 CS-14K ABROGATES THE LIVER STAGE DEVELOPMENT OF SPOROZOITES. 
In order to analyze if the change in physical properties had an impact on the immunogenicity, we 
decided to vaccinate the animals based on a prime/boost strategy as depicted in Figure 10.  
Following vaccination the animals were challenged with 2×10
4
 sporozoites via intravenous route. 
After 42 hours, animals were sacrificed and levels of P.yoelii 18s rRNA levels were assessed by 
qRT-PCR.  
Sterile protection is the ultimate goal of any vaccine. In case of malaria achieving complete 
protection was demonstrated only via vaccinating with irradiated sporozoites (Mellouk et al., 
1990). Although vaccine combinations based on prime / boost regimens involving DNA, 
protein or viral vectors have been studied, sterile protection still remains an elusive goal.  
Here we demonstrate how a vaccine regimen based on CS-14K protein prime and MVA-CS 
boost, without any adjuvant, confers sterile protection. The protection was analyzed both at 
liver stage and the appearance of blood stage parasites 
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Figure 10: Vaccination strategy. Schematic representation of the heterologus prime-boost 
vaccination strategy. Animals were primed with either 100µg of plasmid (DNA-CS; DNA-Ø) or 
20µg of protein (CS; CS-14K) via intradermal route. After two weeks they received a boost of 
2×10
7
 PFU of MVA or MVA-CS virus administered intraperitoneal. Mice were sacrificed on day 
26 and 68 for studying adaptive and memory immune responses. For studying protection, 
animals were challenged 2 weeks post-boost with sporozoites. 
We show that a heterologus protein prime / vaccinia virus boost regime was found to be more 
effective than an homologous protein prime / protein boost regime, a 32% reduction in the liver 
stage burden of parasites was observed in mice receiving CS-14K (CS-14K/CS-14K) compared 
to CS (CS/CS) protein. Furthermore, a MVA-CS boost significantly lowered the parasite levels 
in the liver. Moreover, the CS-14K protein priming followed by a MVA-CS resulted in a near 
complete inhibition (~99.9%; p < 0.005) of parasite development in liver compared to CS protein 
and DNA-CS (Figure 11). 
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Figure 11: Strong inhibition of liver stage parasite development by CS-14K. Mice were 
immunized as described in Materials and Methods. After two weeks post boost animals were 
challenged with 2×10
4
 P.yoelii sporozoites through intra-venous route via tail vein. After 42 
hours the amount of parasites in the liver were estimated by measuring the number of copies of 
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18S rRNA by RT-PCR. The dotted line represents the minimum detectable levels by the highly 
sensitive qRT-PCR (Bruna-Romero et al., 2001). Data are expressed as mean ± s.e. (n = 6 mice 
per group).  *p < 0.05; **p < 0.005. 
4.2.2 CS-14K PROVIDES STERILE PROTECTION AGAINST A LETHAL CHALLENGE. 
Achievement of sterile protection against malaria by vaccination still remains unattainable. Since 
priming with CS-14K reduced the liver stage development of the parasite, we wanted to see if 
this was translated into sterile protection. In other words, we evaluated if the heterologus 
prime/boost strategy based on CS-14K/MVA-CS prevented the blood stage development of 
malaria in mice. For this two weeks post boost, animals were challenged with 300 sporozoites 
via intravenous. The presence of infected RBCs in the blood was detected from the blood smears 
from day 3 to 21.   Animals that received CS-14K as a priming agent were completely protected 
in contrast to control groups which received PBS (Table 2).  
Table 2: CS-14K induces sterile protection. 
a
 20µg of protein administered intra-dermal. 
b
 2×10
7
PFU of virus administered intra-peritoneal. 
c
 Challenge via intra-venous route. 
 
 
Priming
a
 Boosting
b
 Challenge
c 
Protected/Challenged 
(% Protected)
 
Pre-patent 
period
 
 
CS-14K 
 
MVA-CS 
 
300 sporozoites 
14 days post-
boost. 
 
 
 
10/10 (100%) 
 
---- 
 
PBS 
 
PBS 
 
0/10 (0%) 
 
4 days 
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4.3 IMMUNE CORRELATES OF PROTECTION. 
   
 
 
 
 
 
 
4.3.1 CS-14K PROTEIN MODULATES INNATE IMMUNE RESPONSES IN MACROPHAGES. 
Fusion of antigens to immunomodulatory fragments such as TLR´s (Kastenmuller et al., 2011) or 
to complement proteins (Ogun et al., 2008), aimed at improving immunogenicity by aggregation 
of proteins or by exploiting the innate immune signaling of macrophages is an intense area of 
research. Since fusion of 14K protein to CS facilitates its aggregation and protects the mice 
against malaria, we sought to investigate the modulation of innate immune responses in 
macrophages. 
4.3.1.1        Nitric Oxide. 
Ability of macrophages to induce NO to inhibit the growth of parasite has been well documented 
(Seguin et al., 1994); therefore we sought to evaluate the ability of the fusion protein to induce 
NO production. Comparing the NO levels in supernatant of J774 cells treated with fusion protein 
or normal protein, it was apparent that only CS-14K resulted in NO production (Figure 12 A). 
However, when the cells were stimulated with proteins along with recombinant IFN-γ, elevated 
levels of NO were found in all samples. Further analysis revealed a significant increase in NO (p 
= 0.044) at mRNA levels in CS-14K treated macrophages compared to CS protein treatment 
(Figure 12 B). 
An important part of any vaccines is to evaluate the correlates of immune responses in the 
progression of disease. Most of the immune correlates can be classified into two, the innate 
immune system which comprises of various cellular receptors, cytokines and second line of 
defense i.e. the adaptive response consisting of humoral or Cell Mediated Immunity (CMI), 
based on which arm of the immune system is activated, antibody or T-cell response.  
For the development of an efficient vaccine it is important to know not just its protective 
capability but also the mechanism behind. Here we analyzed the difference in the pathways 
and immune parameters activated by CS-14K compared with CS or DNA-CS priming in 
mice. 
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Figure 12: CS-14K improves NO production in macrophages. J774 macrophage cells were 
stimulated with 5 µg/ml of proteins or as positive control with 1 µg/ml of LPS. IFN-γ was used 
at a final concentration of 10 ng/ml. (A). Nitrite accumulation in the supernatant was determined, 
an estimate of NO production, after 48 hours by using Griess reagent. (B). Semi-quantitative RT-
PCR analysis of NO expression. RNA was extracted and the corresponding cDNA was obtained 
as mentioned in Materials and Methods. Proportionate volume of amplified DNA was run on 8% 
agarose gel. 
Having established that CS-14K can mediate the induction of NO in cultured macrophages, we 
sought to assess the ability of splenocytes from vaccinated mice to respond to purified CS 
protein by evaluating NO production. Consequently, splenocytes harvested from animals 
receiving different prime-boost vaccine regime 53 days post-boost were stimulated with 5 µg/ml 
of purified CS protein for 48 hours. Mice that were primed with DNA-CS showed no detectable 
NO. On the other hand, mice that received proteins as priming agents were able to induce NO 
production (Figure 13). While CS
 
protein was able to increase NO by low levels, CS-14K 
increased NO production by four fold (p = 0.001). These data indicates a reduced capability of 
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CS-based vaccination to induce NO compared to CS-14K. The unique nature of CS based 
malaria vaccines to induce NO has not been reported before. 
 
Figure 13:  CS-14K priming elevates NO production in mice. Splenocytes from vaccinated 
groups harvested after 53 days post-boost were incubated with 5 µg/ml of recombinant CS 
protein for a period of 48 hours. Amount of NO in control groups, was deducted from DNA-CS 
and protein primed groups. Data are expressed as mean ± s.e. of triplicate observation (n = 4 
mice per group) and are representative of two independent experiments. *p < 0.05. 
4.3.1.2        Macrophage Signaling and Cytokine Secretion. 
Cytokines secreted by activated macrophages forms an important part of innate immune 
responses. Among the wide array of cytokines secreted, prominent ones such as IL-12, IL-6 and 
TNF-α (Type I Interferon response) has significant role against the pre-erythrocytic stages of 
malaria (Arnold et al., 2010; Shio et al., 2010). Some of these cytokines helps to prime long 
lasting CD8
+
 T-cells. Given the significance of TLR activation and the induction of type I 
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interferon responses, experiments focused on the analysis of the downstream molecules involved 
in IFN signaling such as IRF-3 and STAT-1 were performed in addition to cytokine analysis. 
To study cytokines secreted, J774 cells were stimulated with 5 µg/ml of respective protein or 
1µg/ml of LPS as positive control. Given the role played by the above mentioned cytokines in 
controlling malaria we analyzed the amount of these cytokines secreted by the macrophages 
using Luminex. Chimeric protein was able to induce a significant increase in IL-6 in 
macrophages (Figure 14). While not statistically significant, we also observed increased TNF  
production at 24 h with CS-14K treatment. To detect IL-12 activation we measured the mRNA 
levels following protein treatment. Again CS-14K significantly effected IL-12p40 activation (p = 
0.05). 
 
Figure 14: CS-14K protein induced cytokine production in macrophages. Fusion protein can 
activate innate sensing in macrophages. J774 macrophage cells were stimulated with 5 µg/ml of 
protein. As positive control, cells were stimulated with 1 µg/ml of LPS. (A). Semi-quantitative 
RT-PCR analysis of IL-12p40 expression. RNA was extracted and the corresponding cDNA was 
obtained as mentioned in Materials and Methods. Proportionate volume of amplified DNA was 
run on 8% agarose gel. (B). Cytokine analysis by Luminex assay. Supernatant were collected 
after 6 and 24 hours of protein treatment. Cytokine levels in the supernatant were measured by 
Luminex. 
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From the data we inferred that the chimeric protein was able to induce a type I IFN response 
based on cytokine secretion. To corroborate the results at the cellular level we decided to study 
the signaling molecules involved in type I IFN response namely IRF-3 and STAT-1. The 
analysis was carried out using THP-1 cells (Figure 15 A). It is notable that CS-14K was 
particularly effective in activating STAT-1 and IRF-3. To ensure the activation of STAT-1 and 
IRF-3 is not influenced by any dsRNA contamination, the cells were stimulated with proteins 
previously digested with RNAse III (Figure 15 B).  
 
Figure 15: Chimeric protein activates STAT-1 and IRF-3 in macrophages. 2×10
6
 THP-1 
cells were stimulated with 5 µg/ml of proteins or as positive control with 1 µg/ml of LPS 
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following which the samples were collected at different time intervals. (A). Equal volumes of 
total cell lysate were run on a 12% SDS-PAGE and were probed with phospho-antibodies against 
IRF-3 and STAT-1. (B). Activation of STAT-1 and IRF-3 by CS-14K is independent of dsRNA 
contamination: Proteins (5 µg/ml) and LPS (1 µg/ml) were treated with 2 µl of Shortcut
®
RNase 
III for 30 minutes at 37ºC. Following incubation the proteins were mixed with RPMI medium 
containing 10% serum to inhibit RNase III and incubated with 2×10
6
 cells of THP-1 for defined 
time intervals. The levels of phospho IRF-3 and Stat-1 were detected as mentioned in Materials 
and Methods. 
Previous study has shown that CS protein does not affect the upstream processes leading to NF-
κB activation via IκB degradation, however it prevents the migration of p65 into the nucleus 
(Singh et al., 2007). Hence we determined if there is any activation of NF-κB by the proteins 
based on the movement of p65 into the nucleus using confocal microscopy (Figure 16). We 
observed that both CS and CS-14K behaved similarly, i.e both proteins blocked the migration of 
p65 into the nucleus while leading to IκB degradation. 
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Figure 16: Proteins inhibit NF-κB activation. J774 macrophage cells were stimulated with 
5μg/ml of protein or 1 μg/ml of LPS for defined time intervals. (A). Cells were harvested at 15, 
60 and 120 minutes after stimulation and 15 μg of total cell lysate was run on 10% SDS PAGE. 
WB analysis for IκB degradation was performed. (B). Confocal microscopy of p65 movement 
into the nucleus: Following protein treatment for 15 minutes, fixing and permeabilisation of cells 
was carried out as mentioned in Materials and Methods. An antibody against p65 was used to 
detect the migration of p65 into the nucleus. 
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Based on the NO and cytokine production in addition to the signaling pathways activated we 
proposed that CS-14K is able to activate type I IFN response in macrophages in a MyD88 
independent pathway (Figure 17). 
 
Figure 17: Proposed TLR signaling mechanism by CS-14K. A hypothetical model of TLR-4 
signaling, pathway activated by fusion protein, in a MyD88 independent fashion. Inhibition of 
p65 movement to the nucleus by CS-14K prevents the action of NFkB while activation of IRF-3 
and STAT-1 leading to elevated levels of NO, IL-6 and TNF-α which could inhibit the growth of 
parasite. 
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4.4 CS-14K PROTEIN VACCINE IMPROVES THE QUALITY AND QUANTITY OF HUMORAL 
RESPONSE. 
 
 
 
 
 
 
 
Two weeks after the final phase of the prime-boost vaccination protocol described in material 
and methods, quantitative analysis of the antibodies produced showed that priming with CS-14K 
chimeric protein followed by MVA-CS induced significantly higher titers of antibodies than 
mice primed with DNA-CS or CS
 
protein alone (Figure 18 A). The antibody titers of CS-14K 
primed group was 2 times (p = 0.008) greater than CS primed group and 8 times more than in the 
DNA-CS (p = 0.002) primed group. Even 53 days post-boost the antibody levels in all the 
immunized groups were maintained at similar levels except for DNA-CS, which showed a 
reduction by one log. Further analysis of IgG isotype switching showed that fusion protein 
induced higher IgG1 response while the DNA vaccinated group showed a pre-dominance of 
IgG2a response. The levels of IgG1 (p = 0.012) and IgG2a (p = 0.030) induced by fusion protein 
primed group were almost double than of CS primed group (Figure 18 B).  
 
It is well established that a strong antibody response against CS correlates with higher 
protection in many animal and human models. The magnitude, isotype and systemic 
availability of the antibody produced are important parameters that govern the control of 
parasite and help to resolve disease (Druilhe et al., 2005; Wipasa et al., 2010). Previous 
studies have also shown the ability of oligomeric proteins to induce strong humoral responses 
based on their ability to form large molecular weight aggregates compared to its monomeric 
counterpart (Kovacs et al., 2012).  
Taking into account the imperative role CS antibodies play in controlling malaria, we 
decided to analyze the quantity and quality of antibodies generated.  
 
 
 
 
 
 
 
 
 
                                      RESULTS 
 
 61 
 
 
Figure 18: CS-14K priming improves the quality of antibodies in vivo. Antibody generated 
by the vaccine regime was captured using ELISA plates coated with 2 μg/ml of purified CS 
protein. (A). Total IgG titers produced by vaccination was determined the last positive dilution 
which gave an absorbance value three times higher than naïve serum expressed on a log scale. 
(B). Represents IgG isotypes induced by immunizations. Levels of IgG1 and IgG2a antibodies 
generated by the vaccine regimes. Control groups represent the animals receiving empty DNA or 
PBS for priming and MVA as boost. Data are expressed as mean ± s.e. of triplicate observation 
(n = 4 mice per group) and are representative of two independent experiments. *p < 0.05; **p < 
0.005; ***p < 0.0005. 
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Finally, we sought to determine if the vaccination with chimeric protein affected the avidity of 
the CS specific antibodies. The antibodies from mice primed with CS-14K showed higher avidity 
(EC50 = 4.2 M Urea) whereas those primed with DNA-CS (EC50 = 2.3 M Urea) or CS (EC50 = 
2.5 M Urea) protein had lower affinity (Figure 19).  
 
Figure 19: Chimeric protein priming generates elevated levels of high avidity antibodies. 
Avidity indices of the antibodies against CS protein were estimated as mentioned in Materials 
and Methods. The avidity index was arbitrarily considered as the molarity of urea required to 
reduce the initial absorbance by 50% i.e. Log1050% = 1.69. Data are expressed as mean ± s.e. of 
triplicate observation (n = 4 mice per group) and are representative of two independent 
experiments. **p < 0.005. 
Together, these data indicate that priming with proteins, as compared to DNA alone, enhances 
levels of antibodies against CS. Additionally; priming with CS-14K not only increases the 
overall production of antibodies but appears to induce a more balanced production of high 
affinity IgG1 and IgG2a antibodies.  
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Thus, the fusion of oligomerization domain of 14K protein to CS improves the humoral arm of 
immune responses against the antigen.  
4.5 CS-14K GENERATES DURABLE AND POLYFUNCTIONAL CS SPECIFIC CD8+ T-
CELLS.  
 
 
 
 
 
 
 
 
After mice were immunized, they were sacrificed on day 14 to study the adaptive immune 
response and on day 53 for memory analysis. Efficacy of the vaccination regime was analyzed 
using IFN-γ based ELISPOT assay and multiparameter flow-cytometry. The fusion protein 
significantly improved the CS specific IFN-γ secreting cells (p < 0.05) compared to other 
vaccine regimes during adaptive (Figure 20 A) as well as memory stage (Figure 20 B).  
CD8
+
 T-cell responses against CS protein are known to be an important factor in the 
development of sterile immunity using irradiated sporozoites (Weiss et al., 1988). A role of 
CD8+T cells in subunit vaccine induced protection against malaria was initially established 
in a heterologus prime-boost approach with flu and vaccinia virus vectors expressing CS 
CD8 peptide (Gonzalez-Aseguinolaza et al., 2003).Vaccine regimes based on DNA as well 
as protein prime followed by vaccinia boost have shown to induce CS peptide specific CD8
+
 
T cell responses. 
Given the critical role of 14K fusion in aggregating CS protein and the enhancement of 
innate immune responses, we examined the influence of these factors may have on the 
development and maintenance of CD8
+
 T-cells in-vivo.  
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Figure 20: IFN-γ ELISPOT Assay. Splenocytes from vaccinated mice were harvested and 106 
cells were stimulated with 1μg/ml of CS peptide ``SYVPSAEQI´´. IFN-γ secreted was captured 
IFN-γ antibody pre-coated plates as mentioned in Materials and Methods. (A). Adaptive 
response; 14 days post boost. (B). Memory response; 53 days post boost. Data are expressed as 
mean ± s.e. of triplicate observation (n = 4 mice per group) and are representative of two 
independent experiments. *p < 0.05; **p < 0.005; ***p < 0.0005. 
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We characterized the immune responses in terms of polyfunctionality, CD8
+
 T-cells specific for 
the peptide 280-288 of P.yoelii CS protein, secreting IFN-γ, TNF-α, IL-2, or any combination 
among these three cytokines. A clear dominance in CD8
+
 T-cell secreting cytokines was seen in 
CS-14K primed group of animals over CS protein (2.2 fold) or DNA-CS (4.3 fold) primed 
groups at day 14 post boost (Figure 21 A). Clearly, cells that secreted IL-2 were associated with 
triple cytokine producing cells. Vaccine regime involving DNA-CS priming resulted in single or 
double positive cells and did not induce any triple positive population. In contrast, animals 
receiving protein prime were able to induce IFN-γ+TNF-α+IL2+ secreting cells with CS-14K 
bringing about 3.6 fold increase over CS. In addition, CS-14K significantly increased double 
positive ``IFN-γ+TNF-α+´´ over both CS protein and DNA-CS priming.  
In order to study memory responses the CD8
+
 T-cells were classified into central memory 
(TCM) CD44
high
CD62L
high
, effector cells (TEM) CD44
high
CD62L
low
, terminally differentiated 
memory effector memory cells (TEMRA) CD44
low
CD62L
low
 and naive cells CD44
low
CD62L
high
. 
Upon analyzing memory responses on day 53, we observed rapid proliferation of peptide specific 
effector CD8 T-cell population. Interestingly the frequency of cells secreting IFN-γ was 
maintained even during the memory stage by CS-14K priming compared to other groups. In 
terms of polyfunctionality, priming with fusion protein had a significant increase in triple (IFN-
γ+TNF-α+IL2+) and double (IFN-γ+TNF-α+) population of cytokine secreting cells over both 
DNA as well as CS protein (Figure 21 B). Most of the single positive cells were dominant for 
TNF-α. A 3.5 fold increase in IFN-γ+TNF-α+IL2+ secreting cells by CS-14K primed group over 
CS protein primed and nearly 14-fold increase over DNA-CS primed groups was seen. A clear 
hierarchy in CS peptide specific total CD8 cells secreting cytokines was observed when priming 
was carried out with CS-14K. Mice immunized with proteins showed significant increase in 
magnitude of cytokines released over DNA-CS priming. Indeed, priming with CS-14K protein 
rather that CS protein led to a two fold increase in total IFN-γ (p < 0.05) and TNF-α (p < 0.0005) 
in addition to the three fold increase in IL-2 secreting cells (p < 0.05) (Figure 22). Majority of 
positive CD8 T-cells produced by the vaccine regime had a phenotype resembling either TEM or 
TEMRA. 
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Figure 21: Polyfunctional CD8
+
 T-cells are produced in CS-14K primed mice. 
Characterization of CD8
+
 T-cells secreting IFN-γ, TNF-α and IL-2 by Polychromatic Flow 
cytometry. (A). Adaptive response; 14 days after boost animals were sacrificed and the 
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splenocytes harvested were stimulated with CS peptide ``SYVPSAEQI´´. CD8
+
 T-cells were 
selected from CD3 gated lymphocytes and were differentiated into triple, double or single 
cytokine secreting cells. (B). Memory response was analysed after 53 days post boost. Memory 
CD8
+
 T-cells were classified based on the expression of CD44 and CD62L markers. Pie charts 
represent the polyfunctionality of CD8
+
 T-cells secreting single, double and triple cytokines. 
Data are expressed as mean ± s.e. of triplicate observation (n = 4 mice per group) and are 
representative of two independent experiments. *p < 0.05; **p < 0.005; ***p < 0.0005. 
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Figure 22: Effective cytokine secretion by CD8
+
 TEM in CS-14K primed mice. 
Representation of total CS peptide specific CD8 cells were gated on CD44 and CD62L cell 
surface markers represented on left hand side of the diagram. Total CD8 responses for each 
group are represented inside the box. Different populations of memory CD8 cells secreting 
different cytokines are represented on right hand side with their respective total responses as 
depicted in box. 
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To extend the immune analysis, we evaluated the amount of IFN-γ or TNF-α secreted by the 
different populations based on MFI calculation (Figure 23). We observed that, irrespective of 
priming agent, most of the IFN-γ was produced by IFN-γ+TNF-α+IL2+ or IFN-γ+TNF-α+ cells 
with similar pattern for TNF-α. The lack of CM CD8 T-cells could be explained by the fact that 
upon exposure to peptide stimulus most of the CM cells rapidly acquired effector memory 
characteristics.  
 
Figure 23: Polyfunctional CD8
+
 T-cells produces more IFN-γ and TNF-α per cell basis. 
Mean Fluorescence Intensity (MFI) of IFN-γ and TNF-α produced by different polyfunctional 
population of effector memory CD8
+
 T-cells. Higher amounts of cytokines are produced by 
polyfunctional triple positive cells compared to double or single positive cells (n=4 mice per 
group). 
These data indicate that proteins are able to prime to a higher extent an effective long-term CD8 
T-cell response than DNA. The enhanced CD8 T-cell responses in mice immunized with CS-
14K rather that CS is due to the adjuvant-like effect of the unique A27 element.
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5.1 THEME OF CURRENT STUDY. 
The main objective of the study was to improve the immunogenicity of an antigen by its physical 
modification brought about by fusing it with the N-terminus of the A27 vaccinia viral protein. 
This is because A27 contains different domains, a heparin sulfate binding domain essential for 
the binding of the virus to the cells (21-32 aa), a flexible spacer (33-42 aa), a coiled-coil domain 
critical for oligomerization (43-65 aa), a disulfide-linked domain (66-84 aa) and a C-terminal 
leucine zipper domain (85-110 aa). The N-terminus (1-28 aa) was removed from A27 to avoid 
the induction of neutralizing antibodies. In order to test the hypothesis, we fused the A27 gene 
with CS protein of P.yoelii, a causative agent of malaria in mice. Based on fusion protein 
priming followed by a recombinant vaccinia viral boost in mice, we analyzed the immune 
parameters which protected the vaccinated mice against the disease. From the results we 
concluded that fusing 14K protein to an antigen generates an oligomeric form of the protein that 
enhances its immunogenicity. 
5.1.1 MURINE MALARIA: A PERFECT MODEL FOR DEVELOPING VACCINE CANDIDATES. 
Malaria is a devastating disease against which a vaccine is yet to be developed. There are several 
strains of malaria parasite infecting different animal species. To test the hypothesis we used a 
murine malaria model based on Plasmodium Yoelii. The only vaccine which provided sterile 
protection against malaria in humans is by vaccinating with irradiated sporozoites, proof of 
concept for this vaccine model was first tested in mice. Additionally the importance of CD8
+
 T-
cells secreting cytokines such as IFN-γ and TNF-α was first observed in this model which 
provided the basis for developing more effective vaccines. Murine malaria model is among the 
most favored for testing potential malaria vaccine candidates developed against different stages 
of the disease (Craig et al., 2012; Wykes and Good, 2009). Of several advantages associated with 
this model, of utmost importance was the ability to assess the efficacy of vaccination in 
protecting the animals. Furthermore correlates of immune responses which aided protection in 
animals could be analyzed with ease in this model. Recent advances in molecular biology has 
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aided the development of humanized transgenic malaria mice models to assess the role of 
immune system in controlling malaria (Vaughan et al., 2012).   
The search for better animal models to study malaria has led to the development of transgenic 
parasites. Development of P.berghei parasite expressing the circumsporozoite protein of 
P.falciparum (3D7 strain), has aided the development of improved pre-erythrocytic stage based 
vaccine candidates (Persson et al., 2002).  
Therefore the use of murine malaria models from pre-clinical evaluation of malaria vaccine 
candidates is a viable option. 
5.1.2 FUSION OF 14K TO AN ANTIGEN RESULTS IN OLIGOMERIZATION. 
Bigger antigen results in enhanced immunogenicity, this holds true as shown in many studies 
(Kovacs et al., 2012). Based on this idea we decided to fuse the oligomeric 14K protein of 
vaccinia virus to CS, a monomeric protein. Previous studies have demonstrated the differences in 
CS specific T-cell proliferation using recombinant soluble CS protein, viable sporozoites or heat 
killed sporozoites (Krzych et al., 1992). This could explain the enhancement of polyfunctional T-
cells and antibodies when animals are primed with chimeric protein rather than CS, which 
contains lower amounts of CS aggregates. An obvious advantage of this chimeric protein is the 
incorporation of full length CS protein containing both B and T cell epitopes whose presentation 
would be enhanced as a result of protein aggregation. 
When full length CS expressed by MVA was analyzed we did see some aggregate which were 
absent in presence of tunicamycin, an inhibitor of N-glycosylation. However majority of the 
protein was monomeric in nature. When 14K protein was fused to CS it formed 
oligomers/aggregates evident from sucrose gradient and analytical ultracentrifugation. From 
sucrose gradient analysis it was evident that CS-14K did not exist as a single oligomeric species 
due to presence of various forms upto the last fraction. However the data from analytical 
ultracentrifugation suggested the existence of species that is compatible with a moderately 
elongated protein dimer (calculated frictional ratio f/f0 = 1.8). Existence of the protein in its 
monomeric form during reduced conditions (in presence of ß-mercaptoethanol) suggests that 
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disulphide bridges formed between cysteine residues present in 14K protein contributes to this 
phenomenon. 
14K protein of vaccinia virus, like HbSAg, is potent target for body’s immune system against the 
virus (He et al., 2007). The current advanced malaria vaccine viz; RTS,S was produced by fusion 
of CS protein of P.falciparum to HbSAg. Hence, by fusing a less immunogenic protein to a 
potent one a better response was attained even though for a short period of time and only in the 
presence of AS01 adjuvant. Therefore, in our model the fusion of CS to 14K served dual purpose 
i.e. formation of large oligomers/aggregates and combining a weak immunogenic CS protein to a 
potent immunogen, 14K. 
5.1.3 STERILE PROTECTION USING ADJUVANT FREE VACCINE. 
The main purpose behind vaccine development is complete protection against the disease. Many 
deadly diseases have been eradicated thanks to the development of effective vaccines. Therefore 
vaccines continue to improve the quality of life around the globe and are considered to be one of 
the greatest gifts to mankind by science. 
A vaccine’s success is its ability to provide complete protection for a long time preferably life-
long in addition to its stability and ease of transportation. Once we designed CS-14K protein our 
next step was to analyze whether the protein per se could protect the animals without any 
adjuvants. Additional groups of animals receiving various combination of vaccine were also 
included as discussed earlier. Even though a homologous CS-14K protein prime-boost decreased 
the parasitic load in the liver compared to CS prime-boost; it was not as effective as DNA-CS 
prime MVA-CS boost. However when MVA-CS was used as a boosting agent following CS-
14K priming the animals were all protected. Protection was evaluated using a high dose of 
sporozoites as challenge and the following parasitic burden in the liver was evaluated using qRT-
PCR. So even when challenged with high parasite load all the mice that received chimeric 
protein prime and MVA-CS boost were completely protected. Even though theoretically 
complete absence of parasite in the liver should lead to sterile immunity, there maybe chances 
that a single parasite could have evaded detection by qRT-PCR. Therefore to rule out such 
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possibility we challenged the mice with sporozoites and evaluated the blood stage parasitemia. 
Animals vaccinated with CS-14K did not develop any blood stage infection which is conclusive 
evidence of sterile protection. These evidences points out that all the parasites were eliminated 
within a few minutes before it could establish the liver stage infection.  
Although most of protein vaccine´s incorporate a strong adjuvant to enhance the overall immune 
response, the fusion protein eliminated the requirement of an adjuvant. This is of prime 
importance considering reports suggesting the side effects of adjuvants in vaccines (Gupta and 
Siber, 1995; Nohynek et al., 2012). By oligomerizing the protein we were able to achieve sterile 
protection without adjuvant. LPS contamination of proteins purified from E.coli is a major 
concern for vaccine studies. Being a strong activator of innate immune response, LPS can act as 
a potent adjuvant. Therefore to avoid the problem of LPS contamination in the protein 
preparations, we included TritonX-114 in washing steps (Reichelt et al., 2006). TritonX-114 can 
form micelle with LPS which is easily eliminated during washing step. Quantification of LPS 
contaminant in the final protein solution by LAL assay was below the accepted levels. This 
ensured that immune system activated by the protein leading to sterile protection was based 
solely on protein and not by other factors.  
In recent years many experimental CS based vaccines have been developed using novel 
adjuvants or by modifying the structure of CS protein (Table 2). Sterile protection in murine 
malaria models reported based on protein vaccines often includes strong adjuvant, this study 
showed how antigen modification alone can improve the immunogenicity of CS antigen leading 
to sterile protection without any adjuvants.  
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Table 3: Comparative analysis of immunogenicity of various CS based vaccines. 
 
5.1.4 HIGH QUALITY CS ANTIBODIES: HALLMARK OF A GOOD VACCINE. 
A trademark of an effective vaccine is the induction of high levels of neutralizing antibody. 
However in case of most experimental malaria vaccines even though high titers of antibodies 
were produced protection could not be achieved. This may be explained by the inability of these 
vaccines to induce antibodies against critical epitopes on the antigen. There are reports of 
elevated levels of protective antibodies in people with age in malaria endemic areas. Studies 
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from murine models helped to elucidate the mechanism involved. During primary infection 
short-lived B220
+
 plasma B-cells are produced which following secondary exposure develops 
into long-lived B220
-
 plasma B cells (Stephens et al., 2009). Protective immunity against malaria 
is associated with high avidity IgG antibodies against CS (Moon et al., 2012). Previous studies 
have also shown the ability of fusion proteins to induce strong humoral responses based on their 
ability to form large molecular weight aggregates (Verma et al., 2012). Like the CS-14K priming 
approach presented in this study, the malaria vaccine in the latest stages of clinical trials, RTS,S, 
is also dependent on higher magnitude of antibodies belonging to IgG1 subclass. Vaccine studies 
based only on DNA-CS vaccination lacking GPI anchor improve protection up to 95% based 
only on antibody titers (Scheiblhofer et al., 2001).  
The serum antibody titers obtained by fusion protein priming are much higher than those 
obtained in presence of strong adjuvants such as Freund´s adjuvant (Wang et al., 1995). 
However, unlike vaccination with DNA-CS or protein alone, vaccination with the CS-14K fusion 
protein results in the concomitant induction of high levels of both IgG1 and IgG2a antibodies 
and this could be beneficial in providing protection against malaria. Increase in cytophilic 
antibodies against CS protein, such as IgG1, in older people in malaria endemic areas is 
associated with decreased risk of malaria infection (John et al., 2003). Therefore with constant 
exposure there is an increase in CS protein IgG1 antibodies. A possible explanation for attaining 
higher IgG1 antibody titer with chimeric protein could be attributed to its structure. The 
oligomeric nature of the protein could activate the formation of germinal centre for better 
production of antibodies compared to its monomeric counterpart. This sort of differences with 
antigenic structure and the induction of germinal centers are recently reported by many studies in 
the malaria vaccine field (Moon et al., 2012; Wipasa et al., 2010).  
The chimeric protein proved to be superior in inducing high avidity antibodies against CS 
comparable with those achieved by using nanoparticle based CS peptide vaccination (Kaba et al., 
2009). Avidity of an antibody also increases with time. This is usually a result of somatic 
mutations in the germinal centre and competition with B cell clones. High avidity antibodies 
produced by the chimeric protein could be due to the unique folding pattern attained by CS-14K 
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protein resulting in exposure of other potent epitopes. Additionally there is a possibility of the 
chimeric protein to induce CS specific follicular helper T cells (Tfh) which not only improves the 
avidity but also the titer of antibodies (Moon et al., 2012). These data have important 
implications in the design of antigens to induce antibody responses against malaria. 
5.1.5 CS SPECIFIC CD8+ T-CELLS ROLE IN MALARIA: A BALANCE BETWEEN AMOUNT AND 
POLYFUNCTIONALITY. 
CD8
+
 T-cell responses against CS protein are known to be an important factor in the 
development of sterile immunity using irradiated sporozoites (Overstreet et al., 2008). CD8
+
 T-
cells during the liver stages are predominantly directed against CS protein (Schmidt et al., 2010). 
A role of CD8
+
 T-cells in subunit vaccine induced protection against malaria was initially 
established in a heterologus prime-boost approach with flu and vaccinia virus vectors expressing 
CS (Li et al., 1993).Vaccine regimes based on DNA as well as protein prime followed by 
vaccinia boost have shown to induce CS peptide specific CD8
+
 T cell responses (Sedegah et al., 
1998; Stewart et al., 2007). Site of vaccination can affect the CD8 response and since in case of 
malaria the priming of CD8
+
 T-cells occurs in the draining lymph node all proteins were given 
intradermally (Chakravarty et al., 2007). The ability of CS-14K regime to produce significantly 
elevated levels of IFN-γ and TNF-α single as well as double positive secreting CD8+ T-cells 
even after 53 days makes it a suitable vaccine candidate. Report of adjuvant-antigen complex 
promoting CD8 responses compared to an antigen adjuvant mix further strengthens our findings 
(Olvera-Gomez et al., 2012). We also report a shift in polyfunctionality of CD8 T-cells secreting 
all the three cytokines produced by chimeric protein which may be effective in controlling the 
growth of parasite. Furthermore, the ability of CS-14K vaccine regime to induce large amount of 
TNF-α has an added advantage since it is known to be an important cytokine for the maintenance 
of memory CD8 T-cells in malaria (Butler et al., 2010). The concomitant increase in TNF-α by 
CS-14K could also contribute to elevated NO and antibody responses (Li and Langhorne, 2000; 
Pombo et al., 2002). The need for IL-12 in the development of effective adaptive responses is in 
agreement with our study which shows the ability of CS-14K protein to prime enhanced T-cell 
response (Hoffman et al., 1997a). The data from MFI studies shows that double or triple positive 
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population are better in producing elevated levels of cytokines, both of which are elevated by 
CS-14K priming. The low levels of CD8 responses against DNA-CS suggest that the protective 
capability of this regime may be based on the antibodies induced. The maintenance of such 
durable and polyfunctional memory responses even after 4 months of vaccination taken together 
with sterile protection, justifies the potent nature of A27 protein fusion and its use for developing 
better malaria vaccines.  
5.1.6 ENGAGING THE INNATE IMMUNE SYSTEM. 
Of the first resistance that any foreign body encounters when it enters the body is the innate 
immune system. A future cataclysmic event that aids in eliminating the pathogen is the direct 
effect of signaling by the innate immune system (Arnold et al., 2010; Shio et al., 2010). Often the 
innate immune activation involves signaling via the TLR’s leading to the activation of various 
pathways. In our case we did observe how CS-14K affected the innate immune system based on 
which we proposed a hypothetical model.  
Given that an early activation of innate immune responses curbs the pre-erythrocytic 
development of parasite, activation of type I interferon signaling by fusion protein further 
validates its use as a priming agent.  Indeed, activation of type I interferon signaling by the 
chimeric protein did result in elevated levels of cytokines belonging to this family such as IL-6, 
TNF-α and IL-12. It is believed that the parasiticidal action of TNF-α in hepatocytes is mediated 
through the synthesis of IL-6 (Nussler et al., 1991). Furthermore, engaging TLR’s is critical in 
developing anti malarial immunity which could be explained by the poor immunogenicity of 
RTS,S without a strong adjuvant like AS01E, a TLR-4 agonist (Mettens et al., 2008). A recent 
study also shows the importance of TLR signaling for effective development of protective 
antibodies to Plasmodium (Wiley et al., 2011). This is in agreement with our study which shows 
how enhancement in STAT-1 and IRF-3 by CS-14K suggested a role in TLR-4 activation 
(Figure 17), resulting in improved immunogenicity and inhibiting the liver stage development of 
the parasite (Imada and Leonard, 2000; Spath et al., 2009).  
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It is known how parasites such as Leishmania and Plasmodium down regulate synthesis of NO 
(Liew, 1994). Our study shows the inherent capacity of chimeric protein to enhance the 
production of NO both in vitro and in vivo. Since neither CS nor 14K protein alone could induce 
NO, it seems reasonable to conclude that the CS-14K protein aggregation is responsible for NO 
induction. The persistently elevated levels of NO at 53 days post-vaccination with chimeric CS-
14K protein compared to priming with DNA-CS or protein alone, suggest that differences exists 
in the processing of these antigens by APCs. In addition, early production of NO has been 
proposed to be required for proliferation of CD8
+
 T-cells against the parasite (Scheller et al., 
1997). Taking into consideration all of the innate, adaptive, memory and protective efficacy 
results described in this work, we can infer immune correlates of protection as indicated in Table 
4. In conclusion, fusion of 14K to CS leads to a more favorable immunogenic milieu to enhance 
the efficacy of the vaccine.  
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Table 4: Comparison of immune correlates defined in this thesis with those observed in 
humans. 
STAGE 
(Immune Response) 
Parameters 
Upregulated 
Correlates References 
 
 
INNATE 
NO Inconsistent data 3, 75, 78 
IL-6 ND 55, 85 
IL-12 Surrogate 101, 116, 172 
IRF-3 ND ---- 
STAT-1 ND ---- 
 
 
ADAPTIVE 
 
 
IFN-γ secreting CD8+ 
T-cells. 
Correlate 90, 98, 157 
CS Antibody Titre Correlate 71, 105, 156, 171 
Antibody Avidity Surrogate 18, 102 
 
MEMORY 
Effector Memory 
Polyfunctional CD8
+
 T-
cells. 
 
ND 
 
 
84, 131 
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      From the study we concluded the following: 
 14K protein (A27) of vaccinia virus when fused at the C-terminus of the CS antigen can 
form oligomers/aggregates. 
 
 The oligomers/aggregates of CS-14K are of high molecular weight which is evident from 
sucrose gradient and analytical ultracentrifugation studies. 
 
 CS-14K protein of high purity could easily be purified from E.coli facilitated by a GST 
tag with low levels of LPS contamination. 
 
 Comparative studies of a homologous protein prime-boost in mice showed that CS-14K 
was more effective in reducing the parasitic load in the liver compared to CS protein 
when challenged with a high dose of sporozoites. 
 
 A heterologus protein prime followed by MVA-CS boost protected more animals than the 
homologous treatment, with complete elimination of parasites in the liver when primed 
with CS-14K protein. 
 
 Sterile protection was achieved only in animals primed with CS-14K and boosted with 
MVA-CS. 
 
 Elevated levels of antibodies with high avidity were observed in mice which received 
CS-14K as priming agent. A higher ratio of IgG1:IgG2a was attained in CS-14K 
vaccinated animals. 
 
 Increased number of IFN-γ secreting CD8+ T-cells was observed in mice primed with 
CS-14K protein versus CS. The number of cells secreting IFN-γ was maintained during 
the memory phase, only in animals vaccinated with CS-14K. 
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 Enhanced levels of polyfunctional CD8+ T-cells secreting cytokines was achieved in 
animals receiving CS-14K, during the adaptive and memory phase. 
 
 Chimeric CS-14K protein was able to induce IL-12, TNF-α and NO in macrophages via 
IRF-3 and STAT-1 activation. 
 
From the data observed we concluded that fusion of 14K protein to an antigen improves its 
immunogenicity. Our findings provide the platform for the development of 14K as an effective 
adjuvant. In this study, we observed how a fusion protein based on CS antigen affect its 
immunogenicity and evaluated the correlates of protection in malaria murine model. Moreover, 
the stability of the fusion protein at room temperature and the ease with which it can be produced 
and administered makes this a candidate adjuvant for the development of effective vaccines. 
Signaling of CS-14K via the TLR-4 pathway can shed light in producing better vaccines against 
malaria. Taken together, this thesis extends previous observations on the role of CS as an 
immunogenic component against malaria and highlights the development of vaccines based on 
presentation of antigens as oligomers/aggregates using the immunogenic molecule of A27 from 
vaccinia virus. 
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7.1 RESUMEN. 
El desarrollo de vacunas-subunidades para la malaria que inducen una fuerte respuesta a largo 
plazo de memoria es un área de intensa investigación, enfocado en la mejora de la 
inmunogenicidad de una vacuna basada en la proteína de circumsporozoite (CS). En este estudio, 
se encontró que una proteína quimérica, formado por proteína de fusión del virus vaccinia 14K 
(A27) a la CS de Plasmodium yoelii, induce una fuerte respuesta de memoria de células T CD8
+
 
efectoras, además de anticuerpos de alta afinidad cuando se usa como un agente de ``priming´´ 
en la ausencia de cualquier adyuvante, seguido por una dosis recuerdo ``boost´´ del virus 
vaccinia atenuado (MVA) que expresa CS en modelo murino. Por otra parte, el priming con la 
proteína permite una mejora de la magnitud y la polifuncionalidad de células T CD8
+
 secretoras 
de citoquinas. Esta proteína de fusión forma oligómeros/agregados que llevan a la activación de 
STAT-1 y IRF-3 en los macrófagos humanos, lo que indica una respuesta a IFN de tipo I, dando 
como resultado la inducción de NO, IL-12, e IL-6. Además, la combinación de CS-14K junto 
con el vector MVA-CS en protocolo de inmunización inhibió el desarrollo de la etapa hepática 
del parásito, lo que resulta en una protección completa. En resumen, se propone un nuevo 
enfoque en el diseño de vacunas pre-eritrocíticas basadas en CS contra el Plasmodium utilizando 
el efecto adyuvante de la proteína inmunogénica del virus vaccinia 14K. 
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7.2 INTRODUCCIÒN. 
7.2.1 MALARIA LA ENFERMEDAD. 
Malaria significa "Aire malo" en italiano debido a su prevalencia en las zonas pantanosas, 
continúa presentando un importante problema de salud pública y de carga para el desarrollo 
económico de muchos países. Plasmodium falciparum, el principal agente causal de la malaria en 
humanos, se sabe que causa aproximadamente 225 millones de casos y alrededor de 781.000 
muertes al año. La malaria sigue siendo un factor clave en la mortalidad y morbilidad entre los 
niños pequeños y las madres en zonas de África y subsaharianos (Informe Mundial sobre el 
Paludismo, 2010). Las áreas que han sido declaradas previamente libre de malaria también están 
bajo la constante amenaza de un resurgimiento debido a los cambios en el clima mundial y la 
globalización. La situación ha empeorado aún más debido a la aparición de parásitos resistentes a 
los medicamentos y a vacunas ineficaces. Con varios medicamentos en desarrollo, la necesidad 
de una vacuna eficaz contra la malaria se hace patente. 
Hasta la fecha, las vacunas han jugado un papel importante en la eliminación de muchas 
enfermedades. Sin embargo el desarrollo de una vacuna contra la malaria se ve limitado por la 
capacidad del parásito para engañar al sistema inmunitario. La inmunidad natural a la malaria se 
observa en las zonas endémicas, en las que también se requiere una exposición repetida y un 
tiempo considerable para desarrollarse. Sin embargo, este tipo de rangos de inmunidad parcial a 
completa protección, generalmente se observa en la población anciana. Por lo tanto el desarrollo 
de una vacuna eficaz contra el paludismo es esencial. A pesar de que un gran repertorio de 
antígenos presentes en las diversas etapas de la malaria está disponible, la selección de un 
candidato es todavía una tarea en proceso. Una vacuna eficaz debe superar varios obstáculos 
tales como que debería proporcionar una protección de larga duración con independencia de las 
variaciones genéticas que existen entre las poblaciones humanas así como en el parásito. 
Además, debería ser fácil de producir y transportar con un coste mínimo. Además, la vacuna 
puede incorporar antígenos de diferentes etapas del desarrollo del parásito. Con el advenimiento 
de las nuevas tecnologías en el desarrollo de una vacuna contra el paludismo una vacuna eficaz 
podría no ser un sueño lejano. 
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7.2.2 LAS VACUNAS CONTRA LA MALARIA. 
Las vacunas son una herramienta esencial en el arsenal para luchar contra la malaria. Teniendo 
en cuenta la evolución de insecticidas y parásitos resistentes a fármacos, el desarrollo de una 
vacuna eficaz es imprescindible. Desarrollo de una vacuna rentable está limitada por la 
capacidad del parásito para manipular el sistema inmune del huésped. A pesar de la amplia gama 
de los antígenos disponibles, que se expresan por el parásito en varias etapas de su ciclo de vida, 
la selección de un antígeno específico ha sido bastante intrincada. Dependiendo del ciclo de vida 
del parásito, las vacunas desarrolladas se pueden clasificar en tres clases (1). Vacunas pre-
eritrocíticas (2). Vacunas eritrocíticas y (3). Vacunas para el bloqueo en la transmisión 
parasitaria. 
7.2.2.1       Proteína circumsporozoite: Potente candidate vacunal pre-eritrocítica. 
La mayoría de las vacunas contra la etapa pre-eritrocítica se orientan hacia las proteínas que se 
expresan en la superficie del esporozoito. Respecto de todos los antígenos que se encuentran 
expresados en esta etapa, sobresalen la proteína CS y la proteína TRAP. Sin embargo, las 
vacunas basadas en proteína CS han resultado ser más prometedoras y han entrado con éxito en 
ensayos clínicos de fase III (como es el caso de RTS, S). 
La proteína CS es una importante proteína monomérica que se encuentra en la superficie de los 
esporozoitos. La importancia de la proteína CS como candidato vacunal principal fue reportada 
por primera vez por  Nussenzweig y Nussenzweig (1985). La mayor parte de la protección en el 
modelo de vacuna de esporocitos γ-irradiados y vacunas de esporozoitos atenuados 
genéticamente estaba mediada por respuestas humorales específicas de CS y CMI (Kumar et al., 
2009). La proteína mantiene similaridades respecto de las propiedades estructurales, bioquímicas 
e inmunológicas entre las diferentes especies de Plasmodium. El dominio central de todas las 
especies de Plasmodium contiene una región de repetición que contiene epítopos 
inmunodominantes para células B y células T (Lal et al., 1987). Esta región está generalmente 
flanqueada por la región conservada I en el extremo N-terminal  y  la región III y la región II + 
en el extremo C-terminal. La unión de los esporozoitos a las cadenas de GAG de HSPG de los 
hepatocitos está mediada por la región II de la proteína CS (Pinzon-Ortiz et al., 2001). CS 
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presenta una estructura cilíndrica que está anclada a la superficie de los esporocitos por un 
dominio GPI que se encuentra la región C-terminal (Plassmeyer et al., 2009). En un estudio se 
demostró que la CS se une a los ribosomas interrumpiendo la síntesis de proteínas en hepatocitos 
infectados (Frevert et al., 1998). Proteína CS también ayuda a la supervivencia de los 
esporozoitos en hepatocitos mediante el bloqueo de la translocación de p65 en el núcleo lo que se 
traduce en un bloqueo la vía de NFkB. Además, también promueve la expresión de diversos 
genes vitales en el proceso metabólico para permitir que el parásito pueda prosperar dentro de las 
células infectadas (Singh et al., 2007). A pesar de ciertas desventajas, el desarrollo de vacunas 
basadas en la proteína CS están progresando. 
7.3 RESULTADOS Y DISCUSIÓN. 
Circumsporozoito (CS) es una proteína monomérica de superficie de esporozoitos de 
Plasmodium, el agente causante de la malaria (Nussenzweig y Nussenzweig, 1985). Sin 
embargo, el CS nativa de esporozoitos también se conoce para formar algunos agregados/ 
oligómeros que pueden facilitar la unión de CS a los hepatocitos (Pinzon-Ortiz et al., 2001). 
Dado que los niveles de agregados de CS / oligómeros son comparativamente mucho menor que 
sus monómeros, creemos que niveles más altos de agregados CS / oligómeros se requiere para 
alcanzar una mejor protección. 
Basándose en esta hipótesis, decidimos fusionar CS con una proteína inmunogénica del virus 
vaccinia, 14K, lo que facilita la formación de oligómeros superiores a través de su enrollado de 
la bobina de dominio. La proteína CS carece de la secuencia señal de GPI y C-terminal fue 
fusionado con la proteína 14K del virus vaccinia carece de los primeros 28 aminoácidos. CS y 
CS14K fueron entonces purificados de E. coli. Proteína CS existía como un monómero de 50 
kDa ~ mientras CS14K existía como oligómeros grandes / agregados. La forma monomérica de 
CS14K cuando bajo condiciones reductoras existían como molécula de 60 kDa. Los datos de la 
ultracentrifugación analítica sugirió la existencia de especies que sean compatibles con un 
dímero de proteína moderadamente alargado (calculó la razón de fricción f/f0 = 1,8). Existencia 
de la proteína en su forma monomérica durante condiciones reducidas (en presencia de ß-
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mercaptoetanol) sugiere que los puentes disulfuro formados entre restos de cisteína presentes en 
la proteína 14K contribuye a este fenómeno. 
Con el fin de analizar si el cambio en las propiedades físicas de la proteína influye en su 
inmunogenicidad, se decidió vacunar a los animales sobre la base de una estrategia de 
sensibilización / refuerzo. Después de la vacunación los animales fueron desafiados con 2 × 104 
esporozoitos por vía intravenosa. Después de 42 horas, los animales fueron sacrificados y los 
niveles de 18S rRNA P.yoelii niveles se evaluaron por qRT-PCR. Hemos observado que una 
proteína heteróloga prime / vaccinia régimen reactivación del virus se encontró que era más 
efectiva que una proteína homóloga de cebado / régimen de impulso de proteínas, una reducción 
del 32% en la carga de parásitos etapa hígado se observó en ratones que recibieron CS-14K (CS- 
14K/CS-14K) en comparación con CS (CS / CS) de proteínas. Además, una dosis recuerdo con 
MVA-CS redujo significativamente los niveles de parásitos en el hígado. Por otra parte, el 
``priming´´ con proteína CS-14K seguido de una segundo dosis ``booster´´ con MVA-CS resultó 
en una inhibición casi completa (~ 99,9%, p <0,005) de desarrollo del parásito en el hígado en 
comparación con la proteína CS y ADN-CS. Para confirmar aún más que la reducción de la 
parasitemia se traduce en la protección estéril después de dos semanas después de aumentar los 
ratones se estimularon con 300 esporozoitos y la presencia de iRBCs en la sangre se analizó en 
los frotis de sangre de 3 a 21 días. Los animales que recibieron la proteína CS-14K como agentes 
de cebado estaban completamente protegidos en comparación con el grupo control. Aunque la 
mayor parte de la vacuna de proteína es incorporar un adyuvante fuerte para potenciar la 
respuesta inmune en general, la proteína de fusión elimina el requisito de un adyuvante. Esto es 
de gran importancia teniendo en cuenta los informes que sugieren los efectos secundarios de los 
adyuvantes de las vacunas (Gupta y Siber, 1995;. Nohynek et al, 2012). Mediante la 
oligomerización de la proteína hemos sido capaces de conseguir una protección estéril sin 
adyuvante. LPS contaminación de las proteínas purificadas a partir de E. coli es una 
preocupación importante para los estudios de la vacuna. Siendo un fuerte activador de la 
respuesta inmune innata, LPS puede actuar como un potente adyuvante. Por lo tanto, para evitar 
el problema de la contaminación de LPS en las preparaciones de proteína, que incluye Triton X-
114 en pasos de lavado (Reichelt et al., 2006). Triton ® X-114 se pueden formar micelas con 
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LPS, que es fácilmente eliminado durante la etapa de lavado. La cuantificación de LPS 
contaminante en la solución final de proteína por el ensayo de LAL era inferior a los niveles 
aceptados. Esto aseguró que el sistema inmune activado por la proteína que conduce a la 
protección estéril se basa únicamente en la proteína y no por otros factores. 
Los títulos de anticuerpos de suero obtenidos mediante cebado proteína de fusión son mucho 
mayores que los obtenidos en presencia de los adyuvantes fuertes, tales como el adyuvante de 
Freund (Wang et al., 1995). Sin embargo, a diferencia de la vacunación con ADN-CS o proteína 
por sí sola, la vacunación con los resultados de proteína CS-14K de fusión en la inducción 
concomitante de altos niveles de anticuerpos IgG1 e IgG2a y esto podría ser beneficioso en la 
protección contra la malaria. Aumento de los anticuerpos contra la proteína CS citofílicos, como 
IgG1, en las personas mayores en las zonas endémicas de malaria se asocia con un menor riesgo 
de infección por malaria (John et al., 2003). Por lo tanto con la constante exposición hay un 
aumento en la proteína CS anticuerpos IgG1. Una posible explicación para la consecución de 
mayor título de anticuerpos IgG1 con proteína quimérica podría atribuirse a su estructura. La 
naturaleza oligomérica de la proteína podría activar la formación de centro germinal para una 
mejor producción de anticuerpos en comparación con su contrapartida monomérica. Este tipo de 
diferencias con estructura antigénica y la inducción de centros germinales se informó 
recientemente por muchos estudios en el campo de vacuna contra la malaria (Luna et al, 2012;.. 
Wipasa et al, 2010). La proteína quimérica demostró ser superior en la inducción de anticuerpos 
de alta avidez contra CS comparables con los obtenidos mediante el uso de nanopartículas 
basadas CS vacunación péptido (Kaba et al., 2009). Avidez de un anticuerpo también aumenta 
con el tiempo. Este es generalmente el resultado de mutaciones somáticas en el centro germinal y 
la competencia con los clones de células B. Anticuerpos de alta avidez producidos por la proteína 
quimérica podría ser debido a el patrón único de plegado alcanzado por CS-14K proteína 
resultante de la exposición de otros epítopos potentes. Además, hay una posibilidad de que la 
proteína quimérica para inducir CS específicos foliculares células T auxiliares (TFH) que no sólo 
mejora la avidez, sino también el título de anticuerpos (Moon et al., 2012). Estos datos tienen 
implicaciones importantes en el diseño de antígenos para inducir respuestas de anticuerpos 
contra la malaria. 
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CD8 + respuestas de células T contra la proteína CS se conocen por ser un factor importante en 
el desarrollo de la inmunidad estéril usando esporozoitos irradiados (Overstreet et al., 2008). 
CD8 + células T durante las etapas del hígado son predominantemente dirigido contra la proteína 
CS (Schmidt et al., 2010). La capacidad de régimen CS14K para producir niveles 
significativamente elevados de IFN-γ y TNF α-única, así como secreción de doble positivo CD8 
+ células T, incluso después de 53 días lo convierte en un candidato de vacuna adecuado. La 
formación del complejo antígeno-adyuvante promoción de respuestas de CD8 en comparación 
con una mezcla de adyuvante antígeno refuerza nuestras conclusiones (Olvera-Gómez et al., 
2012). También el reportar un cambio en la polifuncionalidad de células T CD8 secretora de 
todas las tres citoquinas producidas por la proteína quimérica que pueden ser eficaces en el 
control del crecimiento de parásito. Además, la capacidad de régimen de vacuna para inducir 
CS14K con gran cantidad de TNF-α tiene una ventaja añadida ya que se sabe que es una citocina 
importante para el mantenimiento de la memoria de las células T CD8 en malaria (Butler et al., 
2010). Los datos de los estudios MFI muestra que la población positiva doble o triple son 
mejores niveles en la producción de citoquinas, ambos de los cuales son elevados por cebado 
CS14K. Los bajos niveles de respuestas de CD8 anti-DNA-CS sugieren que la capacidad 
protectora de este régimen puede estar basado en los anticuerpos inducidos. El mantenimiento de 
tales respuestas de memoria duraderos y polifuncional, incluso después de 4 meses de la 
vacunación tomado junto con la protección estéril, justifica la potente naturaleza de la proteína 
de fusión A27 y su uso para el desarrollo de mejores vacunas contra la malaria. 
Dado que una activación temprana de la respuesta inmune innata impide el desarrollo pre-
eritrocítico del parásito, la activación de interferón de tipo I a través de señalización por la 
proteína de fusión, valida aún más su uso como un agente de inducción de respuesta innata. De 
hecho, la activación de interferón de tipo I por la proteína quimérica sí resultó en niveles 
elevados de citocinas pertenecientes a esta familia, tales como IL-6, TNF-α e IL 12-. Se cree que 
la acción parasiticida de TNF-α en los hepatocitos está mediada por la síntesis de IL-6 (Nüssler 
et al., 1991). Además, la participación TLR es crítica en el desarrollo de la inmunidad contra la 
malaria que podría ser explicado por la pobre inmunogenicidad de RTS, S sin un adyuvante 
fuerte como AS01E, un agonista de TLR-4 (Mettens et al., 2008). Un estudio reciente también 
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muestra la importancia de la señalización TLR para el desarrollo eficaz de anticuerpos 
protectores a Plasmodium (Wiley et al., 2011). Esto está de acuerdo con nuestro estudio, que 
muestra cómo la mejora en STAT IRF-1 y 3-por CS14K sugiere un papel en la activación de 
TLR-4 (Figura 17), lo que resulta en la inmunogenicidad mejorada y la inhibición de la fase de 
desarrollo del parásito hepático (Imada y Leonard, 2000; Spath et al, 2009). 
Se sabe cómo los parásitos, tales como Leishmania y Plasmodium regulan a la baja la síntesis de 
NO (Liew, 1994). Nuestro trabajo demuestra la capacidad inherente de la proteína quimérica 
para mejorar la producción de NO tanto in vitro como in vivo. Dado que ni el CS ni proteína 14K 
por sí sola podrían inducir NO, parece razonable concluir que la agregación de proteínas CS14K 
produce NO como molécula responsable de la inducción. Los niveles persistentemente elevados 
de NO a 53 días después de la vacunación con la proteína quimérica CS14K en comparación con 
el cebado con ADN o proteína-CS sola, sugieren que las diferencias existen en el procesamiento 
de estos antígenos por las APC. Además, la producción temprana de NO se ha propuesto que se 
requiere para la proliferación de células T CD8
+
 contra el parásito (Scheller et al., 1997). En 
conclusión, la fusión de 14K a CS conduce a un medio inmunogénico mucho más favorable para 
potenciar la eficacia de la vacuna CS-14K. 
 
7.4 CONCLUSIONES. 
Del studio se concluye lo siguiente: 
 La proteína 14K de vaccinia puede formar oligómeros/agregados cuando se fusiona a un 
antígeno. 
 Los oligómeros / agregados son de alto peso molecular según se evidencia en ensayos de 
gradiente de sacarosa y estudios analíticos de ultracentrifugación. 
 La proteína CS-14K de alta pureza puede ser fácilmente purificada de E. coli empleando 
una etiqueta de GST con niveles bajos de contaminación por LPS. 
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 Estudios comparativos empleando protocolos de inmunización homólogos “prime/boost” 
con proteína in vivo mostraron que CS-14K es más eficaz en la reducción de la carga 
parasitaria en el hígado en comparación con CS cuando son desafiados con una dosis alta 
de esporozoitos. 
 Un ``prime´´ con proteína CS-14K seguido de un ``boost´´ con MVA-CS mejora la 
protección en animales, después de un desafio con Plasmodium yoelii, con una 
eliminación total de los parásitos en el hígado.  
 La protección completa sólo se logró en los animales vacunados con CS-14K / MVA-CS. 
 Se observó, mediante el empleo de ELISPOT-IFN-γ, un aumento del número de células T 
CD8
+
 que secretan IFN-γ en ratones que recibieron el prime con proteína CS-14K. El 
número de células secretoras de IFN-γ en el grupo de los animales vacunados con CS-
14K se mantuvo incluso durante la fase de memoria, sin presentar ninguna disminución. 
 Mejora en los niveles células T CD8+ polifuncionales secretoras de citoquinas en los 
animales que recibieron CS-14K, tanto durante la fase la respuesta adaptativa como la de 
memoria. 
 La proteína quimérica era capaz de inducir IL-12, TNF-α y NO en los macrófagos a 
través de IRF-3 y la activación de STAT-1. 
De los datos se observó que la fusión de la proteína 14K a un antígeno puede mejorar su 
inmunogenicidad. Nuestro hallazgo proporciona la plataforma para el desarrollo de 14K como un 
adyuvante eficaz. Además se observó cómo una proteína de fusión basada en el antígeno CS , 
afecta a su inmunogenicidad. De la misma forma se evaluaron las correlaciones de protección de 
la malaria. Además, la estabilidad de la proteína de fusión a temperatura ambiente y la facilidad 
con la que pueden ser producidas y administradas, hace de éste un mejor adyuvante para el 
desarrollo de vacunas eficaces. La señalización de CS-14K a través de la vía TLR-4 puede 
arrojar luz en la producción de mejores vacunas contra la malaria. En conjunto, esta tesis ofrece 
una amplia evidencia para el desarrollo de vacunas basado en modificaciones estructurales de los 
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antígenos mediante la molécula A27 de virus vaccinia y formación de oligómeros/aggregados 
proteicos como inmunògenos. 
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Adjuvant-like Effect of Vaccinia Virus 14K Protein: A Case
Study with Malaria Vaccine Based on the Circumsporozoite
Protein
Aneesh Vijayan,* Carmen E. Go´mez,* Diego A. Espinosa,† Alan G. Goodman,*
Lucas Sanchez-Sampedro,* Carlos Oscar S. Sorzano,‡ Fidel Zavala,† and
Mariano Esteban*
Development of subunit vaccines for malaria that elicit a strong, long-term memory response is an intensive area of research, with
the focus on improving the immunogenicity of a circumsporozoite (CS) protein-based vaccine. In this study, we found that a chimeric
protein, formed by fusing vaccinia virus protein 14K (A27) to the CS of Plasmodium yoelii, induces strong effector memory CD8+
T cell responses in addition to high-affinity Abs when used as a priming agent in the absence of any adjuvant, followed by an
attenuated vaccinia virus boost expressing CS in murine models. Moreover, priming with the chimeric protein improved the
magnitude and polyfunctionality of cytokine-secreting CD8+ T cells. This fusion protein formed oligomers/aggregates that led to
activation of STAT-1 and IFN regulatory factor-3 in human macrophages, indicating a type I IFN response, resulting in NO, IL-12,
and IL-6 induction. Furthermore, this vaccination regimen inhibited the liver stage development of the parasite, resulting in
sterile protection. In summary, we propose a novel approach in designing CS based pre-erythrocytic vaccines against Plasmodium
using the adjuvant-like effect of the immunogenic vaccinia virus protein 14K. The Journal of Immunology, 2012, 188: 6407–6417.
M
alaria continues to present a major public health
challenge and burden on economic development in
many countries. Plasmodium falciparum, the main
causative agent of malaria in humans, is known to cause ∼225
million cases and ∼781,000 deaths annually (1). Development of
a cost-effective vaccine continues to be a daunting task because of
the confounding ability of the parasite to manipulate the host
immune system. The most advanced malaria vaccines have fo-
cused on the use of protein-in-adjuvant formulations, and a phase
III clinical trial with RTS,S/AS01E (a liposome-based adjuvant
system) is under way (2). First results of the phase II trial of RTS,
S/AS01E in Africa revealed vaccine-reduced clinical episodes of
malaria and severe malaria by about half during 12 mo after
vaccination in children 5–7 mo age (3). The rationale behind the
development of RTS,S is its ability to form virus-like particles,
which enhances the immunogenicity of monomeric circumspo-
rozoite (CS) protein. The ability of protein aggregates to stimulate
strong immune responses compared with their monomeric coun-
terparts has been studied for many decades and is supported by
a number of recent studies (4–6).
CS protein is a monomeric protein of ∼40–60 kDa covering
the surface of infective sporozoites (7). However, the native CS
from sporozoites is also known to form some aggregates that may
facilitate the binding of CS to hepatocytes (8). The CS protein
is GPI-anchored and consists of a central portion of immunodo-
minant repeat regions of B and T cell epitopes (9). Reports of
successful vaccination against malaria in humans have been at-
tributed to the development of CS-specific humoral and cell-
mediated immune responses (10). Therefore, the strong immu-
nogenic nature of the CS protein and its presence during
pre-erythrocytic and liver stages (11) make it a promising candi-
date for the development of a malaria vaccine.
Control of infection for most pathogens requires different
strategies of intervention, including humoral or cell-mediated
immune responses at different times in their life cycle. There-
fore, an effective vaccination regimen should encompass these
aspects to develop sterile immunity. Viral vaccine vectors ex-
pressing CS protein and other Plasmodium Ags as promising
vaccine candidates have been previously described (12, 13). Many
of these studies have focused on using DNA as priming agent,
which met with success rates as high as 70–100% in mouse
models, even though it was short-lived (14, 15). However, DNA-
based vaccines have recently come under renewed scrutiny for
a number safety factors such as integration of the DNA into host
gene (16) and also by their induction of tolerance against the
Ag (17). Another disadvantage is the reduced capacity of DNA
vaccines to induce a strong Ab response. The quality of immune
responses generated by DNA vaccines administered alone is
comparatively weaker to the traditional vaccines such as subunit
vaccines or attenuated organisms (18). Currently, most licensed
vaccines are based on attenuated whole pathogens or subunit
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particles. Therefore, as an alternative to DNA vectors, the use of
proteins as priming agents is gaining acceptance due to their better
efficacy and safety.
In this study, we describe the development of a novel CS-based
chimeric protein, which when combined in a heterologus prime–
boost vaccine regimen with an attenuated vaccinia virus vector-
induced enhanced immune responses. Additionally, this vaccine
regimen gave sterile protection in mice when challenged with
sporozoites. Our chimeric CS protein (CS14K) makes use of the
oligomerization domain of the A27L gene of vaccinia virus. Our
previous studies helped in the understanding of the structural or-
ganization of the 14-kDa protein encoded by the A27L gene (19).
Considering the drawbacks of using a DNA priming strategy and
CS protein encoding its C-terminal GPI sequence, we sought to
determine the possible differences in the quality and quantity of
humoral and T cell responses induced by different vaccine con-
structs and define how this might influence protection.
We also show how the differences in the induction of CD8+
T cells and Abs could influence the protective capacity of malaria
vaccines. In agreement with previous studies with fusion protein
(4, 20), we found that priming with CS14K resulted in the de-
velopment of high avidity and balanced IgG Ab production. An
important aspect of this work is the extensive analysis of quantity
and quality of CD8+ T cells during primary and memory stages.
Comparing our vaccine regimen to a protective vaccination regi-
men based on DNA priming followed by poxvirus boost, we
showed that priming with CS14K followed by a modified vaccinia
virus Ankara (MVA)-CS boost triggered strong memory poly-
functional effector T cell responses, an important component for
providing long-term protection (21).
These results demonstrate that by fusing the vaccinia virus 14K
(A27 protein) to CS we achieved a significant improvement in the
quality and quantity of the humoral and T cell responses against CS
in addition to protection of mice against liver stage development of
malaria parasites. This study demonstrates that fusing an immu-
nogenic protein from vaccinia virus improved the overall immu-
nogenicity of the Plasmodium CS Ag in the absence of adjuvants.
Materials and Methods
Cells and viruses
Construction of recombinant MVA virus expressing circumsporozoite
protein of Plasmodium yoelii 17XNL strain (MVA-CS) has been describe
previously (13). The virus was grown and titrated in primary chicken
embryo fibroblastcells and in DF-1 cells (22). Murine J774 and human
THP-1 macrophages used for the in vitro cell culture studies were main-
tained at appropriate conditions as specified by the American Type Culture
Collection.
Plasmid construction
pCI-Neo-CS The PyCSP gene was amplified MVA-CS using the primers
CS-XhoI-F (59-ACTTACTCGAGATGTGTTACAATGAAGAAAATG-39)
and CS-NotI-R (59-ATTGCGGCCGCTTTAAAATATACTTGAAC-39) to
yield a 972-bp fragment lacking the N-terminal signal sequence and C-
terminal GPI sequence. The gene was inserted into a mammalian expres-
sion vector, pCI-Neo, that had been previously digested with XhoI and
NotI followed by shrimp alkaline phosphatase treatment. The CS gene
in both the virus and plasmid were sequenced (Secugen, Madrid, Spain).
The plasmid was purified using a Qiagen Mega Prep kit according to the
manufacturer’s protocol. Expression of CS from pCI-Neo-CS was con-
firmed by transfecting DF-1 cells followed by Western blot analysis with
CS specific Abs.
pGEX-CS/pGEX-CS14K. The CS gene from pCI-Neo-CS plasmid was
amplified using the primers CS-EcoRI-F (59-ACTTAGAATTCATGTGT-
TACAATGAAGAAAATG-39), CS-NotI-R (59-ATTGCGGCCGCTTTAA-
AATATACTTGAAC-39) for pGEX-CS, and with primers CS-EcorI-F and
CS-14K-NotI-R (59-ATTGCGGCCGCTATTAAATATACTTGAAC-39) for
pGEX-CS-14K. The A27L open reading frame from vaccinia strain WR
(accession no. YP_233032; www.ncbi.nlm.nih.gov/genbank/) was ampli-
fied with the primers A27L-NotI-F (59-GCTGCTAGCGGCCGCGAGG-
CTAAACGCGAAG-39) and A27L-XhoI-R (59-CCCTCGAGTGGGTTA-
CTCATATGGACG-39) to generate a 276-bp fragment that lacks the first
28 aa from the original sequence. The chimeric gene fragment was gen-
erated by digesting with NotI followed by ligation. The fusion gene
fragment was then inserted into pGEX-6p-1 plasmid to produce pGEX-
CS14K plasmid.
Recombinant protein construct and protein isolation
The recombinant proteins were purified from Escherichia coli strain
DH5-a. The starter culture was diluted 1:100 in fresh Luria-Bertani media
and allowed to grow at 37˚C until the OD600 reached 0.7, following which
isopropyl b-D-thiogalactoside was added to a final concentration of 1 mM.
The culture was then incubated in an orbital shaker at 18˚C and 200 rpm
for 24 h. After the incubation, the cells were harvested and the pellet was
suspended in extraction buffer (50 mM Tris-HCl [pH 7.5], 250 mM NaCl,
1 mM EDTA and protease inhibitor tablets; Roche). The cells were then
lysed with lysozyme, added to a final concentration of 1 mg/ml, and in-
cubated on ice for 20 min. Following lysozyme treatment, 1% Sarkosyl
detergent and 1% Triton X-100 was added and incubated at 37˚C for 10
min. Clarified supernatant from the lysis was incubated with glutathione-
Sepharose 4B beads at 4˚C overnight. The beads were then washed using
three washes with wash buffer I (extraction buffer with 0.5% Triton X-114)
and three with wash buffer II (extraction buffer with 0.1% Triton X-114)
followed by two washes with extraction buffer. The purified protein was
then eluted with 20 mM reduced glutathione. The protein was desalted
using an Amicon centrifugal concentrator and the protein concentration
was determined using Bradford reagent. The GST tag from the protein
was cleaved using PreScission protease (GE Healthcare) according to
the manufacturer’s protocol. The proteins were tested for LPS contami-
nation using a chromogenic Limulus amebocyte lysate kit (QCL-1000;
Lonza), which was maintained at ,2 endotoxin units per microgram of
protein.
Neutralization assay
Sera from immunized rabbit were inactivated at 56˚C for 30 min, following
which 2-fold serial dilutions of the serum were made and incubated with
200 PFU MVA at 37˚C for 1 h. Afterwards, confluent DF-1 cells were
infected in triplicate and were visualized by immunostaining with anti-WR
serum after 48 h. As a control, nonimmune serum from nonimmunized
animals was used. The number of plaques obtained from each serum di-
lution was normalized to this control value.
Nitrite measurement
NO synthesis was measured by estimating the levels of nitrite present in the
supernatant. Briefly, J774 cells were stimulated with proteins. For in vivo
nitrite analysis, 106 splenocytes from vaccinated animals, sacrificed
53 d after boost, were treated with 5 mg/ml CS protein. Nitrite accumu-
lation was measured by treating 50 ml supernatant with 50 ml Griess re-
agent I (1% sulfanilamide solution in 2.4 N HCl) for 10 min in dark
followed by the addition of 50 ml Griess reagent II (0.1% naph-
thylethlyenediamine in 2.4 N HCl) for 10 min. The assay was read by a
spectrophotometer at 540 nm.
RNA extraction and RT-PCR
Total RNA was extracted from cells treated with respective proteins for
24 h, using a RNeasy Mini kit according to the manufacturer’s instruc-
tions. Analysis of RNA was carried out using RT-PCR as described in the
kit for reverse transcriptase (Invitrogen). Briefly, 1 mg RNA was reverse
transcribed into cDNA using oligo(dT) primers (Invitrogen). For relative
quantitative PCR, 2 ml cDNAwas used as a template with primers specific
for inducible NO synthase, IL-12p40, and GAPDH (23). All the experi-
ments were done in triplicates and the bands from gel electrophoresis were
quantified using Adobe Photoshop CS4.
Confocal microscopy
Immunostaining was carried out as described previously (24). Briefly, after
fixation (30 min; 4% formaldehyde in PBS; 37˚C), permeabilization in
0.1% Triton X-100 (Sigma-Aldrich), and blocking with 10% FCS in PBS,
cells were incubated with primary Ab (anti-CS Ab, 1:500; C3-anti-14K,
1:400; NF-kBp65, 1:500) along with DNA staining dye, DAPI (1:200), for
1 h at room temperature. Following extensive washing with PBS secondary
Abs (Alexa 546 goat anti-mouse and Alexa 488 goat anti-rabbit, 1:500)
were applied for 1 h at room temperature. The slides were washed three
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times with PBS and mounted in ProLong antifade medium and analyzed
with a Bio-Rad Radiance 2100 confocal laser microscope.
Animals and immunizations
All animal procedures were approved by the Ethical Committee of Animal
Experimentation of Centro Nacional de Biotecnologia (Consejo Superior de
Investigaciones Cientificas). Female BALB/C mice (H-2d), 6–8 wk old,
were obtained from Harlan U.K. A standard immunization protocol based
on a heterologus prime–boost approach designed in the laboratory was
followed (25). In short, animals were primed with DNA (100 mg; DNA-CS
or empty DNA-f) or protein (20 mg; CS or CS-14K) via intradermal route
and were boosted after 2 wk with 2 3 107 PFU respective sucrose-purified
viruses (MVA or MVA-CS) through i.p. injection. All the preparations
were made in endotoxin-free PBS.
P. yoelii sporozoite challenge study
Challenge experiments were performed as previously described (26).
Briefly, sporozoites were obtained from the salivary glands of Anopheles
stephensi mosquitoes. Two weeks after boost, mice were challenged with
2 3 104 sporozoites via i.v. route through the tail vein. After 42 h, animals
were sacrificed and levels of P. yoelii 18S rRNA levels were assessed
by quantitative RT-PCR. To determine sterile protection 2 wk after im-
munization, mice were challenged i.v. with 300 P. yoelii sporozoites.
Parasitemia was monitored by performing daily blood smears from days 3
to 21.
ELISA and Ab avidity
Abs present in the serum of immunized animals were determined using
ELISA as previously described (25). Purified CS protein was coated to
the 96-well Nunc MaxiSorp plates at a concentration of 2 mg/ml in
coating buffer (NaHCO3/Na2CO3) at 4˚C overnight. Bound Abs were
detected using 1:2000 dilution of alkaline phosphate-conjugated goat
anti-mouse Ab total IgG or IgG1 or IgG2a (SouthernBiotech, Birming-
ham, AL). Plates were developed by adding TMB substrate (Sigma-
Aldrich) and stopping the reaction with 1 M H2SO4. OD was read at
450 nm. Endpoint titer values were determined as the last positive di-
lution of serum giving an absorbance value 3-fold higher than naive
serum. For analyzing the avidity of Abs, an initial serum dilution that
gave an absorbance of 2.7 ELISA units was selected. Following incu-
bation, with serum, the Ag/Ab interaction was disrupted using a range of
dilutions from 0 to 5 M urea (Invitrogen) in Tris-HCl (pH 8.0) for 15 min
before the addition of secondary Ab. EC50 was then calculated by lin-
ear regression (R2 = 0.99) between 1 and 5 M urea concentration (log of
50% reduction, 1.699).
IFN-g ELISPOT analysis
Fresh IFN-g ELISPOT analysis was carried out as previously described
(27).
Multiparameter flow cytometry
Flow cytometry and intracellular cytokine staining analysis were performed
to detect the different phenotype of lymphocytes secreting cytokines, as
reported previously (25). Briefly, 43 106 splenocytes were stimulated with
1 mg/ml CD8+ peptide, PyCS280–288 (SYVPSAEQI), with GolgiPlug (BD
Biosciences) for 6 h in a 96-well plate. The cells were then washed and Fc
receptors were blocked using anti-CD16/CD32, following which the cells
were stained with surface-specific mouse Abs, namely CD4-Alexa 700,
CD3-FITC, and CD8-PerCP for adaptive response studies, or CD8-FITC,
CD44-PeCy5, and CD62L-PE for memory studies. Cells were per-
meabilized using the BD Cytofix/Cytoperm kit (BD Biosciences) and
were stained for intracellular cytokines IFN-g/allophycocyanin, IL-2/PE,
and TNF-a/PeCy7 for adaptive response or with IFN-g/PeCy7, IL-2/allo-
phycocyanin, and TNF-a/PE for memory response. A million cells were
then passed through an LSRII flow cytometer (BD Biosciences) and the
data were analyzed with FlowJo (Tree Star) and Spice (version 5.0). Ap-
propriate controls were used and the values from unstimulated samples
were subtracted.
Statistical Analysis
Statistical analysis was performed using Minitab for Windows. For
ELISA, to determine the differences between groups we performed
a linear regression of the logarithmic absorbance versus the logarithmic
dilution, removing those samples clearly not following a linear trend (R2
. 0.98). We then computed the logarithmic dilution at which this re-
gression line was crossing the threshold given by twice the absorbance of
the control values for that mouse. Doing this for the four mice we have
four estimates of the logarithmic dilution beyond which the absorbance is
smaller than twice the absorbance given by the control. We will refer to
this value as the critical logarithmic dilution. Finally, we compared with
a Student t test the hypothesis that the critical logarithmic dilution be-
tween the groups. For intracellular cytokine staining and ELISPOT,
statistical analysis was done based on a previously described method
(25). Briefly, we developed a novel method for analysis by correcting the
control values (RPMI 1640) for determining standard deviations and
p values for the samples.
Results
14K fusion aids CS protein aggregation
To investigate the effects of 14K conjugation with CS, we deter-
mined the structural organization of CS protein and its reactivity
against Abs generated from P. yoelii sporozoites. With the aim of
improving the immune response against CS, we removed the GPI
motif (28) and signal sequence in the CS and fused it with the 14K
protein after deleting the first 28 aa from A27, which is respon-
sible for producing neutralizing Abs against vaccinia virus (Sup-
plemental Fig. 1A). Abs generated against CS14K did not neu-
tralize the infectivity of MVA as seen by neutralization assay
(30–36 spots/well) (Supplemental Fig. 1B). Using SDS-PAGE
analysis under reducing and nonreducing conditions, we evalu-
ated the oligomerization/aggregation status of recombinant pro-
teins and their reactivity with a CS-specific mAb obtained after
immunization with sporozoites (Fig. 1A, 1B). Under reducing
conditions CS14K has a molecular mass of ∼60 kDa, compared
with ∼50 kDa for CS, whereas under nonreducing conditions
CS14K has a size apparently .250 kDa, in contrast to 50 kDa
for CS. Additional experiments by analytical ultracentrifugation
revealed that CS14K protein has a main sedimenting species with
a standard s value of 4.3 6 0.1, which is compatible with a
moderately elongated protein dimer (calculated frictional ratio
f/f0 = 1.8). The CS14K has high tendency to form oligomers/
aggregates (data not shown). To determine the kinetics of CS
expression by the vector MVA-CS, we performed time-course
analysis of cells infected with the MVA recombinant expressing
CS (Fig. 1C). We observed that after infection with MVA-CS,
CS was detectable 2 h postinfection, and these expression levels
remained elevated up to 6 h postinfection. Next, to determine
whether CS expressed by MVA undergoes posttranslational
modifications, we incubated infected cells in the presence of
tunicamycin and observed that most of the CS expressed in the
virus-infected cells was glycosylated, as indicated by the reduced
intensity of the protein bands (Fig. 1D). We also investigated
whether there was any difference in the localization of proteins in
macrophages expressed by virus or upon transient transfection. To
study the subcellular localization of full-length CS during infec-
tion with MVA-CS, J774 cells were infected at a multiplicity of
infection of 5 PFU/cell for 18 h. We observed that MVA-CS
expresses CS as punctuated spots with complete cytoplasmic
spread (Supplemental Fig. 1C). In contrast, when macrophages
were transfected with DNA encoding CS and CS14K, we observed
that CS and CS14K were strongly localized with the nuclear en-
velope of the cell.
Taken together, these data show that the 14K (A27L) protein of
vaccinia virus when fused to CS protein of Plasmodium is able to
form oligomers/aggregates displaying an apparent molecular mass
of .250 kDa compared with its monomeric CS counterpart of 50
kDa. A moderately elongated protein forming oligomers/aggre-
gates was observed when CS14K protein was run under nonre-
ducing conditions by analytical ultracentrifugation. The lower
band that we see in the immunoblot under reducing condition is
the cleaved CS14K protein. We therefore sought to investigate
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a possible biological effect on the immunogenicity of CS protein
when fused with A27.
CS14K protein modulates innate immune responses in
macrophages
Fusion of Ags to immunomodulatory fragments such as TLRs
(5) or to complement proteins (29), which is aimed at improving
immunogenicity by aggregation of proteins or by exploiting the
innate immune signaling of macrophages, is an intense area of
research. Because fusion of 14K protein to CS facilitates its ag-
gregation, we sought to investigate whether this could also mod-
ulate the innate immune responses in macrophages.
Ability of macrophages to induce NO to inhibit the growth of
parasite has been well documented (30); therefore, we sought to
evaluate the ability of the fusion protein to induce NO production.
When comparing the NO levels in supernatant of J774 cells
treated with fusion protein or normal protein, it was apparent that
only CS14K resulted in NO production (Fig. 2A). However, when
the cells were stimulated with proteins along with recombinant
IFN-g, elevated levels of NO were found in all samples, regardless
of the presence of additional proteins (data not shown). Further
analysis revealed a significant increase in NO (p = 0.044) and IL-
12p40 (p = 0.05) mRNA levels in CS14K-treated macrophages
compared with CS protein treatment (Fig. 2B). We next investi-
gated the effects of proteins on IL-6 and TNF-a secretion, given
their possible role in controlling pre-erythrocytic stages of ma-
laria. Chimeric protein was able to induce a significant increase in
IL-6 in macrophages (Fig. 2C). Although not statistically signifi-
cant, we also observed increased TNF-a production at 24 h with
CS14K treatment.
Given the significance of TLR activation and the induction of
type I IFN, experiments focused on the analysis of the downstream
molecules involved in IFN signaling such as IFN regulatory factor
(IRF)-3 and STAT-1 were performed. To determine whether there
are differences between CS and CS14K, human macrophage
THP-1 cells were stimulated and harvested at different time intervals
and probed with phospho-Abs against STAT-1 and IRF-3 (Fig. 2D).
It is notable that CS14K was particularly effective in activating
STAT-1 and IRF-3. To ensure that the activation of STAT-1 and
IRF-3 is not influenced by any dsRNA contamination, the cells
were stimulated with proteins previously digested with RNAse III
(Supplemental Fig. 2).
NF-kB, an important transcription factor responsible for acti-
vating several genes involved in innate immune signaling in
macrophages, has been shown to be blocked by CS protein (11).
Therefore, we analyzed whether CS14K could overcome this
constraint. Although both CS and CS14K proteins led to early
degradation of IkB (Fig. 2E), the movement of p65 into the nu-
cleus was inhibited (Fig. 2F).
In summary, these data establish that the fusion of A27 protein to
CS could alter the innate immune responses in macrophages by
STAT-1 and IRF-3 activation without the involvement of NF-kB,
which possibly resulted in increased levels of NO, IL-6, and IL-12
production, suggesting signaling via the TLR4 pathway. CS14K
was also able to activate higher levels of CD54, a marker for
macrophage activation (data not shown). We therefore sought to
investigate whether such a response could alter the immunoge-
nicity of the protein in vivo.
CS14K fusion protein priming arms the humoral responses
in vivo
It is well established that a strong Ab response against CS corre-
lates with higher protection in many animal and human models (31,
32). The magnitude, isotype, and systemic availability of the Ab
produced are important parameters that govern the control of
parasites and help to resolve disease (33, 34).
Two weeks after the final phase of the prime–boost vaccination
protocol described inMaterials and Methods, quantitative analysis
FIGURE 1. Biophysical and biochemical properties
of recombinant proteins: Coomassie blue-stained SDS
page and immunoblot with mAb against CS (NYS1;
1:1000 dilution) of 1 mg recombinant (A) CS protein or
(B) CS14K protein, under reduced (R) and nonreduced
(NR) conditions. Western blots of DF-1 cells infected
with MVA-CS virus at 1 MOI for (C) 2, 6, and 8 h or
for (D) 16 h in the presence and absence of 10 mg/ml
tunicamycin and probed with NYS1 Ab.
6410 A CHIMERIC CS14K PROTEIN AS IMMUNOGEN
 at CSIC-Ctro N
ac de Biotechnologia on A
pril 17, 2013
http://jimmunol.org/
D
ow
nloaded from
 
of the Abs produced showed that priming with CS14K chime-
ric protein followed by MVA-CS induced significantly higher
titers of Abs than mice primed with DNA-CS or CS protein alone
(Fig. 3A). The Ab titers of CS14K-primed group was 2-fold
greater than the CS-primed group (p = 0.008) and 8-fold more
than in the DNA-CS–primed group (p = 0.002). Even 53 d after
boost, the Ab levels in all of the immunized groups were main-
tained at similar levels except for DNA-CS, which showed a re-
duction by 1 log (data not shown).
Further analysis of IgG isotype switching showed that fusion
protein induced a higher IgG1 response whereas the DNA-
vaccinated group showed a predominance of IgG2a response.
The levels of IgG1 (p = 0.012) and IgG2a (p = 0.030) induced
by the fusion protein-primed group were almost double those of
the CS-primed group (Fig. 3B). Finally, we sought to determine
whether the vaccination with chimeric protein affected the avidity
of the CS-specific Abs. The Abs from mice primed with CS14K
showed higher avidity (EC50 = 4.2 M urea) whereas those primed
with DNA-CS (EC50 = 2.3 M urea) or CS (EC50 = 2.5 M urea)
protein had lower affinity (Fig. 3C). Taken together, these data
indicate that priming with proteins, as compared with DNA alone,
enhances levels of Abs against CS. Additionally, priming with
CS14K not only increases the overall production of Abs but
appears to induce a more balanced production of high-affinity
IgG1 and IgG2a Abs.
Having established that CS14K can mediate the induction of
NO in cultured macrophages, we sought to assess the ability of
splenocytes from vaccinated mice to respond to purified CS protein
by evaluating NO production. Consequently, splenocytes harvested
from animals receiving a different prime–boost vaccine regimen
53 d after boost were stimulated with 5 mg/ml purified CS protein
for 48 h. Mice that were primed with DNA-CS showed no de-
tectable NO. Alternatively, mice that received proteins as priming
agents were able to induce NO production (Fig. 3D). Whereas CS
protein was able to increase NO by low levels, CS14K increased
NO production by 4-fold (p = 0.001). These data indicate a re-
duced capability of CS-based vaccination to induce NO compared
with CS14K. The unique nature of CS-based malaria vaccines to
induce NO has not been reported before. Thus, the fusion of
oligomerization domain of 14K protein to CS improves the hu-
moral arm of immune responses against the Ag along with in-
creased production of NO.
CS14K generates durable and polyfunctional CS-specific
CD8+ T cells in mice
Given the critical role of 14K fusion in aggregating CS protein and
the enhancement of innate immune responses, we examined the
influence of these factors may have on the development and
maintenance of CD8+ T cells in vivo.
After mice were immunized, they were sacrificed on day 14 to
study the adaptive immune response and on day 53 for memory
analysis. Efficacy of the vaccination regimen was analyzed using
an IFN-g–based ELISPOT assay and multiparameter flow cytome-
try. The fusion protein significantly improved the CS-specific IFN-g–
secreting cells (p, 0.05) compared with other vaccine regimes (Fig.
4A, 4B). We characterized the immune responses in terms of
polyfunctionality, CD8+ T cells specific for the peptide 280–288
of P. yoelii CS protein, secreting IFN-g, TNF-a, IL-2, or any
combination among these three cytokines. A clear dominance in
CD8+ T cell-secreting cytokines was seen in CS14K-primed group
of animals over CS protein (2.2-fold)- or DNA-CS (4.3-fold)-
primed groups (Fig. 4B) at day 14 after boost. Clearly, cells that
secreted IL-2 were associated with triple cytokine-producing cells.
Vaccine regimen involving DNA-CS priming resulted in single- or
FIGURE 2. Modulation in innate immune sensing
of CS14K by macrophages: fusion protein can acti-
vate innate sensing in macrophages. THP-1 or J774
macrophage cells were stimulated with 5 mg/ml pro-
teins or as positive control with 1 mg/ml LPS. (A)
Induction of NO by proteins in macrophages. Nitrite
accumulation in the supernatant was determined after
48 h protein treatment in J774. (B) Semiquantitative
RT-PCR analysis of NO and IL-12p40 expression.
RNAwas extracted and the corresponding cDNAwas
obtained as mentioned in Materials and Methods.
Proportionate volume of amplified DNA was run on
8% agarose gel. (C) Cytokine analysis by Luminex
assay. Supernatants were collected after 6 and 24 h
treatment. Cytokine levels in the supernatant were
measured by Luminex. (D) CS14K induces IRF-3 and
STAT-1 phosphorylation: 2 3 106 THP-1 cells were
stimulated with proteins, following which the samples
were collected at different time intervals and probed
with phospho-Abs against IRF-3 and STAT-1. Nor-
malization was carried out using total STAT-1 and
IRF-3 Abs (1:1000). (E and F) Proteins inhibit NF-kB
activation: proteins block the movement of p65
(mouse anti-p65 NF-kB Ab p65, 1:500) into the nu-
cleus in J774 macrophages inspite of IkB degradation.
Images were acquired at363 objective magnification.
Data are expressed as mean 6 s.e. of triplicate ob-
servation and are representative of two independent
experiments. *p , 0.05, **p , 0.005.
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double-positive cells and did not induce any triple-positive pop-
ulation. In contrast, animals receiving protein prime were able to
induce IFN-g+TNF-a+IL-2+–secreting cells with CS14K bringing
an ∼3.6-fold increase over CS. Additionally, CS14K significantly
increased double-positive IFN-g+TNF-a+ over both CS protein
and DNA-CS priming.
To study memory responses, the CD8+ T cells were classi-
fied into central memory (CD44highCD62Lhigh), effector cells
(CD44highCD62Llow), terminally differentiated memory effector
memory cells (CD44lowCD62Llow), and naive cells (CD44low
CD62Lhigh) (35, 36). Upon analyzing memory responses on day
53 and also on day 120 (data not shown), we observed rapid
proliferation of the peptide-specific effector CD8 T cell pop-
ulation. Interestingly, the frequency of cells secreting IFN-g was
maintained even during the memory stage by CS14K priming
compared with other groups (Fig. 4C). In terms of poly-
functionality, priming with fusion protein had a significant in-
crease in the triple-positive (IFN-g+TNF-a+IL-2+) and double-
positive (IFN-g+TNF-a+) population of cytokine-secreting cells
over both DNA as well as CS protein (Fig. 4D). Most of the
single-positive cells were dominant for TNF-a. A 3.5-fold in-
crease in IFN-g+TNF-a+IL-2+–secreting cells by the CS14K-
primed group over the CS protein-primed group and a nearly
14-fold increase over the DNA-CS–primed groups was seen. A
clear hierarchy in CS peptide-specific total CD8 cells secreting
cytokines was observed when priming was carried out with
CS14K (Fig. 5A). Mice immunized with proteins showed signif-
icant increase in magnitude of cytokines released over DNA-CS
priming. Indeed, priming with CS14K protein rather that CS pro-
tein led to a 2-fold increase in total IFN-g (p , 0.05) and TNF-a
(p , 0.0005) in addition to the 3-fold increase in IL-2–secreting
cells (p , 0.05). Interestingly, all of the positive CD8 T cells
produced by the vaccine regimen had a phenotype resembling
either T effector cells or terminally differentiated effector memory
cells. To extend the immune analysis, we evaluated the amount of
IFN-g or TNF-a secreted by the different populations based on the
mean fluorescence intensity (MFI) calculation (Fig. 5B). We ob-
served that, irrespective of priming agent, most of the IFN-g was
produced by IFN-g+TNF-a+IL-2+ or IFN-g+TNF-a+ cells with a
similar pattern for TNF-a. The lack of CM CD8 T cells could be
explained by the fact that upon exposure to peptide stimulus most
of the CM cells rapidly acquired effector memory characteristics.
These data indicate that proteins are able to prime to a higher
extent an effective long-term CD8 T cell response than does DNA.
The enhanced CD8 T cell responses in mice immunized with
CS14K rather that CS is due to the adjuvant-like effect of the
unique A27 element.
CS14K fusion protein abrogates the liver stage development of
parasites when challenged with sporozoites
Given that polyfunctional CD8+ T cell responses in addition to
high-avidity Abs are crucial in enhancing protection against par-
asite infection, and also that CS14K improved both adaptive and
memory immune responses, compared with CS or DNA-CS
FIGURE 3. Chimeric protein generates elevated
levels of high-avidity Abs in addition to NO. (A) Total
IgG serum Ab responses against CS protein as mea-
sured by ELISA. (B) IgG isotypes induced by immu-
nizations. Levels of IgG1 and IgG2a Abs generated by
the vaccine regimes are shown. Control groups rep-
resent the animals receiving empty DNA or PBS for
priming and MVA as boost. (C) Avidity indices of the
Abs against CS protein. The avidity index was arbi-
trarily considered as the molarity of urea required to
reduce the initial absorbance by 50% (i.e., log10
50% = 1.69). (D) Splenocytes from vaccinated groups
harvested after 53 d after boost were incubated with 5
mg/ml recombinant CS protein for a period of 48 h.
Amount of NO in control groups was deducted from
DNA-CS– and protein-primed groups. Data are
expressed as means 6 SEM of triplicate observation
(n = 4 mice/group) and are representative of two in-
dependent experiments. *p , 0.05, **p , 0.005,
***p , 0.0005.
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priming, we sought to investigate the efficacy of immunization
against sporozoite challenge. Protection was evaluated by mea-
suring levels of P. yoelii 18S rRNA in liver and also by deter-
mining parasitemia in sporozoite-challenged animals. To in-
vestigate the protective capacity of this subunit vaccine, groups
of mice were immunized in various prime–boost protocols (Fig.
6). We show that a heterologus protein prime/vaccinia virus boost
regimen was found to be more effective than a homologous pro-
tein prime/protein boost regimen, and a 32% reduction in the liver
stage burden of parasites was observed in mice receiving CS14K
(CS14K/CS14K) compared with CS (CS/CS) protein. Further-
more, a MVA-CS boost significantly lowered the parasite levels in
the liver. Moreover, the CS14K protein priming followed by
MVA-CS resulted in a near complete inhibition (∼99.9%; p ,
0.005) of parasite development in liver compared with CS protein
and DNA-CS (Fig. 6).
To evaluate whether protection from liver-stage parasites in-
duced by CS14K/MVA prime–boost can prevent the development
of blood stages, mice were challenged with 300 live P. yoelii
sporozoites and monitored until patency. Importantly, none of the
vaccinated animals developed blood stages from days 3 to 21 of
daily follow-up after challenge with sporozoites (Table I).
Thus, priming with CS14K protein in combination with a boost
by MVA-CS is a highly effective vaccine regimen against murine
malaria liver stage parasites. A proposed mechanism is shown in
Fig. 7.
Discussion
In this study, we report a novel approach in designing effective
protein vaccines based on the fusion of 14K (A27) protein of
vaccinia virus with a model Ag, CS of P. yoelii, for developing an
effective vaccination regimen based on protein prime/vaccinia
virus boost against murine malaria. An obvious advantage of
this vaccine strategy is the concomitant increase in both CS-
specific humoral and CD8+ T cells up to 4 mo. By comparing
CS14K protein with other priming agents such as CS- and DNA-
CS–based vaccines, we showed the correlation between the im-
mune responses generated and protective efficacy generated in
the murine malaria model.
In this study, we showed that the fusion of 14K protein with
CS results in a protein with high tendency to form oligomers/
aggregates of CS14K, which, in turn, enhanced the immune re-
sponse profile leading to protection against murine malaria. Pre-
vious studies have demonstrated the differences in CS-specific
T cell proliferation using recombinant soluble CS protein, viable
sporozoites, or heat-killed sporozoites (37). This could explain the
enhancement of polyfunctional T cells and Abs when animals are
primed with chimeric protein rather than CS, which contains
lower amounts of CS aggregates. An obvious advantage of this
chimeric protein is the incorporation of near full-length CS protein
containing both B and T cell epitopes whose presentation would
be enhanced as a result of aggregation. Additionally, the use of
viral vaccinia vectors for boosting could further enhance the de-
velopment of long-term effector CS-specific T cells. In Fig. 6, we
show how the vaccine regimen based on CS14K prime/MVA-CS
boost inhibits the liver stage development of the parasite in mice
when challenged with a high dose of sporozoites. When we cal-
culated the CT value of individual mice in each group we found
that for the CS14K/MVA-CS group the values were well .35, the
reference value in naive mice (indicated as dotted lines in Fig.
FIGURE 4. Enhanced immunogenicity of vaccine regimen based on chimeric protein. BALB/c mice were primed intradermally with DNA or proteins
and boosted with i.p administration of 23 107 PFU MVA-CS after 2 wk. Splenocytes were stimulated with CS peptide SYVPSAEQI. The primary immune
responses were analyzed on day 14 by (A) IFN-g ELISPOT assay and (B) CD8+ cells secreting IFN-g, TNF-a, and IL-2 by polychromatic flow cytometry.
Memory responses were analyzed on day 53 after boost (C) IFN-g ELISPOT assay and (D) memory CD8 analysis using CD44 and CD62L memory
markers. Pie charts represent the polyfunctionality of CD8+ T cells secreting single, double, and triple cytokines. Data are expressed as means 6 SEM of
triplicate observations (n = 4 mice/group) and are representative of two independent experiments. *p , 0.05, **p , 0.005, ***p , 0.0005.
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6). This suggests that the mice in this group did not have any
parasite in the liver. Moreover, given that sterile protection is the
target of pre-erythrocytic vaccines, we showed that CS14K/MVA-
CS prime–boost prevented the development of blood stage para-
sites (Table I). The maintenance of both cellular and humoral
responses even after 4 mo indicated the strong nature of the vac-
cine regimen used in this study.
Besides protein aggregation, another mechanism that could
explain the enhanced immunogenicity of CS14K is its ability to
activate type I IFN signaling. Given that an early activation of
innate immune responses curbs the pre-erythrocytic development
of parasites (38, 39), activation of type I IFN signaling by fusion
protein further validates its use as a priming agent. Indeed, acti-
vation of type I IFN signaling by the chimeric protein did result in
elevated levels of cytokines belonging to this family such as IL-6,
TNF-a, and IL-12. It is thought that the parasiticidal action of
TNF-a in hepatocytes is mediated through the synthesis of IL-6
(40). Furthermore, engaging TLRs is critical in developing anti-
malarial immunity, which could be explained by the poor immu-
nogenicity of RTS,S without a strong adjuvant such as AS01E,
a TLR4 agonist (41). A recent study also shows the importance
of TLR signaling for effective development of protective Abs
to Plasmodium (42). This is in agreement with our study, which
shows how enhancement in STAT-1 and IRF-3 by CS14K sug-
gested a role in TLR4 activation (Fig. 7), resulting in improved
immunogenicity and inhibiting the liver stage development of the
parasite (43, 44).
It is known how parasites such as Leishmania and Plasmodium
downregulate synthesis of NO (45). Our study shows the inherent
capacity of chimeric protein to enhance the production of NO both
in vitro and in vivo. Because neither CS nor 14K protein alone
could induce NO, it seems reasonable to conclude that the CS14K
FIGURE 5. Polyfunctionality related to increased cytokine production by CS14K induced memory CD8+ T cells: characterization of memory CD8+
T cells. (A) Representation of total CS peptide specific CD8 cells were gated on CD44 and CD62L cell surface markers represented on left-hand side of the
diagram. Total CD8 responses for each group are represented inside the box. Different populations of memory CD8 cells secreting different cytokines are
represented on the right-hand side with their respective total responses as depicted insdie the box. (B) MFI of IFN-g and TNF-a produced by different
polyfunctional population of effector memory CD8+ T cells (n = 4 mice/group).
6414 A CHIMERIC CS14K PROTEIN AS IMMUNOGEN
 at CSIC-Ctro N
ac de Biotechnologia on A
pril 17, 2013
http://jimmunol.org/
D
ow
nloaded from
 
protein aggregation is responsible for NO induction. The persis-
tently elevated levels of NO at 53 d after vaccination with chi-
meric CS14K protein compared with priming with DNA-CS or
protein alone suggest that differences exist in the processing of
these Ags by APCs. Additionally, early production of NO has
been proposed to be required for proliferation of CD8+ T cells
against the parasite (46). In conclusion, fusion of 14K to CS leads
to a more favorable immunogenic milieu to enhance the efficacy
of the vaccine.
Protective immunity against malaria associates with circulating
IgG Abs against CS (47). Previous studies have also shown the
ability of fusion proteins to induce strong humoral responses
based on their ability to form large molecular mass aggregates
(20). Similar to the CS14K priming approach presented in this
study, the malaria vaccine in the latest stages of clinical trials,
RTS,S, is also dependent on a higher magnitude of Abs belonging
to the IgG1 subclass (48). Vaccine studies based only on DNA-CS
vaccination lacking the GPI anchor improve protection up to 95%
based only on Ab titers (49). Also, the serum Ab titers obtained by
fusion protein priming are much higher than those obtained in
presence of strong adjuvants such as Freund’s adjuvant (50).
However, unlike vaccination with DNA-CS or protein alone,
vaccination with the CS14K fusion protein results in the con-
comitant induction of high levels of both IgG1 and IgG2a Abs,
and this could be beneficial in providing protection against
malaria. The chimeric protein proved to be superior in inducing
high-avidity Abs against CS comparable to those achieved by
using nanoparticle-based CS peptide vaccination (51). High-
avidity Abs produced by the chimeric protein could be due to
the unique folding pattern attained by CS14K protein resulting in
exposure of other potent epitopes. These data have important
implications in the choice of Ags designed to induce Ab responses
against malaria.
CD8+ T cell responses against CS protein are known to be an
important factor in the development of sterile immunity using ir-
radiated sporozoites (52). A role of CD8+T cells in subunit vac-
cine-induced protection against malaria was initially established in
a heterologus prime–boost approach with flu and vaccinia virus
vectors expressing CS (53).Vaccine regimes based on DNA as well
as protein prime followed by vaccinia boost have shown to induce
CS peptide-specific CD8+ T cell responses (15, 54). The ability of
the CS14K regimen to produce significantly elevated levels of
IFN-g and TNF-a single-positive– as well as double-positive–se-
creting CD8 T cells even after 53 d makes it a suitable vaccine
candidate. We also report a shift in polyfunctionality of CD8
T cells secreting all three cytokines produced by chimeric protein,
which may be effective in controlling the growth of parasites.
Furthermore, the ability of CS14K vaccine regimen to induce
a large amount of TNF-a has an added advantage because it is
known to be an important cytokine for the maintenance of
memory CD8 T cells in malaria (55). The concomitant increase in
TNF-a by CS14K could also contribute to elevated NO and Ab
responses (56, 57). The need for IL-12 in the development of
effective adaptive responses is in agreement with our study, which
shows the ability of CS14K protein to prime an enhanced T cell
response (58). The data from MFI studies show that double- or
triple-positive populations are better in producing elevated levels
FIGURE 6. Strong inhibition of liver stage parasite development by
CS14K. Mice were immunized as described in Materials and Methods.
Two weeks after boost animals were challenged with 2 3 104 P. yoelii
sporozoites through i.v. route via tail vein. After 42 h, the amounts of
parasites in the liver were estimated by measuring the number of copies of
18S rRNA by RT-PCR. The dotted line represents the minimum detectable
levels by the highly sensitive quantitative RT-PCR (26). Data are expressed
as means 6 SEM (n = 6 mice/group). *p , 0.05, **p , 0.005.
Table I. CS14K priming induces sterile protection
Priminga Boostingb Challengec
Protected/Challenged
(% Protected)
Prepatent
Period
CS14K MVA-CS 300 sporozoites 10/10 (100) —
PBS PBS 14 d after boost 0/10 (0) 4 d
aProtein (20 mg) administered intradermally.
bVirus (23107 PFU) administered i.p.
cChallenge via i.v. route.
FIGURE 7. Proposed TLR signaling mechanism by CS14K: a hypo-
thetical model of TLR4 signaling, pathway activated by fusion protein, in
a MyD88-independent fashion. Inhibition of p65 movement to the nucleus
by CS14K prevents the action of NF-kB while activation of IRF-3 and
STAT-1 leads to elevated levels of NO, IL-6, and TNF-a, which could
inhibit the growth of parasites.
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of cytokines, both of which are elevated by CS14K priming. The
low levels of CD8 responses against DNA-CS suggest that the
protective capability of this regimen may be based on the Abs
induced. The maintenance of such durable and polyfunctional
memory responses even after 4 mo of vaccination, taken together
with sterile protection, justifies the potent nature of A27 protein
fusion and its use for developing better malaria vaccines.
In recent years, many experimental CS-based vaccines have been
developed using novel adjuvants or by modifying the structure of
CS protein (Supplemental Fig. 3). The assessment of protective
capacity of vaccine regimen gave a good platform to study the
efficacy of chimeric protein generated by 14K fusion. Chimeric
protein prime–boost alone could inhibit the liver stage develop-
ment better than those attained by DNA-CS prime and MVA-CS
boost under a high challenge dosage. This could be explained by
the potent nature of the attenuated vaccinia viral boost (59).
Developing an effective pre-erythrocytic vaccine against ma-
laria is difficult because it requires high levels of both humoral and
cell-mediated immune responses. The role of CSPAbs in providing
protection is a much debated topic. However, the latest trial of
RTS,S vaccine does show that the protection could be mediated by
CSPAbs (60, 61). In this study, we describe an optimal prime–boost
approach using modified CS protein fused to the 14K protein of
vaccinia virus as priming and MVA-CS as a boost. This unique
approach is able to improve the magnitude and polyfunctionality
of both humoral as well as cell-mediated immune responses,
resulting in complete protection of vaccinated animals compared
with other experimental CS based vaccines (62–65). Additional
studies in primates could be performed using the chimeric protein
in prime–boost protocols. These data establish a ground for the
development of vaccines based on structural modifications of Ags
using the immunogenic molecules from vaccinia virus.
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Abstract
With the aim to develop an efficient and cost-effective approach to control malaria, we have generated porcine parvovirus-
like particles (PPV-VLPs) carrying the CD8+ T cell epitope (SYVPSAEQI) of the circumsporozoite (CS) protein from Plasmodium
yoelii fused to the PPV VP2 capsid protein (PPV-PYCS), and tested in prime/boost protocols with poxvirus vectors for efficacy
in a rodent malaria model. As a proof-of concept, we have characterized the anti-CS CD8+ T cell response elicited by these
hybrid PPV-VLPs in BALB/c mice after immunizations with the protein PPV-PYCS administered alone or in combination with
recombinant vaccinia virus (VACV) vectors from the Western Reserve (WR) and modified virus Ankara (MVA) strains
expressing the entire P. yoelii CS protein. The results of different immunization protocols showed that the combination of
PPV-PYCS prime/poxvirus boost was highly immunogenic, inducing specific CD8+ T cell responses to CS resulting in 95%
reduction in liver stage parasites two days following sporozoite challenge. In contrast, neither the administration of PPV-
PYCS alone nor the immunization with the vectors given in the order poxvirus/VLPs was as effective. The immune profile
induced by VLPs/MVA boost was associated with polyfunctional and effector memory CD8+ T cell responses. These findings
highlight the use of recombinant parvovirus PPV-PYCS particles as priming agents and poxvirus vectors, like MVA, as
booster to enhance specific CD8+ T cell responses to Plasmodium antigens and to control infection. These observations are
relevant in the design of T cell-inducing vaccines against malaria.
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Introduction
The development of a malaria vaccine is a major goal in the
fight against infectious diseases, as infection with Plasmodium
falciparum causes an estimated 225 million cases of malaria and
781,000 deaths from the disease worldwide, mostly among
children in Africa [1]. Progress in this direction has been obtained
with the demonstration in phase 2 clinical trials that the
administration of an anti-sporozoite vaccine based on the parasite
CS protein fused with the hepatitis B antigen (referred as RTS,S)
in combination with the adjuvants AS01 and AS02 generates in
children and infants around 50% clinical efficacy against malaria
[2,3,4] [5]. Immunological analysis indicates that the likely main
protective mechanism is the induction of antibodies against the CS
protein, while CD8+ T cell responses might play a minor role as
they are very modest [4,6]. The combination of anti-CS antibody
concentrations titers and CS-specific TNFa(+) CD4(+) T cells
could account for the about 50% level of protection against clinical
malaria conferred by RTS,S/AS01(E) [4,7]. Based on the CS-
protective efficacy, a phase III clinical trial is ongoing in 11 centers
in Africa with RTS,S (NCT00866619). Thus far, initial results of
this trial at 12 months provided about 50% reduction of clinical
episodes of malaria and severe malaria in vaccinated children 5 to
17 months of age [8]. The limited protection thus far obtained
with the RTS,S vaccine, suggest the need to improve the efficacy
of this malaria vaccine.
Because both B and T cell responses might be required for the
control of Plasmodium infection, it could be beneficial for the
current RTS,S vaccine to also enhance CD8+ T cell responses.
Numerous protocols have been developed that trigger specific B
and T cell responses to Plasmodium antigens with different
degrees of protection in animal models, using a combination of
viral and non viral vectors [9]. Among vaccine protocols, the
heterologous prime/boost immunization using poxvirus vectors as
booster has been shown to be quite effective at inducing T cell
responses with protection in animal model systems. In fact,
influenza and VACV vectors both expressing the CS antigen of
Plasmodium yoelii (P. yoelii), provided evidence in mice that the
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combination of influenza/poxvirus vectors was highly effective at
inducing specific CD8+ T cell responses and high levels of
protection against rodent malaria, and that the order of vector
immunization was critical [10]. The question of which are the
most appropriate vectors for use in human trials is still unclear and
is based on several assessments in which nature of antigens,
immune potency, durability, efficacy, safety and cost play
important roles. Recently, a combination of poxvirus vectors
(fowlpox and MVA) expressing different Plasmodium antigens has
shown lack of protection in phase I/IIa clinical trials [11], and this
could be related to the complex nature of the six pre-erythrocytic
malaria antigens linked together in a single protein. The use of
single protein components as immunizing agents that can prime
an anti-malaria immune response which is expanded after a boost
with a poxvirus vector could be a favorable option to avoid antigen
competition. Proteins can be delivered either alone, conjugated
with adjuvants, in the form of fusion polypeptides or as part of
virus-like particles (VLPs).
The use of VLPs might be preferable due to the ease of
production and of presentation of the malaria antigen, as the VLPs
behave as native virus particles during entry and processing into
antigen-presenting cells. It has been previously demonstrated that
chimeric PPV-VLPs carrying heterologous epitopes, when injected
intraperitoneally (i.p) into mice, activate strong CD4+ and CD8+
T-cell responses specific for the foreign epitopes, and these
responses are mediated by dendritic (DC) cells and influenced by
the flanking sequences [12,13,14]. PPV-VLPs are formed by the
assembly of 60 copies of the major virus capsid protein (VP2) of
PPV [15]. PPV-VLPs have been engineered to deliver CD8+ T-
cell epitopes [12] or CD4+ T cell helper epitopes [16] inserted into
the N terminus of the PPV VP2. Cytotoxic T lymphocyte (CTL)
response was characterized by a high frequency of specific T cells
of high avidity [17]. Moreover, the CTL activation does not
require CD4+ T cell help [12]. PPV-VLPs are captured by DC
through macropinocytosis and these cells are the only antigen
presenting cells (APCs) for PPV-VLPs [13]. VLPs can be found in
the endosome of DC, where processing of the epitopes inserted in
the VLPs takes place [13]. In addition, B cell epitopes can be
engineered on the surface of the parvovirus VLPs by manipulating
the VP2 loops to elicit a potent antibody response [18].
Thus, to enhance the CD8+ T cell response of a CS-based
immunization procedure, in this investigation we compared in
mice the immunogenicity and anti-malaria efficacy of protocols
based on priming with parvovirus PPV-VLPs carrying a CD8+ T-
cell epitope from the P. yoelii CS protein, restricted by the H-2Kd
molecule (SYVPSAEQI) and boosted with either a recombinant
replication competent (WR strain) or replication restricted (MVA
strain) of VACV, both vectors expressing the entire P. yoelii CS
protein.
Results
The CS-T cell priming effect induced by PPV-PYCS VLPs is
markedly enhanced by boosting with a replication
competent VACV vector
Recombinant PPV-VLPs have been shown to be effective
delivery systems of heterologous sequences that trigger specific
Th1 type of immune responses to the foreign epitopes when
inoculated in animal models [12,16]. With the aim to define the
priming capacity of PPV-VLPs in prime/boost combination of
immunogens, we generated recombinant PPV-VLPs by the
insertion into PPV VP2 of the specific CD8+ T cell epitope
(SYVPSAEQI) from P. yoelii CS protein, restricted by the H-2Kd
molecule [10]. A DNA fragment coding for the CS epitope was
fused to the 59-end of the gene coding for PPV VP2 capsid protein.
This chimeric gene, when expressed by the baculovirus system,
produces a CS epitope-VP2 fusion protein that self assembles
generating PPV-PYCS VLPs that can be easily purified (Figure 1).
Production and purification of PPV-PYCS from baculovirus
infected insect cells was performed as described under Materials
and Methods. Figure 1A shows a coomassie blue stained SDS-
PAGE of the purified PPV-PYCS. A main single band of about
67 kDa was observed on the gel, indicating high purity of the
recombinant protein. This was also confirmed by electron
microscopy as shown by a photomicrograph of the purified VLPs
in Figure 1B. To study the ability of PPV-PYCS to induce a
specific anti-CS T cell immune response, and to test whether the
achieved immune response could be enhanced after booster with a
replication competent VACV recombinant from WR strain
expressing the complete CS protein (VV-PYCS), we immunized
groups of BALB/c mice (5 per group) with PPV-PYCS given
subcutaneously (s.c) (10 or 50 mg/ per mouse), and boosted
14 days later with 107 pfu/mouse of VV-PYCS by the same route.
At 14 days after the booster, splenocytes from immunized animals
were subjected to a standardized and quantitative ELISPOT
assay, measuring IFN-c secreting cells [19]. We used MHC-class I
P815 cells (H-2d) as APC, pulsed with 1026 M of the synthetic
peptide SYVPSAEQI, corresponding to the P. yoelii CS protein.
Previous studies have shown the CD8+ T cell responses of the P.
yoelii CS-peptide (SYVPSAEQI), which is specific for IFN-c
secreting cells [10] [20]. As shown in Figure 2, animals immunized
with two doses of 10 mg of PPV-PYCS did not develop a
significant CS-specific CD8 T cell response. However, when
animals were boosted with a VV-PYCS a significant (p,0.001;
one-way ANOVA) increase in the response was observed. This
increment was dose-dependent, since animals primed with the
highest dose of PPV-PYCS (50 mg) developed the strongest
response. In addition, this response was specific, as a non-related
recombinant VACV expressing luciferase when used for booster
(VV-LUC) had no effect on T cell responses. These findings
revealed that while PPV-PYCS per se is low inducer of IFN-c
secreting cells, however, is an effective priming component when
booster is done with the replication competent VV-PYCS
recombinant vector.
Priming with PPV-PYCS followed by booster with
replication competent VV-PYCS protects mice against
liver stage parasites after challenge with P. yoelii
To determine whether PPV-PYCS prime/VV-PYCS boost
immunization could induce protective immunity against pre-
erythrocytic stages of the parasite, BALB/c mice (5 per group)
were immunized with 10 or 50 mg of PPV-PYCS administered s.c
and 2 weeks later were boosted with one dose of 107 pfu of VV-
PYCS administered by the s.c route. Thereafter, immunized mice
were challenged i.v with 5x105 P. yoelii highly infective sporozoites.
Parasite development was monitored at 42 h after challenge by
measuring plasmodial rRNA in the liver of the challenged mice by
semi-quantitative RT-PCR assay, a well defined and standardized
protocol to evaluate protection [10,21]. We found that mice
immunized following the prime-boost immunization scheme had
very low levels of the parasite load in the liver, with an 86%
percent reduction when the dose of PPV-PYCS was 50 mg and
81% reduction in parasitemia with a dose of 10 mg (Figure 3;
p,0.001 by one-way ANOVA). Mice immunized with either two
doses of PPV-PYCS or VV-PYCS showed a partial decrease of the
parasite load in the liver in comparison with non-vaccinated
control mice. These findings showed that administration of PPV-
VLPs alone does not protect against sporozoite challenge while the
Vaccine Efficacy against Malaria by VLPs/Poxvirus
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combination of PPV-VLPs/VACV is an effective protocol to
control P. yoelii infection.
Booster with a replication-restricted MVA-PYCS vector
triggers strong CD8+ T cell responses to CS after priming
with PPV-PYCS
While studies shown in Figures 2 and 3 were performed with
replication competent VACV, it was of interest to know to what
extent the use of a replication restricted and highly attenuated
vector like MVA [22] could boost PPV based anti-malaria
immune response. Thus, groups of BALB/c mice (5 per group)
were primed s.c with different doses of PPV-PYCS (10, 50 and
100 mg) and two weeks later those mice were boosted s.c with
107 pfu of the attenuated MVA-PYCS vector. A group of mice
immunized with 50 mg of PPV-PYCS and boosted with 107 pfu of
VV-PYCS was included as comparison for replication competent
vector. Also groups of mice primed/boosted with 100 mg of PPV-
PYCS, or primed with PPV-VLPs lacking the CS-specific CD8+ T
Figure 1. Characterization of PPV-PYCS VLPs. Conditions for generation of the PPV vector expressing the specific CD8+ T cell epitope of P. yoelii
CS, growth in baculovirus-infected insect cells and purification of the PPV-VLPs is described under Materials and Methods. (A). Proteins were resolved
by 9% SDS-PAGE and visualized after coomassie-blue staining. Molecular masses of standard proteins (lane 1) are indicated at the left. Lane 2, shows
partial purification and lane 3, purified protein with the size corresponding to the PPV VP2. (B). Electron microscope image of negatively stained PPV-
PYCS VLPs.
doi:10.1371/journal.pone.0034445.g001
Figure 2. The CS-specific CD8+ T-cell priming effect of PPV-
PYCS is markedly enhanced by boosting with replication
competent VACV vector expressing CS. Different groups of
BALB/c mice (5 per group) were immunized s.c with 10 or 50 mg of
PPV-PYCS [PPV(10 mg) and PPV(50 mg) respectively] or with VACV
vectors in prime/boost protocols. Fourteen days after the boost CS-
specific IFN-c secreting cells for the plasmodial epitope SYVPSAEQI in
splenocytes were measured by ELISPOT as described under Materials
and Methods. The results are expressed as the mean of triplicate assays
using cultured pooled splenocytes. Statistical values were determined
by one-way ANOVA; P values, *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0034445.g002
Figure 3. Protective capacity of PPV-PYCS prime followed by
booster with replication competent VACV vector expressing
CS. Groups of BALB/c mice (5 per group) were immunized with
different amounts of PPV-PYCS [PPV(10 mg) and PPV(50 mg)] or non-
vaccinated and two weeks later animals were boosted with the
replication competent VACV vector from the WR strain (referred as VV-
PYCS) or with PPV-PYCS. Thirteen days later, animals were challenged
with sporozoites and the amount of parasite rRNA in the liver of each
animal was estimated 42 h after the challenge, as described under
Materials and Methods. Results are expressed as the mean with
standard deviation. Statistical values were determined by one-way
ANOVA; P values, *P,0.05, **P,0.01, ***P,0.001. Lane (–), non-
vaccinated.
doi:10.1371/journal.pone.0034445.g003
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cell epitope and boosted with MVA-PYCS were included for
reference. The frequencies of ex vivo splenocytes producing IFN-c
upon MHC class-I restricted peptide stimulation was determined
by ELISPOT assay two weeks later. As shown in Figure 4, the
groups of animals receiving PPV-PYCS/MVA-PYCS had the
highest values of IFN-c secreting cells (p,0.001 by one-way
ANOVA). These values were even higher than those observed in
the group PPV-PYCS/VV-PYCS. Significantly, a low immune
response was obtained when single dose of MVA-PYCS was used,
or when it was given after priming with non-recombinant VLPs.
In addition, a minor immune response was obtained when PPV-
PYCS was used at 100 mg/per dose (Figure 4).
These findings clearly demonstrate that priming with PPV-
PYCS is necessary to activate specific T cells, but to obtain large
expansion of these T cells it required MVA-PYCS boost.
Protection against parasites after prime/boost with PPV-
PYCS/MVA-PYCS protocol
Next we examined if the increase in immune response observed
after MVA-PYCS boost is translated into a high degree of
protection. In this experiment we compared the protective
immunity elicited against parasite challenge after prime-boost
immunization with PPV-PYCS followed by VV-PYCS or MVA-
PYCS, with that obtained in a group of mice immunized with a
recombinant influenza virus expressing P. yoelii CS-CD8+ T cell
epitope (Flu-PYCS) and boosted with VV-PYCS. As shown in
Figure 5 the degree of protection, based on reduced parasitic
burden in the liver, was higher in the group of mice primed with
PPV-PYCS and boosted with MVA-PYCS than in the group of
mice boosted with VV-PYCS (p,0.001 by one-way ANOVA. On
the other hand the 97% inhibition of parasite development in the
group of mice boosted with MVA was similar to that obtained in
the group of mice immunized with Flu-PYCS/VV-PYCS which
serves as a reference, as it is a well established and standardized
protocol previously described to induce high level protection after
parasite challenge [10]. These findings demonstrate the high
degree of protection against liver stage parasites obtained by a
PPV/MVA regime.
PPV-PYCS priming followed by MVA-PYCS boost
improved the polyfunctionality and magnitude of
memory CD8 T-cell responses
Enhancement in the quality and magnitude of memory CD8+ T-
cell response is known to correlate with better protection in malaria
[23,24]. Therefore, to define the CD8+ T cell responses induced by
VLP-PYCS/MVA-PYCS prime-boost, we performed intracellular
cytokine staining (ICS) study with splenocytes obtained from mice
immunized by various protocols and collected 53 days post-boost to
evaluate memory T cells. The vaccination regime based on VLP-
PYCS prime/MVA-PYCS boost generated a robust response in
mice when compared to VLP-PYCS prime/boost or DNA-PYCS/
MVA-PYCS prime/boost, as revealed after separation of CD8 T-
cells based on memory markers CD127 and CD62L (Figure 6). This
approach helped to differentiate TEffector; TE (CD127
LoCD62LLo),
TEffector Memory; TEM (CD127
HiCD62LLo) and TCentral Memory; TCM
(CD127HiCD62LHi). Considering the negligible CD8+ T-cell
responses generated when using DNA-PYCS as priming agent, a
VLP-PYCS/MVA-PYCS vaccine regime elevated the CS specific
Figure 4. Booster with replication restricted MVA-PYCS vector
triggers strong CS CD8+ T-cell response after priming with
PPV-PYCS. Groups of BALB/c mice (5 per group) were immunized s.c
with different amounts of PPV-PYCS [PPV(10 mg), PPV(50 mg)
PPV(100 mg)], with non-recombinant PPV-VLPs (nrPPV) or with VACV
vectors (VV-PYCS or MVA-PYCS) in prime/boost protocols and 14 days
after the boost CS-specifc IFN-c secreting cells for the plasmodial
epitope SYVPSAEQI in splenocytes were measured by ELISPOT as
described under Materials and Methods. Purified PPV-VLPs without the
peptide insert were used as control. The results are expressed as the
means of assay triplicates of cultured pooled mouse splenocytes.
Statistical values were determined by one-way ANOVA; P values,
*P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0034445.g004
Figure 5. Protection against malaria after prime/boost with
PPV-PYCS/MVA-PYCS protocol. Groups of BALB/c mice (5 per
group) were immunized with different amounts of PPV-VLPs
[PPV(10 mg) and PPV(50 mg)] and two weeks later animals were boosted
with the replication restricted MVA-PYCS or the replication competent
VV-PYCS. A positive control group primed with an influenza virus
recombinant expressing the CD8+ T cell epitope and booster with VV-
PYCS, a protocol previously shown to induce high protection against
the parasite, was included [10]. Thirteen days later, animals were
challenged with sporozoites and the amount of parasite rRNA in the
liver of each animal was estimated 42 h after the challenge, as
described under Materials and Methods. Results are expressed as the
mean with standard deviation. Statistical values were determined by
one-way ANOVA; P values, *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0034445.g005
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CD8+ T cell response by 1.5 fold (p,0.001 determined as in ref 33)
(Fig 6). Interestingly, the majority of the CD8+ T cells, following
stimulation, rapidly acquired TE phenotype. However a significant
increase in the TEM population was also observed (Fig 6).
Furthermore, the polyfunctional nature of the CD8 T-cells
generated, suggested the enhanced capability of VLP priming
followed by VACV boost. The majority of the CD8 cells produced
were double positive for IFN-c and TNF-a (IFN-c+TNF-a+)
(p,0.001) (Figure 7). In addition, there was high surge in the
TNF-a secreting cells (p,0.005). Although, at lower levels, there
was a significant induction of triple positive cytokine secreting cells
(IFN-c+TNF-a+IL-2+) (p,0.001). Thus, the data revealed how
VLP-PYCS prime/MVA-PYCS boost improves the polyfunction-
ality and the population of memory CD8+ T cells in immunized
mice, immune parameters which might be relevant in protection
against malaria.
Discussion
While one of the main interests in the malaria vaccine field is to
develop immunogens based on proteins for safety considerations,
however, the immune response triggered by proteins is generally
weak with a bias for Th2 type. Thus, efforts have been directed to
combine proteins with adjuvants and immunostimulatory mole-
cules, to enhance specific innate immune responses and to drive
the response to a Th1 type. In fact, the current phase III clinical
trial with malaria vaccine RTS,S is based on CS protein fused to
hepatitis B antigen and combined with a potent adjuvant AS01.
Because previous studies with the RTS,S vaccine have shown
Figure 6. PPV-PYCS/MVA-PYCS prime/boost improves cytokine secretion by memory CD8+ T-cells. Groups of BALB/c mice (4 per group)
were immunized in prime/boost as indicated in Table 1 and 53 days post boost splenocytes were processed for ICS as described under Materials and
Methods. Phenotypic differentiation of CD8+ T-cells based on memory markers CD127 (V450) and CD62L (FITC). Each quadrant represents different
memory population of CD8 cells with its respective percentages. The distribution of antigen specific CD8+ T-cells secreting cytokines in response to
CS peptide stimulation, within the different memory population is also shown. The total CD8+ T-cell response is indicated by the black boxes. The
boxes on left indicate the responses towards CS peptide stimulation while the ones on right represent its respective RPMI controls.
doi:10.1371/journal.pone.0034445.g006
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weak CD8+ T cell responses in vaccinees, in this investigation we
have asked the question as to what extent CS antigen presentation
by chimeric VLPs obtained from PPV is able to prime CD8+
T cell responses, and how these responses can be enhanced when
combined with poxvirus vectors expressing CS. In addition, we
have asked in which grade specific CD8+ T cell immune responses
are associated with protection against malaria and what are the
CD8+ T cell populations induced. This proof-of-concept has been
tested in mice. In this work we have generated recombinant
parvovirus-derived VLPs expressing the CTL epitope from the P.
yoelii CS protein.
The PPV-VLP system presents several advantages such as the
long term stability of VLPs in addition to high levels of protein
expression. Although the system has not been rigorously tested for
the largest insert size that can be accommodated without
disrupting the particle, there would be two ways to overcome
the limitation of the system to accept large insertions. First, it is
relatively simple to build different PPV-VLPs containing different
CD8+ epitopes that can be mixed during administration. Second,
PPV VP2 containing different epitopes can be co-expressed in the
baculovirus system to prepare VLPs with mixtures of different
epitopes. These possibilities would facilitate the use of multiple
CD8+ epitopes, as required for human vaccines, or their
combination with CD4+ or B cell epitopes. These combinations
should result in a more efficient vaccine design.
Groups of mice immunized in a prime/boost regimen with two
doses of PPV-PYCS did not develop significant anti-CS cellular
immune response, determined by the ELISPOT assay. However,
when animals were immunized with different doses of PPV-PYCS,
followed by the recombinant VV-PYCS, expressing the full CS
protein from P. yoelii, a strong CD8+ T cell response was generated
against this antigen. This response was about 10 times higher that
the one obtained with two doses of VV-PYCS. When we used for
priming two different doses (10 and 50 mg) of PPV-PYCS followed
by a booster with 107 PFU of VV-PYCS there was a dose response
effect, obtaining the highest CD8+ T cell response with the highest
dose of PPV-PYCS. In this experiment we observed again that this
response was much higher than that obtained with two doses of
VV-PYCS. We have also included as control a non-related
recombinant VACV for booster, which showed that the CD8+ T
cell response primed by the recombinant VLPs is boosted in an
antigen dependent manner, and cannot be boosted by a non-
related VACV recombinant.
Importantly, when we analyzed protection after challenge with
the parasite in animals immunized as described above, quantified
as reduction in the amount of Plasmodium rRNA in the liver with
respect to non-immunized animals, we observed maximal
protection in mice primed with PPV-PYCS followed by a booster
with VV-PYCS or MVA-PYCS. Because safety is a major concern
for developing poxvirus based vaccines, we included for boosting a
recombinant vector expressing the full-length CS protein based on
the highly attenuated MVA strain instead of the recombinant
based on replicating WR strain. When mice were immunized with
10, 50 or 100 mg of PPV-PYCS followed by the MVA
recombinant (107 pfu), we obtained a stronger cellular immune
response that was about 2 to 3 times higher than that obtained
when we used for boosting a recombinant based on the WR strain.
While two doses of PPV-PYCS did not elicit significant cellular
immune responses, these PPV-VLPs were able to prime a specific
anti-CS CD8+ T cell response that could be subsequently be
boosted by MVA-PYCS. When PPV-PYCS was substituted by
PPV-VLPs without the CS epitope during priming, the magnitude
of the response after booster with the virus was similar to that
obtained with only one dose of MVA-PYCS.
The magnitude of the specific cellular immune response was
associated with protection, defined by markedly reduced parasites
Figure 7. Polyfunctionality of CD8+ T-cells is improved by heterologous prime/boost. Groups of BALB/c mice (4 per group) were
immunized in prime/boost as indicated in Table 1 and 53 days post boost splenocytes were processed for ICS as described under Materials and
Methods. Memory CD8 T-cells were differentiated into single, double or triple positive cells secreting IFN-c (PeCy7), TNF-a (PE) and IL-2 (APC).
Polyfunctionality is indicated by the pie chart.The data was then analyzed using SPICE software. Data are expressed as mean 6 s.e. (n = 4 mice per
group). Statistical values were determined by a novel approach previously described (33). P values were calculated between PPV/MVA-PYCS and PPV/
PPV groups. **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0034445.g007
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in the liver two days after challenge. Thus, when groups of mice
immunized as before were challenged with the Plasmodium
parasite, maximal protection was observed in animals boosted with
the MVA-PYCS recombinant. The high protection (about 95%)
obtained after priming with PPV-PYCS and boosting with MVA-
PYCS was comparable to that obtained after immunization in
similar prime/boost approach but using instead two live
recombinant viral vectors, i.e influenza expressing the CD8+ T
cell epitope followed by VV-PYCS, that we have previously
reported to be protective [10]. This is an important consideration,
since by using PPV-VLPs and MVA immunogens we are able to
achieve similar protective immune response than previously
attained with two replicating viral vectors.
How can we explain the enhanced response obtained by PPV-
VLPs/poxvirus prime/boost approach and its association with
protection against the malaria parasite? Based on current
understanding of prime/boost protocols, and due to the induction
of anti-vector immunity by the VACV prime, we suggest that
during priming with PPV-PYCS the particles which are able to
enter the cells, are processed by antigen presenting cells and
trigger an innate immune response that activate T cells; after
booster the primed T cells are expanded as a result of infection of
antigen presenting cells by MVA-PYCS and cross-priming effects
by induction of apoptosis [25]. In addition, the innate immune
response triggered by MVA [26] can also be responsible for T cell
expansion. Significantly, the T cell responses observed in the two
protocols PPV/VV and PPV/MVA were associated with high
levels of protection against the parasite, while low levels of T cells
were ineffective to control the parasite. While it is difficult to
compare immune correlates between studies performed with
different vectors, the magnitude of CD8+ T cell responses after the
PPV-VLPs prime/pox boost and degree of protection against the
parasite in this study are remarkable. In fact, analysis of the
memory CD8+ T cells after prime/boost revealed that the
protocol VLP/MVA induced a polyfunctional response with
activation of effector memory CD8+ T cells, both immune
parameters that could be relevant in protection against malaria
[24].
While a number of different prime/boost combination of
vectors expressing malaria antigens have shown activation of
CD8+ T cell responses and different degrees of protection against
murine malaria [9,27], [28] there are several advantages in the use
of PPV-VLPs and MVA vectors expressing the CS antigen for T
cell activation. First, CS has shown good immunogenicity profile
with efficacy in preclinical assays whether from DNA, Ty-particles,
a fusion protein or delivered by viral vectors, but most importantly
when fused with hepatitis B antigen plus an adjuvant it induced
significant protection in children exposed to malaria, indicating
the CS protective capacity if formulated properly for immune B
and T cell activation. Second, expression of CS as part of PPV-
VLPs is able to prime the antigen presenting cell in a way that
further booster with the poxvirus vector MVA triggered high levels
of CD8+ T cells, which are polyfunctional and of effector memory
phenotype, that are associated with high degree of protection after
challenge when evaluated by liver stage parasite inhibition. Third,
both vectors PPV-VLPs [29] and MVA recombinants [22] can be
easily grown to large scale for vaccination purposes. Future studies
on potential clinical applicability of the the PPV-VLP platform will
require to define if these capsids are capable of carrying large
regions of antigen or carrying multiple T-cell epitopes which
diverse humans will respond.
Overall, the results reported here demonstrate that prime/boost
immunization with PPV-VLPs and MVA expressing CS is a
logical vaccine approach to optimize cellular immunity and
protection against malaria. These findings are relevant in the
design of vaccine strategies against Plasmodium.
Materials and Methods
Ethics Statement
The animal studies were approved by the Ethical Committee of
Animal Experimentation (CEEA-CNB) of Centro Nacional de
Biotecnologia (CNB-CSIC, Madrid, Spain) in accordance with
national and international guidelines and with the Royal Decree
(RD 1201/2005), permit number: 130/07.
Cells
African green monkey kidney cells (BSC-40; ATCC CRL-2761)
were grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% newborn calf serum (NCS). Chick
embryo fibroblast (CEF) cells were obtained from sterile
pathogen-free eggs provided by INTERVET (Salamanca, Spain),
and primary cultures were prepared according to standard
procedures and maintained in DMEM supplemented with 10%
fetal calf serum (FCS) (GibcoH, Grand Island, NY, USA). P815
(ATCC TIB-64) mastocytoma cells that express MHC class I
molecules H-2d were cultured in DMEM containing 10% FCS.
Spodoptera frugiperda clone 9 (Sf9, CRL 1711, ATCC) cells were
grown and maintained in suspension at 27uC using Grace’s insect
tissue culture medium (GibcoH, Grand Island, NY, USA)
supplemented with 10% FCS, 0.2% Pluronic F-68 (Sigma-Aldrich,
Steinheim, Germany) and antibiotics.
Growth and purification of VACV expressing the CS
protein from P. yoelii
The recombinant VACV virus VV-PYCS carrying in the TK
locus the entire CS gene of P. yoelii, has been previously described
[10]. To generate the recombinant virus MVA-PYCS, the CS
gene was inserted by homologous recombination into the TK
region of the genome of the MVA strain, by using the VV transfer
plasmid pSC-PYCS containing the CS DNA sequence under the
control of the VACV p7.5 promoter. b-galactosidase-producing
plaques were picked, cloned three times, and amplified in CEF
cells as previously described [21]. VV-PYCS and MVA-PYCS
were propagated and titrated in monkey BSC-40 and CEF cells
respectively [30]. Both viruses were purified by banding in sucrose
gradients, as previously described [31].
Construction of a recombinant baculovirus expressing
PPV-PYCS
Oligonucleotide 59-TCGAGATGTCATACGTTCCCTCGG-
CCGAACAAATCC-39 and its complementary 59-TCGAG-
GATTTGTTCGGCCGAGGGAACGTATGACATC-39 were
designed in order to regenerate the PYCS CD8 epitope
SYVPSAEQI plus an initiation codon and two cohesive XhoI
sites. The oligonucleotides were phosphorylated with T4 polynu-
cleotide kinase, annealed at 70uC for 15 min and ligated into XhoI-
digested pPPV29mod, which contains a unique XhoI restriction
site immediately downstream of the initiation codon of the PPV
VP2 gene, as previously described [12]. Then, the chimeric VP2
sequence containing the PYCS epitope was isolated by BamHI
digestion and subcloned into BamHI-digested pAcYM1. The
recombinant baculovirus transfer vector was called pAcYM1-
PPV-PYCS.
The recombinant viruses were obtained by cotransfection of
Spodoptera frugiperda (Sf9) insect cells with a mixture of 2 mg of
purified transfer vector DNA plus 500 ng of parental BacPAK6
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baculovirus DNA, previously linearized with Bsu36I, in the
presence of cationic liposomes [18]. Transfected cultures were
collected when the cells started to show signs of infection, usually
5–6 days later. Recombinant baculoviruses were plaque-purified
in the presence of X-Gal (5-bromo-4-chloro-3-indolyl-b-D-galac-
topyranoside) until no more blue plaques (wild-type) were
detected. Then, high-titers stocks (.108 pfu/ml) of the recombi-
nant baculovirus AcPPV-PYCS were obtained.
Characterization and purification of PPV-PYCS VLPs
Sf9 cells were infected with AcPPV-PYCS at a multiplicity of
infection of 0.5 plaque-forming units (pfu) per cell. Cells were
collected at 72 h post-infection with a clear cytophatic effect.
Purification of PPV-VLPs was carried out as previously described
[12,16]. Briefly, infected Sf9 cells were lysed by hypotonic shock
with 25 mM bicarbonate solution at 4uC. Cell debris was removed
by centrifugation and the PPV-VLPs present in the supernatant
were precipitated with 20% ammonium sulfate, resuspended in
PBS and dialysed. The purity of the preparation of PPV-PYCS
VLPs was confirmed by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). Protein concentration was estimated
by densitometric assay with the Bio-Rad protein assay reagent,
and using BSA as reference.
Recombinant baculovirus, AcPPV-PYCS, which express under
the polyhedrin promoter the PPV VP2 capsid protein fused at its
amino-terminus with the PYCS CD8+ epitope, was used for
antigen preparation.
Plasmid construction
pCI-Neo-CS. The gene coding for P. yoelii CS protein was
amplified from MVA-PYCS using the primers CS-XhoI-F (59-
ACTTACTCGAGATGTGTTACAATGAAGAAAATG-39) and
CS-NotI-R (59-ATTGCGGCCGCTTTAAAATATACTTGAAC-
39) to yield a 972 bp fragment lacking the N-terminal signal
sequence and C-terminal GPI sequence. The gene was inserted
into a mammalian expression vector, pCI-Neo, that had been
previously digested with XhoI and NotI followed by SAP treatment
(Shrimp Alkaline Phosphatase). The CS gene in both the virus and
plasmid were sequenced (Secugen; Spain). The plasmid was
purified using Qiagen Mega Prep Kit according to manufacturer’s
protocol. Expression of CS from pCI-Neo-CS was confirmed by
transfecting DF-1 cells followed by western blot analysis with CS
specific antibodies.
Parasites
P. yoelii (17XNL strain) was maintained by alternating passages
in Anopheles stephensi mosquitoes and Swiss Webster mice.
Sporozoites were collected through infected mosquito’s salivary
glands dissection.
Immunization of mice and challenge
Six to eight weeks old female BALB/c mice (Harlan), were used
for immunization purposes. Both, PPV-PYCS and recombinant
viruses, resuspended in sterile PBS, were injected subcutaneously
(s.c). Immunization schedules (dose, route, number of mice) are
indicated in Table 1. Non-immunized and immunized mice were
challenge 13 days after the booster by inoculation of 56105 P.
yoelii sporozoites by the intravenous (i.v) route into the mouse tail
vein.
ELISPOT assay
The ELISPOT assay was used to detect epitope-specific IFN-c-
secreting cells [19]. Briefly, nitrocellulose-bottomed 96-well plates
were coated with anti-mouse IFN-c mAb R4-6A2 (8 mg/ml,
Pharmingen, San Diego, CA). After overnight incubation at room
temperature, wells were washed three times with RPMI 1640, then
100 ml of medium supplemented with 10% FCS were added to
each well, and plates incubated at 37uC for 1 h. Triplicate cultures
were prepared with serial doubling dilutions of immunized
splenocytes, beginning with 106 cells/well. P815 cells (H-2d), used
as antigen-presenting cells (APC), were pulsed with 1026 M of the
synthetic peptide SYVPSAEQI, corresponding to the P. yoelii CS
protein, and treated with mitomycin C (30 mg/ml, Sigma). After
several washes with culture medium, 105 P815 cells were added to
each well. Control P815 cells were not pulsed with the peptide.
Plates were incubated for 26–28 h at 37uC, washed with PBS
containing 0.05% Tween-20 (PBS-T) and incubated overnight at
4uC with biotinylated anti-mouse IFN-c mAb XMG1.2 (2 mg/ml,
Pharmingen) in PBS-T. Plates were washed with PBS-T and
peroxidase-labeled avidin (Sigma; 100 ml, 1/800 dilution in PBS-
T) was added to each well. One hour later, wells were washed with
PBS/T and PBS. Spots were developed by adding 50 mM Tris-
HCl, pH 7.5 containing 1 mg/ml of 3,39-diaminobenzidine
tetrahydrochloride (Sigma) and 0.015% H2O2. When the plates
were completely dry, the number of spots was determined with the
aid of a stereomicroscope.
Intra-cellular Cytokine Staining (ICS) Analysis
Multiparameter flow cytometry was performed to study the
efficacy of vaccination regimes in altering the magnitude and
polyfunctionality of CD8+ T-cells, as previously described [32].
Groups of mice (4 per group) were inoculated with different
combination of immunogens, VLP-PYCS/VLP-PYCS (50 mg
each time), VLP-PYCS (50 mg)/MVA-PYCS (107 pfu), DNA-
PYCS (100 mg)/MVA-PYCS (107 pfu), non-recombinant VLP/
VLP (50 mg each) and PBS/PBS. Following immunization, the
animals were sacrificed after 56 days post-boost to study memory
responses. Splenocytes (46106) from the sacrificed animals were
stimulated with 1 mg/ml of CS specific CD8 peptide (SYVP-
SAEQI) along with Brefeldin (1 mg/ml) (BD Bioscience) for
6 hours in a 96 well plate. After incubation, the cells were washed
twice with PBS and stained with LIVE/DEAD fixable dead cell
stain kit, following which, the cells were washed and blocked with
CD16/CD32 antibody (Fc Block; BD Bioscience). The cells were
then stained for surface markers with CD4-Alexa 700, CD8-V500,
CD127-V450 and CD62L-FITC (BD Bioscience). This was
followed by permeabilisation using BD Cytofix/CytopermTM Kit
(Becton Dickinson) and staining for intracellular cytokines using
IFN-c PeCy7, TNF-a PE and IL-2 APC. Nearly 50,000 cells were
then passed through LSRII flow cytometer (Becton Dickinson).
The data generated were analyzed using Flo-Jo (Tree Star. Inc)
and SPICE (ver 5.0).
Quantitation of liver stages
At 42 h following sporozoite challenge, livers were removed and
P. yoelii liver-stage parasites were measured by quantification of
parasite-specific 18S rRNA in total liver RNA as described
elsewhere [20]. Livers were homogenized in a Ten Broeck tissue
grinder (VWR Scientific) in 4 ml of a denaturing solution (4 M
guanidinium thiocyanate, 25 mM sodium citrate [pH 7], 0.5%
sarcosyl) made fresh as a working solution (50 ml of denaturing
solution, 0.2 M -2-mercaptoethanol). Total liver RNA was then
isolated from the liver homogenate by using the TRIzol reagent
(Gibco/BRL, Grand Island, N.Y.) as outlined in the product
insert. One microgram of RNA was treated with 1.0 U of DNase I
(Boehringer Mannheim, Mannheim, Germany) and was then
converted to cDNA by the Superscript preamplification system for
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first-strand cDNA synthesis (Gibco/BRL), using random hexamers
in a 21-ml total volume as outlined in the product insert.
For quantification of parasite-specific rRNA by quantitative-
competitive reverse transcription-PCR (RT-PCR)[21], parasite-
specific rRNA was amplified from 5 ml of the cDNA mixture in a
PCR master mix containing 46 ml of PCR Supermix (Gibco/
BRL), 1 ml each of parasite-specific primers PB1 and PB2 (1)
(12 mM, final concentration), 0.2 ml (1 U) of Taq DNA polymerase
(Sigma, St. Louis, Mo.), and 1 ml of a known concentration of
competitor plasmid. Then 35 cycles of amplification in a PCR
Express (Hybaid, Middlesex, United Kingdom) thermocycler were
performed under the following conditions: 94uC for 1 min, 60uC
for 2 min, and 72uC for 1 min. An initial denaturation step at
94uC for 2 min and a terminal elongation step at 72uC for 10 min
were also included. Target and competitor amplicons were
resolved on ethidium bromide-stained 2% agarose gels and
photographed by the Eagle Eye II still video system (Stratagene,
La Jolla, California), and the image was stored electronically.
Target-to-competitor ratios were then determined using the NIH
Image software program. We performed a series of amplifications
with different competitor concentrations and used target-to-
competitor ratios from each competitor concentration in linear
regression analysis to determine the competitor concentration
where target and competitor amplicon ratios were equivalent. This
concentration was used as a relative measure of liver parasite
burden. Equal cDNA synthesis between samples was ensured by
amplification of the housekeeping ß-actin gene at PCR conditions
below saturation.
Statistical analysis
Statistical analysis of ELISPOT and protection assays was
performed by a one-way ANOVA with Tukey post test and
Bonferroni correction to all groups. For the statistical analysis of
ICS data we used a novel approach that corrects measurements
for the medium response (RPMI) and at the same time allows the
calculation of confidence intervals and p-values of hypothesis tests
[33]. The background for the different cytokines in the
unstimulated controls never exceeded 0.05%. The data analysis
program, Simplified Presentation of Incredibly Complex Evalua-
tions (SPICE, version 4.1.5, Mario Roederer, Vaccine Research
Center, NIAID, NIH), was used to analyze and generate graphical
representations of T cell responses detected by polychromatic flow
cytometry. All values used for analyzing proportionate represen-
tation of responses are background-subtracted. In all cases, P
values of less than 0.05 were considered statistically significant. All
statistic tests were performed using GraphPad Prism version 4.03
for Windows (GraphPad Software, San Diego, C).
Table 1. Dosage of different vaccination regimes: A summary of priming and boosting agents used in the study with the
corresponding dosages.
Experiment Priming Boosting Number of mice
Agent Dose Agent Dose
IFN-c ELISPOT VV-PYCS 107 PFU VV-PYCS 107 PFU 5
PPV1 10 mg VV-PYCS 107 PFU 5
PPV 50 mg VV-PYCS 107 PFU 5
PPV 10 mg MVA-PYCS 107 PFU 5
PPV 50 mg MVA-PYCS 107 PFU 5
PPV 100 mg MVA-PYCS 107 PFU 5
PPV 10 mg VV-LUC 107 PFU 5
– MVA-PYCS 107 PFU 5
nrPPV2 50 mg MVA-PYCS 107 PFU 5
PPV 10 mg PPV 10 mg 5
PPV 100 mg PPV 100 mg 5
Intra-cellular Cytokine Staining
(ICS)
PPV 50 mg PPV 50 mg 4
PPV 50 mg MVA-PYCS 107 PFU 4
DNA-PYCS 100 mg MVA-PYCS 107 PFU 4
nrPPV 50 mg nrPPV 50 mg 4
PBS PBS 4
Challenge Studies VV-PYCS 107 PFU VV-PYCS 107 PFU 5
PPV 10 mg VV-PYCS 107 PFU 5
PPV 50 mg VV-PYCS 107 PFU 5
PPV 50 mg MVA-PYCS 107 PFU 5
FLU-PYCS 107 PFU MVA-PYCS 107 PFU 5
PPV 10 mg PPV 10 mg 5
– – 5
All agents were administered s.c except for DNA-PYCS which was injected intradermally.
1PPV refers to PPV-VLPs containing the CD8 epitope of P.yoelii CS protein.
2nrPPV refers to non-recombinant PPV-VLPs.
doi:10.1371/journal.pone.0034445.t001
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Abstract
There is a need to develop a universal vaccine against influenza virus infection to avoid developing new formulations of a
seasonal vaccine each year. Many of the vaccine strategies for a universal vaccine target strain-conserved influenza virus
proteins, such as the matrix, polymerase, and nucleoproteins, rather than the surface hemagglutinin and neuraminidase
proteins. In addition, non-disease-causing viral vectors are a popular choice as a delivery system for the influenza virus
antigens. As a proof-of-concept, we have designed a novel influenza virus immunogen based on the NP backbone
containing human T cell epitopes for M1, NS1, NP, PB1 and PA proteins (referred as NPmix) as well as a construct containing
the conserved regions of influenza virus neuraminidase (N-terminal) and hemagglutinin (C-terminal) (referred as NA-HA).
DNA vectors and vaccinia virus recombinants expressing NPmix (WR-NP) or both NPmix plus NA-HA (WR-flu) in the cytosol
were tested in a heterologous DNA-prime/vaccinia virus-boost vaccine regimen in mice. We observed an increase in the
number of influenza virus-specific IFNc-secreting splenocytes, composed of populations marked by CD4+ and CD8+ T cells
producing IFNc or TNFa. Upon challenge with influenza virus, the vaccinated mice exhibited decreased viral load in the
lungs and a delay in mortality. These findings suggest that DNA prime/poxvirus boost with human multi-epitope
recombinant influenza virus proteins is a valid approach for a general T-cell vaccine to protect against influenza virus
infection.
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Introduction
Millions of people worldwide are infected with influenza virus
every year. Although most yearly outbreaks are characterized by
fewer than 40,000 deaths in the United States, highly virulent
strains can evolve that cause worldwide pandemics, resulting in a
dramatically increased incidence of death. While ribavirin and
oseltamvir can be used to combat infection, there has been recent
emergence of strains resistant to these drugs [1], demonstrating the
need for better therapeutics or vaccine strategies against influenza
virus infection.
The major cause of influenza pandemics involves the combi-
nation of the two major glycoproteins on the virion surface [2].
These two glycoproteins, hemagglutinin (HA) and neuraminidase
(NA), contribute to the considerable antigenic variation of
influenza virus because they have 16 and 9 subtypes, respectively.
When a new glycoprotein subtype appears on the virion surface,
the population is immunogenically naı¨ve to this new strain, raising
the possibility of a pandemic. The worst influenza pandemic to
date occurred in 1918, by the so-called ‘‘Spanish flu,’’ an H1N1
virus, which led to over 40 million deaths worldwide [3]. In 2005,
there were outbreaks of an H5N1 virus in Southeast Asia and
Europe. While this strain caused death in humans, it has been
unable to be transmitted from person to person [4].
Besides increased mortality and morbidity, how else would an
influenza pandemic impact society? Compounded with the fact that
influenza-associated hospitalizations have increased substantially
over the last two decades [5], the economic loss due to another
pandemic would be unimaginable. Based on a model which takes
into account variables such as different types of vaccination
strategies and illness percentages, Thompson et al. proposed that
another pandemic would cause up to 207,000 and 734,000
hospitalizations, and 18 to 42 million outpatient visits in the United
States alone. Based upon these numbers, they estimate that due to
loss of life and medical care, the economic cost of a pandemic to the
United States would be up to $167 billion dollars [6].
The current vaccination strategy against influenza virus consists
of a live-attenuated or killed virus vaccine regimen containing the
three strains of virus (two A subtypes and one B subtype) that are
thought to be most prevalent in the upcoming influenza season.
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Determining which strains the vaccine will contain is based on
bioinformatics analysis of epidemiological data from the previous
season. Since the current vaccine strategy requires changing of the
vaccine formulation every year, there is a push to develop a
universal vaccine [7]. Development of these next generation
influenza vaccines is based on technologies utilizing recombinant
proteins, virus-like particles, viral vectors, and DNA-based
vaccines [8]. Another strategy is prime-boost, using DNA for
priming and virus vectors expressing antigens of interest as a boost
[9]. Attenuated poxvirus vectors, such as MVA and NYVAC, have
been used successfully to induce a greater immune response
towards HIV antigens [10,11,12]. In fact, one of the more
successful HIV vaccine trials in humans to date utilized a poxvirus
vector [13], and there are ongoing phase I/II clinical trials using
the MVA poxvirus vector [12,14,15,16].
Regarding influenza virus, many vaccination strategies have
used the nucleoprotein (NP) as an antigen to induce immune
responses since it is well-conserved across influenza virus subtypes
[17,18,19]. However, in some cases, vaccines developed around
NP have failed to provide protection [20,21]. Recently, MVA
vectors expressing influenza virus antigens have been shown to
provide protection against virus challenge, even in human clinical
trials [22,23,24]. Novel design strategies using viral antigens in
combination with NP may be able to improve immunogenicity to
influenza virus and provide more universal protection.
In this study, we designed recombinant influenza virus antigens
for use in a DNA prime/vaccinia virus boost vaccination strategy,
and studied the ability of these proteins to induce an adaptive
immune response and protective response to heterologous
challenge. One immunogen was designed around influenza virus
NP, which included human epitopes from the M1 (matrix), NS1
(non-structural), PB1 (basic polymerase), and PA (acidic polymer-
ase) viral proteins. The vaccinia virus construct containing NPmix
was referred to as WR-NP. The other immunogen contained
conserved sequences from H5N1 viruses: the N-terminal NA fused
to the C-terminal HA and was combined with the NPmix to
generate the viral vector WR-flu. We also generated plasmid DNA
vectors from pCIneo expressing independently NPmix and HA-
NA. We show that our recombinant vaccinia virus constructs grow
well in cell cultures and produce the recombinant products
(NPmix or both NPmix and NA-HA) in the cytoplasm of infected
cells, similarly as for the DNA vectors. After the DNA prime/
poxvirus boost vaccination protocol in mice we observed increased
IFNc-secreting cells, along with an increased CD4+ and CD8+ T
cell response with regard to IFNc+ and IFNc+TNFa+ cells. Upon
challenge with influenza virus, lung viral titers were decreased in
animals vaccinated with the viral vectors expressing recombinant
influenza virus proteins. Taken together, this study demonstrates
how a T cell vaccine based on a DNA prime/poxvirus boost
strategy containing multiple human influenza virus epitopes can
reduce viral load during heterologous challenge and provides a
rational design for the generation of universal influenza vaccines.
Results
Immunogen design and characterization of vaccinia virus
vectors expressing influenza virus antigens
The goal in developing our T cell vaccine against influenza virus
was first to design an immunogen utilizing the conserved regions of
influenza virus proteins as antigens and then to produce a
recombinant vaccinia virus that can be used as a broad-spectrum
vaccine to induce specific immune response to influenza. For this
aim, we generated two types of immunogens. One was based on
the nucleoprotein (NP) as a backbone, which is well-conserved
among H1N1, H2N3, H5N1, H9N2, and H7N7 strains of
influenza virus (Figure S1). Within the NP backbone, we added
conserved human T cell epitopes for other influenza virus proteins,
specifically M1, NS1, PB1, and PA (Figure 1B; NPmix). Briefly, we
were guided by Epstein, et al., which lists the influenza virus gene
products and peptide sequences that are presented by certain
MHC molecules [25]. We narrowed down this list to four M1, one
NS1, one PA, and two PB1 epitopes that were the most conserved
among the virus strains listed in Figure S1. These, in addition to
the NP epitopes, were included in the NPmix recombinant gene
shown in Figure 1B. In choosing the amino acids to swap, we were
careful in selecting regions without significant secondary structure,
and we avoided swapping hydrophilic for hydrophobic regions.
We also did not remove any known NP T cell epitopes. The
second construct involved fusing the conserved regions of
neuraminidase (NA) and hemagglutinin (HA) from H5N1
influenza viruses (Figure 1B and S2; NA-HA). These HA and
NA subtypes are not homologous those in the H3N2, H9N2, or
H7N7 strains listed in Figure S1; however, the NP protein shown
in Fig. S1 is conserved in the H5N1 strains. The NPmix construct
alone or together with the NA-HA construct was inserted in the
TK locus of the Western Reserve strain of vaccina virus
(Figure 1A). We termed the vaccinia virus recombinants
containing NPmix insertion alone ‘‘WR-NP’’ and the insertion
of NPmix and NA-HA ‘‘WR-flu.’’
We also produced plasmid vectors for their use in the priming
stages of the vaccination protocol. The NPmix and NA-HA
immunogens were inserted into the pCIneo mammalian expres-
sion vector, which could efficiently express the proteins upon
transient transfection in cell culture, either transfected alone or in
tandem (Figure 2A). Lower levels of NP and HA were observed
during double transfections since only 5 mg of each vector was
used, as opposed to 10 mg in single transfections. We also verified
that the influenza insert was maintained in the recombinant
viruses, as shown after staining viral plaques from purified viral
stocks for NP and WR protein and observing that the recombinant
viruses produced the same number of plaques expressing NP and
WR proteins (Figure 2B); the H5 HA antibody did not strongly
stain viral plaques. We further tested how the expression of
influenza virus proteins from the recombinant viruses was
dependent on MOI. We observed that the NA-HA and NPmix
protein is strongly expressed by 24 h p.i. during both WR-NP and
WR-flu infection (Figure 2C). Finally, all viruses replicate to
similar levels (Figure 2D). Together, these results indicate that the
recombinant viruses are correctly expressing the influenza virus
proteins and that the expression of these proteins does not alter the
infection profile as compared to wild-type vaccinia virus.
To further characterize the viruses, we examined the subcellular
localization of the influenza virus proteins. The recombinant
proteins were expressed mainly in the cytoplasm of cells during
either WR-NP or WR-flu infection. HA showed a higher degree of
co-localization with viral factories (Figure 3A), as marked by
staining for the 14K vaccina virus protein (A27 gene), as compared
to colocalization of the NP protein with 14K (Figure 3B). NPmix
also exhibits greater distribution throughout the cell.
Immunogenicity of vaccinia virus recombinants during
DNA prime/poxvirus boost vaccination
We next examined the influenza virus-specific immune
responses induced in mice by the WR-NP and WR-flu
recombinant viral constructs. Four BALB/c mice for each group,
WR, WR-NP, or WR-flu, were vaccinated according to the
schedule in Figure 4A and sacrificed to evaluate the adaptive
immune response elicited. Mice were primed with 100 mg DNA by
Vaccinia Virus-Based Influenza Virus Vaccine
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intramuscular injection. 100 mg of empty DNA (pCIneo-Ø) was
used for the WR group; 100 mg DNA containing the NPmix
vector (pCIneo-NPmix) was used for the WR-NP group; 50 mg of
NPmix DNA and 50 mg of DNA containing the NAHA vector
(pCIneo-NAHA) was used for the WR-flu group. Two weeks post-
prime, the animals were boosted by intraperitoneal infection of 107
PFU of WR, WR-NP, or WR-flu. Eleven days post-boost, the
adaptive immune response was evaluated using a fresh IFNc
ELISPOT assay with splenocyte stimulation using a peptide
corresponding to influenza virus NP (TYQRTRALV) or vaccinia
virus E3 (VGPSNSPTF).
As shown in Figure 4B, animals that were vaccinated with WR-
NP or WR-flu exhibited a significant increase in splenic T cell
responses against the NP peptide. Vaccination with WR-NP lead
to a ,7.6-fold increase in IFNc-secreting cells while vaccination
with WR-flu lead to a ,6.5-fold increase, as compared to
vaccination with WR alone. All vaccination protocols exhibited
similar response levels to the E3 peptide, indicating that all viruses
are replicating similarly in the vaccinated animals. We also
performed experiments to determine the levels of neutralizing
antibodies in the serum of vaccinated mice. However, we did not
observe any significant increase in neutralizing antibodies against
influenza virus nor against NA or HA in mice vaccinated with
WR-NP or WR-flu versus WR alone (data not shown).
Functional profile and polyfunctionality of WR-NP and
WR-flu induced CD4+ and CD8+ T cell responses
To determine the phenotypic characteristics of the T cell
populations activated after immunization with the DNA-prime/
poxvirus-boost protocol, we utilized multiparameter intracellular
flow cytometry staining (ICS) analysis to identify influenza virus-
specific T cell responses. Splenocytes from four mice per group
were cultured overnight and then stimulated with the NP-specific
peptide in the presence of brefeldin for 6 h.
Figure 1. Design and characterization of vaccine constructs. (A) Recombinant influenza virus gene constructs (NPmix or NA-HA) were inserted
at the TK locus of the Western Reserve (WR) of vaccinia virus and are driven by the synthetic early/late promoter (pE/L). The cloning vectors (shown)
were introduced into the wild-type WR virus by homologous recombination and iterative plaque purification. (B) Amino acid sequences of NPmix and
NA-HA recombinant influenza virus protein constructs. The backbone for the NPmix construct is influenza virus NP into which was inserted other
influenza virus protein human T cell epitopes. Human T cell epitopes for influenza virus M1, NS1, NP, PB1, and PA proteins are indicated. The NA-HA
construct consists of the conserved regions of H5N1 influenza virus neuraminidase (N-terminal amino acids 108–231) and hemagglutinin (C-terminal
amino acids 347–511).
doi:10.1371/journal.pone.0025938.g001
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As shown in the pie charts of Figure 5, both the WR-NP and
WR-flu vaccination protocols induced a greater magnitude of T
cell responses as compared to WR alone. WR-NP induced a,2.9-
fold increase in T cell response as compared to WR, and WR-flu
induced a ,9.1-fold increase. While T cells secreting cytokines
following WR-NP vaccination were mostly CD8+, WR-flu induced
both CD4+ and CD8+ T cells. However, the CD8+ T cells
activated following WR-NP infection secreted both IFNc and
TNFa, while the T cells following WR-flu vaccination secreted
mainly IFNc.
The simultaneous measurements of three secreted cytokines
allows for the assessment of the quality of the vaccine-induced
CD4+ and CD8+ T cell responses. Upon analyzing concurrent
secretion of IFNc, TNFa, and IL2 by T cells, seven distinct
influenza virus-specific CD4+ and CD8+ T cell populations can be
identified. To further characterize the immunogenicity triggered
in each immunized group, we assessed polyfunctional T cell
responses. Regarding CD4+-secreting T cells (Figure 6A), we
observed only a significant response following WR-flu vaccination,
and this profile was not polyfunctional; CD4+ T cells secreted only
IFNc. However, WR-flu vaccination increased the overall
magnitude of the CD4+ T cell response ,19-fold (Figure 6B).
With regard to CD8+ T cells, we did observe polyfunctionality
following vaccination with WR-NP, but not WR-flu (Figure 6C).
While vaccination with WR-flu elicited significantly higher levels
of CD8+ T cells secreting IFNc as compared to WR, vaccination
with WR-NP exhibited significant levels of IFNc/TNFa-secreting
CD8+ T cells. While not statistically significant, WR-NP
vaccination also lead to high levels of triple, IFNc/TNFa/IL2-
secreting, CD8+ T cells. As compared to vaccination with WR, the
magnitude of the CD8+ T cell response was ,3.5-fold higher for
WR-NP and ,5.7-fold higher for WR-flu (Figure 6D).
Overall, these results indicated that immunization with WR-NP
induced a polyfunctional influenza virus-specific T cell response,
while immunization with WR-flu was monofunctional with CD4+
and CD8+ T cells only producing IFNc. Nevertheless, we show
that WR-NP and WR-flu immunization improved the magnitude
and quality of the anti-influenza virus response compared to WR.
However, even though we observed an adaptive immune response
characterized by polyfunctional T cells, we did not observe a
memory response 53 days post- vaccination with the single NP
peptide used as a test system (data not shown). This apparent lack
of a memory response could be associated with the fact that we did
not observe the production of neutralizing antibodies.
Virus load is reduced in the lungs of mice upon challenge
with influenza virus following vaccination
Upon measuring the adaptive immune response induced by
vaccination with the recombinant DNA and vaccinia virus
constructs, next we determined what effect vaccination had on
challenge with influenza virus. Two weeks following the end of the
vaccination protocol, mice from each vaccination group, along
with 9 mice that had received PBS alone, were infected
intranasally with 106LD50 of the A/WSN/33 (WSN), A/PR/8/
Figure 2. Recombinant viruses synthesize NP and HA proteins and replicate to similar levels. (A) 10 mg of pCIneo (neo) vectors
containing the NPmix (NP) or NA-HA (HA) inserts were transfected into BSC40 cells. For double transfections, 5 mg of each vector was used. 48 h post-
transfection, cells were lysed and levels of influenza virus proteins were determined using antibodies for NP and HA. (B–D) BSC40 cells were infected
with WR, WR-NP, or WR-flu at an MOI of 0.01 (B, D), 0.1, 1, or 10 (C) PFU/cell. (B) At 24 h p.i., cells were fixed and plaques were stained with NP
antibody. (C) At 24 h p.i., the levels of NP and HA in the lysates were determined by immunoblot analysis. (D) At 8 or 24 h p.i., infectious virus present
in the cells was measured in triplicate standard plaque assay on BSC40 cells.
doi:10.1371/journal.pone.0025938.g002
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34 (PR8), or A/California/07/09 (CA) strains of influenza virus,
corresponding to 104, 103, or 105 PFU/mouse, respectively. Each
day following challenge, mice were weighed and sacrificed when
body weight reached at least 75% of their starting weight. While
vaccination with WR-NP or WR-flu did not protect mice from
death or weight loss, mortality was generally delayed by 1–2 days
(Figure 7). However, we did observe a significant decrease in lung
viral titers following vaccination with WR-NP and WR-flu as
compared to WR (Figure 8). WR-NP vaccination decreased lung
viral titers by ,5.2-, ,55-, and ,8.6-fold upon challenge with
WSN, PR8, and CA, respectively. Vaccination with WR-flu lead
to a significant decrease in lung viral titer only upon challenge with
PR8 (,33-fold). We hypothesize that vaccination with WR-NP
resulted in viral titers lower than vaccination with WR-flu because
we observed a higher quality, polyfunctional T cell response
during WR-NP vaccination.
Taken together, our study indicates that recombinant vaccinia
viruses containing human T cell epitopes for influenza virus
proteins embedded in NP or the conserved N-terminal of NA
fused with the conserved C-terminal of HA can elicit specific T cell
immune responses following heterologous vaccination utilizing a
DNA-prime/poxvirus-boost protocol. While we observed signifi-
cant levels of T cells secreting cytokines in a polyfucntional
manner, this was not sufficient to protect mice from mortality;
however, we did observe a decrease in lung viral replication upon
vaccination with the recombinant viruses.
Discussion
The vaccination strategy of heterologous prime-boost vaccina-
tion to elicit specific protective T cell responses has been widely
established ever since its ground-breaking conception almost two
decades ago [26], in which an influenza virus prime followed by
vaccinia virus boost provided protection against Plasmodium
infection in mice. Since this first evidence that vaccinia virus
boost was required for strong activation of specific T cells, many
different techniques have arisen, including the use of different viral
vectors, DNA, and protein, in the presence and absence of
adjuvant. In the present study, we constructed two different
vaccinia virus vectors expressing recombinant influenza virus
Figure 3. Recombinant influenza virus proteins are present in the cytosol of infected cells. BSC40 cells were infected with WR, WR-flu (A),
or WR-NP (B) at an MOI of 1 PFU/cell. At 24 h p.i., cells were fixed with 2% paraformaldehyde, permeabilized, and stained with DAPI or antibodies
recognizing influenza virus HA (A), NP (B), or vaccinia virus 14 K (A27 gene). Bar = 25 mm.
doi:10.1371/journal.pone.0025938.g003
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proteins, based on an NP backbone, which is one of the more well-
conserved influenza virus proteins. Also utilized in our vaccine
design were the N-terminal of NA and the C-terminal of HA,
which are the well-conserved regions of H5N1 influenza virus
subtypes. These recombinants were part of a DNA-prime/
poxvirus-boost vaccination strategy in which a mammalian
expression vector expressing the same sequences that were inserted
into the vaccinia virus genome was used for the DNA priming
stage. While our vaccination strategy elicited an immune response
marked by CD4+ T cells expressing IFNc, CD8+ T cells expressing
IFNc and TNFa, and resulted in decreased viral replication in the
lungs of influenza-virus infected mice, these mice were not
protected against mortality.
There has been some disparity regarding the ability of influenza
virus NP in vaccine constructs to protect mice from mortality. A
recent report describes a human vaccine trial using a vaccinia
virus-based vaccine encoding the NP and M1 proteins against
influenza virus [24]. This vaccine protocol elicited increased IFNc-
secreting CD8+ T cells in response to NP and M1. On the other
hand, Lawson, et al., observed no protection following vaccination
with vaccinia virus constructs encoding NP, even though they
observed a reduction in lung viral load [20]. Ohba, et al. described
a DNA-based vaccine based on the N-terminal of NP and
observed protection upon challenge with influenza virus [18].
Saha, et al. also observed an improvement in vaccination using NP
when used in conjunction with the VP22 gene of herpes simplex
virus [17]. Finally, Altstein, et al. developed a vaccine using
recombinant NP that included a proteolysis signal which provided
some protection, especially when challenged with low doses of
influenza virus [19]. Therefore, it was our goal to improve upon
vaccine designs based on NP using a strategy in which we included
human T cell epitopes for other influenza virus proteins within the
NP backbone. A strategy based on multiple epitopes was
successfully used to vaccinate against Japanese encephalitis virus
in mice [27], as well as against hepatitis B virus and SIV [28,29].
While we did not specifically test if every influenza virus epitope
was correctly processed and presented, we know that the NP
peptide used for the ELISPOT and ICS experiments was correctly
presented. Following rationale design principles, we expect that
the other epitopes would be presented [30]. However, future
experiments with overlapping peptides for the entire influenza
proteins to fully characterize T cell epitopes, perhaps using a
transgenic humanized MHC class I mouse, should be performed.
In addition to the multi-epitope NPmix recombinant vaccinia
virus, we also constructed a recombinant virus encoding the
conserved regions from HA and NA of H5N1 viruses to examine if
the inclusion of more T cell epitopes would provide cross-clade
protection when challenged with H1N1 viruses.
Although we observed that T cells were able to be stimulated to
produce cytokines with influenza virus antigens, we did not
observe a protection from lethality of the virus. A number of other
Figure 4. Immunogenicity of WR-NP and WR-flu in mice. (A)
Immunization schedule. BALB/c mice were primed with 100 mg of DNA
(either 100 mg pCIneo-NPmix or empty vector, or 50 mg pCIneo-
NPmix+50 mg pCIneo-HANA) intramuscularly (i.m.) at the start of the
vaccination protocol. Two weeks later, the mice were boosted by
intraperitoneal (i.p.) infection with 107 PFU of WR, WR-NP, or WR-flu.
Eleven days post-boost, four mice were sacrificed to analyze the
adaptive immune response. The remaining mice were challenged with
influenza virus A/WSN/33, A/PR/8/34, or A/California/07/09. (B) Vaccine-
elicited T cell responses of splenocytes 25 d after the start of the
immunization protocol were measured in triplicate for each immuni-
zation group by fresh IFNc ELISPOT assay following stimulation with
influenza virus NP peptide TYQRTRALV, vaccinia virus E3 peptide
VGPSNSPTF, or RPMI media alone. The results represent the mean
number of IFNc-secreting cells per 106 splenocytes from three
biological replicates 6 standard deviations. P values from a two-tailed
t test assuming nonequal variance are indicated (*, P,0.05).
doi:10.1371/journal.pone.0025938.g004
Figure 5. Phenotypic analysis of vaccine-induced CD4+ and
CD8+ T cell responses. The same groups of splenocytes as described
in Figure 4 were stimulated with the influenza virus NP-specific peptide
and analyzed using polychromatic flow cytometry. The results represent
the mean number of CD4+ and CD8+ T cells secreting IFNc, TNFa, or IL2
in each immunization group using three biological replicates 6
standard error. The background from unstimulated controls was
subtracted in all cases. The pie charts represent the magnitude and
percentage of CD4+ and CD8+ T cells secreting cytokines in each
immunization group.
doi:10.1371/journal.pone.0025938.g005
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studies also had difficulties in showing that HA and NP could
provide protection from lethality [31,32,33,34,35,36]. It may have
been that our immunization scheme was sub-optimal, or most
importantly, we used the mouse as a test animal. It should be
highlighted that human T cell epitopes were used in the
immunization regimen, and hence, these epitopes in the mouse
might not be properly presented within MHC class I to stimulate
T cells. This is why we had used only a known NP mouse epitope
for stimulation of splenocytes for ELISPOT and ICS experiments.
Also, it may be that the vaccinia virus boost suppressed the
presentation of NP-generated T cell epitopes, as previously
reported [37]. Since we challenged mice with 106LD50, this
may have been too high of a dose to observe the protective effects
of vaccination. While we did observe a decrease in viral replication
in the lungs of mice vaccinated with WR-NP and WR-flu, the
amount of virus in the lungs was still greater than 104 PFU/ml,
which is high enough to cause lethality in mice [38]. It is likely that
mouse lung pathology would be similar in all vaccination groups,
and this would have contributed to mortality. Additionally, since
our vaccine construct utilized a muti-epitope design, we may have
observed increased immunogenicity upon stimulating splenocytes
or T cells, if instead of the single NP peptide that we used pools of
peptides spanning the influenza virus NP, M1, NS1, PB1, and PA
proteins, similar to previously described studies [10,11].
Many approaches exist to improve the vaccine design presented
in this study, one of them being the use of adjuvants. Rapamycin
has been shown to have immunostimulatory effects by improving
antigen presentation and aiding in cytokine production from
macrophages and dendritic cells. Furthermore, it is able to
improve on the generation of memory CD8+ T cells following
vaccination with a poxvirus vector [39,40]. Recent results have
shown that STING plays an important role in the generation of
IFNc-secreting CD8+ T cells [41]. Upon vaccination with a DNA
vaccine, wild-type mice generated significantly increased amounts
of IFNc as compared to STING2/2 mice in response to peptide
stimulation. These results suggest that the development of an
adjuvant to stimulate STING during vaccination would augment
the immune response to antigen presentation. In addition to the
use of adjuvants, many other future directions exist for the
improvement of our vaccine design to move closer to a universal
influenza virus vaccine. Our constructs that elicit T cell responses
could be combined with a vaccine specifically design to elicit a
humoral B cell-producing neutralizing antibody response. Sec-
ondly, we would have to test the vaccine for its efficacy in
protection after challenge with other influenza virus subtypes, such
as H5N1, H3N2, H9N2, and H7N7, all of which contain
conserved NP genes. It would also be prudent to challenge with
influenza B subtypes, since seasonal influenza virus vaccines
contain an attenuated B subtype virus. Since challenge with wild-
type H5N1 strain of influenza virus requires high biosafety levels,
we could challenge with a recombinant strain of PR8 that
expresses HA and NA from H5N1 viruses.
In summary, our study describes the design and development of
recombinant DNA and vaccinia virus vaccine constructs for use in
a DNA-prime/poxvirus-boost vaccine protocol as proof-of concept
protocol for a universal vaccine candidate against influenza virus.
Since these experiments were performed with the aim to show
proof-of-principle, we used the replication-competent WR strain
Figure 6. Polyfunctionality of influenza virus-specific CD4+ and CD8+ T cells. (A, C) Functional composition of CD4+ (A) or CD8+ (C) T cells
responses against influenza virus NP peptide based on the secretion of IFNc, IL-2, or TNFa. All the possible combinations of the responses are shown
on the x-axis, whereas the percentages of the functionally distinct cell populations are shown on the y-axis. Bars correspond to the fraction of
different functionally distinct T-cell populations within total CD4+ or CD8+ populations. Responses are grouped and color-coded on the basis of the
number functions. (*, P,1025; **, P,10225) (B, D) The pie chart summarizes the data and each slice of the pie correspond to the fraction of CD4+ T
cells with a given number of functions within the total CD4+ (B) or CD8+ (D) T cell populations. The size of the pie chart represents the magnitude of
the specific influenza virus immune response induced.
doi:10.1371/journal.pone.0025938.g006
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of vaccinia virus; any future vaccine trials, especially in humans,
non-replicative and safe, attenuated vaccinia virus strains, such as
MVA or NYVAC [12] must be used. Our construct contains
multiple T cell epitopes against influenza virus antigens, which
were aimed to broaden and increase immune responses upon
influenza virus challenge. While our construct elicited an immune
response marked by increased CD4+ and CD8+ T cells expressing
IFNc or TNFa, and resulted in decreased viral replication in the
lungs of influenza-virus infected mice, these mice were not
protected against mortality. Taken together, our results suggest
that a human mutli-epitope vaccine design in a DNA prime/
poxvirus boost approach can stimulate the breath and quality of
specific T cell immune responses to influenza virus antigens
leading to reduction in viral load in the lungs. This reduction
might play an important role to limit influenza virus replication in
a natural infection and to develop host immune resistance. The
protocol of immunization described here can be further improved
through the use of a recombinant attenuated vaccinia virus strain,
like MVA, and combination with adjuvants and vectors inducing
neutralizing antibodies to influenza virus proteins. Hence, a
vaccine construct that elicits broad T cell responses and limits virus
replication to some extent, as described here, could be combined
with a second vaccine that elicits a neutralizing antibody response
to further restrict the virus load. Together, such a vaccine strategy
could bring us closer to creating a universal vaccine against
influenza virus infection.
Materials and Methods
Cells, viruses, and infections
BSC40 monkey kidney epithelial cells and Madin-Darby canine
kidney (MDCK) cells (ATCC) were grown as monolayers in
supplemented high glucose Dulbecco’s modified Eagle’s medium
(hgDMEM) supplemented to contain 2 mM L-glutamine, 0.1 mM
nonessential amino acids, Fungizone Amphotencin B (0.5 mg/ml),
penicillin G (100 units/ml), streptomycin sulfate (100 mg/ml) and
10% newborn calf serum (NCS) or fetal calf serum (FCS) (Sigma),
respectively. Wild-type vaccinia virus (strain WR) and recombi-
nant WR viruses expressing influenza virus proteins were grown
and plaque-purified on monkey BSC-40 cells, purified by two 45%
(w/v) sucrose cushions, and titrated on BSC40 cells by plaque
assay.
Near-confluent monolayers of cells were mock-infected or
infected with vaccinia virus diluted in supplemented hgDMEM
Figure 7. Vaccination delays mortality in influenza virus-challenged mice. Two weeks following the end of the vaccination protocol, 5–8
mice from each vaccination group and 9 mice from control PBS-inoculated animals were infected with 106LD50 of the A/WSN/33 (A, B), A/PR/8/34 (C,
D), or A/California/07/09 (E, F) strains of influenza virus. Mice were sacrificed when body weight reached 75% of starting weight.
doi:10.1371/journal.pone.0025938.g007
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to the indicated multiplicity of infection (MOI). After 1 h of
adsorption at 37uC, virus and medium was removed. Fresh
supplemented hgDMEM containing 2% NCS was added to the
cells and infections were allowed to proceed at 37uC until the
indicated time post-infection.
Mouse inoculations
At day 1, six- to eight-week old mice BALB/c mice (Harlan)
were anesthetized with isoflurane and injected intramuscularly
with PBS alone or 100 mg of empty pCIneo vector or containing
NPmix, NA-HA, or both (n= 19–27). At day 15, mice were
anesthetized and infected intraperitoneally with 107 PFU of WR,
WR-NP, or WR-flu. At day 26, four animals were sacrificed for
adaptive immune response analysis. At day 29, the remaining mice
were anesthetized and challenged intranasally with 106LD50 of
the A/WSN/33, A/PR/8/34, or A/California/07/09 strains of
influenza virus (n = 5–8 for each group). Animals were weighed
each day for ten days and sacrificed when they lost at least 25% of
their starting body weight. Blood and lung tissue was collected
from each mouse at the time of sacrifice. All experiments were
performed in a specially separated negative-pressure HEPA (high-
efficiency particulate air)-filtered biosafety level 2 laboratory. All
animals were handled in strict accordance with good animal
practice as defined by the relevant national, international, and/or
local animal welfare bodies, and with the Royal Decree (RD
1201/2005). All animal work was approved by the Ethical
Committee of Animal Experimentation (CEEA-CNB) of the
Centro Nacional de Biotecnologı´a (CNB-CSIC). Permit number:
10015.
Generation and verification of recombinant vaccinia
viruses
Genes for expression of the recombinant influenza virus
proteins, NPmix and NA-HA (Figure 1B) were designed by us
and sent to GeneArtH for synthesis and insertion into the
pBlueScript vector. During the optimization process for the
sequences, the following cis-acting sequence motifs were
avoided: internal TATA-boxes, chi-sites and ribosomal entry
sites; AT-rich or GC-rich sequence stretches; ARE, INS, CRS
sequence elements; repeat sequences and RNA secondary
structures; (cryptic) splice donor and acceptor sites, branch
points; and AscI, FseI, NotI, PmlI and SalI sites. The influenza
virus genes were codon optimized and contain either an N-
terminal FLAG tag (NPmix) or a C-terminal His tag (NA-HA).
The genes were individually cloned into pCIneo for mammalian
expression, and also cloned into the TK locus of vaccinia virus
using the transfer vector pCyA. In this vector NPmix was
inserted alone, or in front of NA-HA, both of which were driven
by the vaccinia virus early/late promoter (pE/L). Homologous
recombination in the wild-type vaccinia virus strain WR was
performed as previously described [42]. Recombinant virus
containing NPmix was called ‘‘WR-NP,’’ and virus containing
both NPmix and NA-HA was called ‘‘WR-flu’’. Expression of
the influenza genes was driven by a synthetic early/late virus
promoter (Figure 1A).
Protein analyses and plaque assays
Following vaccinia virus infection or transfection with the
pCIneo expression vectors using Lipofectamine 2000 (Invitrogen)
following the manufacturer’s instructions, cells were lysed at the
indicated times p.i. in disruption buffer (0.5% Triton X-100,
50 mM KCl, 50 mM NaCl, 20 mM Tris-HCl [pH 7.5], 1 mM
EDTA, 10% glycerol, 16 Complete protease inhibitor (Roche),
25 mM b-glycerophosphate, 1 mM Na3VO4). Total protein
content was determined for clarified cell lysates by using the
BCA protein assay kit (Pierce). Lysates were separated by SDS-
PAGE with the same amount of total protein being loaded into
each lane and then transferred onto nitrocellulose membranes.
Immunoblots were blocked for 1 h in PBS containing 0.5%
Tween 20 and 5% nonfat dry milk, washed in PBS containing
0.05% Tween 20, and incubated at 4uC overnight with a mouse
monoclonal actin antibody (MP Biochemicals), a rabbit polyclonal
NP antibody (a kind gift from Adolfo Garcı´a-Sastre), or a sheep
polyclonal HA antibody (provided by the National Institute for
Biological Standards and Control) in PBS containing 0.5% Tween
20 and 1% nonfat dry milk. Subsequently, membranes were
washed and incubated for 2 h with horseradish peroxidase-
conjugated goat anti-mouse, goat anti-rabbit, or donkey anti-
sheep immunoglobulin G (Sigma), and bound antibodies were
detected with Amersham ECL Western blotting detection reagent
(GE Healthcare).
At the indicated times post-infection, vaccinia virus-infected
cells and cell media supernatant were collected and assayed in
triplicate for viral yield by standard plaque assay on BSC40
cells. For influenza virus-infected mice, diaphragmatic lung
lobes from each animal were weighed, homogenized in PBS, and
samples were then assayed in triplicate for viral yield by stan-
dard plaque assay on MDCK cells. Viral yields were calculated
according to the formula: log yieldt = x = [log10(PFU/ml)t = x]/
[log10(PFU/ml)t = 0], where t is time and x is the time post-infection.
For immunostaining of vaccinia virus plaques, infected cells
were fixed 24 h p.i. with 1:1 methanol:acetone, washed in PBS,
then incubated for 2 h with primary antibodies for vaccinia virus
(WR strain) or influenza virus NP diluted in PBS containing 3%
FCS. Cells were then washed and incubated for 1 h with
horseradish peroxidase-conjugated goat anti-rabbit diluted in
PBS containing 3% FCS. The spots were developed in PBS
containing 1 mg/ml of the substrate 3,39-diaminobenzidine
tetrahydrochloride (Sigma) with 0.03% hydrogen peroxide and
0.03% nickel sulfate.
Figure 8. Vaccination reduces the levels of infectious virus in
the lungs of influenza virus-challenged mice. Two weeks
following the end of the vaccination protocol, mice from each
vaccination group were infected with 106LD50 of the A/WSN/33
(WSN), A/PR/8/34 (PR8), or A/California/07/09 (CA) strains of influenza
virus. Mice were sacrificed at 5 d p.i. (except for some mice challenged
with CA that died at 3–4 d p.i), and diaphragmatic lung lobes were
isolated and homogenized. Levels of infectious virus were determined
in triplicate by plaque assay on MDCK cells. The results represent the
mean activity of 5–8 independent samples per group 6 standard
deviation. P values from a two-tailed t test assuming nonequal variance
are indicated (*, P,0.05; **, P,0.01).
doi:10.1371/journal.pone.0025938.g008
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Immunofluorescence
Following influenza virus infection of cells cultured on glass
coverslips, cells were fixed in 2% paraformaldehyde in PBS,
permeabilized in 0.1% Triton X in PBS, washed with 2.5% FCS
and 10 mM glycine in PBS, and then blocked with 10% FCS in
PBS. Cells were then incubated for 2 h with primary antibodies
recognizing influenza virus NP, HA, or vaccinia virus 14 K (A27
gene) diluted in 10% FCS in PBS. Subsequently, cells were washed
and incubated for 1 h with Alexa 488- or 586-conjugated anti-
rabbit immunoglobulin G (IgG) (Invitrogen), or fluorescein
isothiocyanate (FITC)-conjugated donkey anti-sheep IgG (Jackson
Immunoresearch). Cells were washed and incubated for 20 min
with DAPI (49,69-diamidino-2-phenylindole) (Sigma) and mounted
onto glass slides using ProLong Antifade reagent (Invitrogen). Cells
were imaged with the Leica TCS SP5 multispectral confocal
microscope (Leica Microsystems) using photomultipliers for laser
lines 405, 488, and 561 nm. LAS AF v.2.3.6 software was used for
image acquisition.
IFNc ELISPOT assay
The vaccine-specific cellular immune response in mice was
determined using ELISPOT assay measuring the secretion of
IFNc by splenocytes after stimulation with a peptide specific for
influenza virus NP (TYQRTRALV), as previously described
[10,11]. Briefly, eleven days after boosting with vaccinia virus,
mice were sacrificed and splenocytes depleted of red blood cells
were isolated. 106 splenocytes were plated in triplicate in 96-well
nitrocellulose-bottomed plates previously coated with 6 mg/ml of
anti-mouse IFNc mAb R4-6A2 (Pharmingen). Cells were
stimulated with the influenza virus-specific peptide (2 mg/ml), a
positive control peptide against the E3 protein of vaccinia virus
(VGPSNSPTF, 5 mg/ml), or without peptide as a negative control.
48 h after stimulation, cells were washed and those secreting IFNc
were developed using a biotin-streptavidin sandwich system and
counted using a stereomicroscope.
Intracellular Cytokine Staining (ICS) assay
Multiparameter flow cytometry was performed as previously
described [10,11]. Briefly, 106 splenocytes were stimulated with
the peptides described above in the presence of 1 ml/ml Brefeldin
(BD Bioscience) for 6 hours in a 96-well plate. The cells were then
washed, stained with the LIVE/DEAD Kit (Invitrogen), and Fc
receptors were blocked using CD16/CD32 antibodies (BD
Biosciences). The cells were then stained with the surface-specific
mouse antibodies, CD4-Alexa700, CD3-FITC, and CD8-PerCP
(BD Biosciences). Cells were permeabilized using the BD Cytofix/
Cytoperm Kit and were stained for the intracellular cytokines,
IFNc-APC, IL2-PE and TNFa-PECy7. Sample acquisition was
performed with an LSRII Flow Cytometer and FACSDiva
software (BD Biosciences) and was further analyzed with FlowJo
(Tree Star). All statistical analysis was performed as previously
described [10,11].
Supporting Information
Figure S1 Alignment of nucleoprotein (NP) from various
influenza virus subtypes. The NP protein of five influenza
virus strains of different subtypes (H1N1, H2N3, H5N1, H9N2,
and H7N7, from top to bottom) was aligned. The conserved
region, as indicated by red underline, from amino acids 19–498,
was used as the backbone for the NPmix multi-epitope protein.
(TIF)
Figure S2 Alignment of hemagglutinin (HA) and neur-
aminidase (NA) from different strains of the H5N1
influenza virus subtype. The NA protein (A) or HA protein
(B) from seven or eight different H5N1 viruses were aligned. The
conserved N-terminal of NA (amino acids 107–231) and conserved
C-terminal of HA (amino acids 347–511), as indicated by red
underline, were fused and used for the NA-HA construct along
with NPmix in the WR-flu recombinant virus.
(TIF)
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